Indazolones as modulators of TNF signaling

ABSTRACT

The disclosure provides compounds of Formula (I) 
                         
pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the disclosure are useful for treating immunological and oncological conditions.

PRIORITY CLAIM

This application claims the benefit of U.S. Provisional Application No.62/149,336, filed Apr. 17, 2015, which is hereby incorporated byreference in its entirety.

FIELD OF THE DISCLOSURE

The present disclosure relates to a class of fused indazolonederivatives, and to their use in therapy. More particularly, thisdisclosure is concerned with pharmacologically active substitutedindazolone derivatives. These compounds are modulators of the signalingof TNFα, and are accordingly of benefit as pharmaceutical agents,especially in the treatment of adverse inflammatory and autoimmunedisorders, neurological and neurodegenerative disorders, pain andnociceptive disorders, cardiovascular disorders, metabolic disorders,ocular disorders, and oncological disorders.

BACKGROUND

TNFα is the prototypical member of the Tumour Necrosis Factor (TNF)superfamily of proteins that share a primary function of regulating cellsurvival and cell death. One structural feature common to all knownmembers of the TNF superfamily is the formation of trimeric complexesthat bind to, and activate, specific TNF superfamily receptors. By wayof example, TNFα exists in soluble and transmembrane forms and signalsthrough two receptors, known as TNFR1 and TNFR2, with distinctfunctional endpoints.

Various products capable of modulating TNFα activity are alreadycommercially available. All are approved for the treatment ofinflammatory and autoimmune disorders such as rheumatoid arthritis andCrohn's disease. All currently approved products are macromolecular andact by inhibiting the binding of human TNFα to its receptor. Typicalmacromolecular TNFα inhibitors include anti-TNFα antibodies; and solubleTNFα receptor fusion proteins. Examples of commercially availableanti-TNFα antibodies include fully human antibodies such as adalimumab(Humira®) and golimumab (Simponi®), chimeric antibodies such asinfliximab (Remicade®), and pegylated Fab′ fragments such ascertulizumab pegol (Cimzia®). An example of a commercially availablesoluble TNFα receptor fusion protein is etanercept (Enbrel®).

TNF superfamily members, including TNFα itself, are implicated in avariety of physiological and pathological functions that are believed toplay a part in a range of conditions of significant medical importance(see, for example, M. G. Tansey & D. E. Szymkowski, Drug DiscoveryToday, 2009, 14, 1082-1088; and F. S. Carneiro et al., J. SexualMedicine, 2010, 7, 3823-3834). The compounds in accordance with thepresent disclosure, being potent modulators of human TNFα activity, aretherefore beneficial in the treatment and/or prevention of various humanailments. These include autoimmune and inflammatory disorders;neurological and neurodegenerative disorders; pain and nociceptivedisorders; cardiovascular disorders; metabolic disorders; oculardisorders; and oncological disorders.

In addition, the compounds in accordance with the present disclosure maybe beneficial as pharmacological standards for use in the development ofnew biological tests and in the search for new pharmacological agents.Thus, in one embodiment, the compounds of this disclosure may be usefulas radioligands in assays for detecting pharmacologically activecompounds. In an alternative embodiment, certain compounds of thisdisclosure may be useful for coupling to a fluorophore to providefluorescent conjugates that can be utilized in assays (e.g. afluorescence polarization assay) for detecting pharmacologically activecompounds.

SUMMARY OF THE DISCLOSURE

The compounds in accordance with the present disclosure, being potentmodulators of human TNFα activity, may be beneficial in the treatmentand/or prevention of various human ailments. These include autoimmuneand inflammatory disorders; neurological and neurodegenerativedisorders; pain and nociceptive disorders; cardiovascular disorders;metabolic disorders; ocular disorders; and oncological disorders.

In addition, the compounds in accordance with the present disclosure maybe beneficial as pharmacological standards for use in the development ofnew biological tests and in the search for new pharmacological agents.Thus, in one embodiment, the compounds of this disclosure may be usefulas radioligands in assays for detecting pharmacologically activecompounds. In an alternative embodiment, certain compounds of thisdisclosure may be useful for coupling to a fluorophore to providefluorescent conjugates that can be utilized in assays (e.g., afluorescence polarization assay) for detecting pharmacologically activecompounds.

The compounds in accordance with the present disclosure potentlyneutralize the activity of TNFα using the TNFα fluorescence polarizationcompetitive binding assay. When tested in this assay, the compounds ofthe present disclosure exhibit an IC50 value of 50 μM or less, generallyof 10 μM or less, usually of 5 μM or less, typically of 1 μM or less,suitably of 500 nM or less, ideally of 100 nM or less, and preferably of20 nM or less (the skilled person will appreciate that a lower IC50figure denotes a more active compound).

In a first embodiment, the disclosure provides a compound of Formula (I)

or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof,wherein:

X, Y and Z are independently CR⁴ or N;

-   -   provided that Y and Z are not both N;

A is —C(R^(z))₂—;

E is CH₂ or O and G is CH; or

E is CH₂ and G is CH or N;

R¹ is optionally substituted aryl or optionally substituted heteroaryl;

R² is —R^(2a)-R^(2b), wherein:

-   -   R^(2a) is an optionally substituted saturated, unsaturated or        partially saturated heterocyclyl or optionally substituted        heteroaryl;    -   R^(2b) is —N(R^(a))(R^(b)), —O(R^(a)), optionally substituted        (C₁-C₅)alkyl, optionally substituted (C₃-C₆)cycloalkyl,        —(CH₂)_(p)-optionally substituted heteroaryl or        —(CH₂)_(p)-optionally substituted heterocyclyl; wherein        -   R^(a) and R^(b) are independently selected from H,            optionally substituted (C₁-C₅)alkyl, and            —(CH₂)_(n)-optionally substituted heterocyclyl;

R⁴ is independently H, halo, CF₃, or (C₁-C₃)alkyl;

R^(z) is independently H, halo, CF₃, or (C₁-C₃)alkyl;

n is 0 or 1; and

p is 0 or 1.

In a second embodiment, the disclosure provides a compound according tothe first embodiment wherein R^(2b) is —N(R^(a))(R^(b)), —O(R^(a)),optionally substituted (C₁-C₅)alkyl, optionally substituted(C₃-C₆)cycloalkyl, or —(CH₂)_(p)-optionally substituted heterocyclyl;wherein R^(a) and R^(b) are independently selected from H, optionallysubstituted (C₁-C₅)alkyl, and —(CH₂)_(n)-optionally substitutedheterocyclyl.

In a third embodiment, the disclosure provides a compound according toany of the foregoing embodiments wherein E is CH₂.

In a fourth embodiment, the disclosure provides a compound according toany of the foregoing embodiments wherein X is CH, Y is CH and Z is CR⁴.

In a fifth embodiment, the disclosure provides a compound according toany of the foregoing embodiments wherein R⁴ is F.

In a sixth embodiment, the disclosure provides a compound according toany of the foregoing embodiments wherein X is CH, Y is CH and Z is CH.

In a seventh embodiment, the disclosure provides a compound according toany of the foregoing embodiments wherein G is N.

In an eighth embodiment, the disclosure provides a compound according toany of the foregoing embodiments wherein R¹ is optionally substitutedphenyl, optionally substituted pyrazolyl, optionally substitutedpyridyl, optionally substituted pyrimidinyl or optionally substitutedthiazolyl.

In a ninth embodiment, the disclosure provides a compound according anyof the foregoing embodiments wherein R¹ is optionally substitutedphenyl.

In a tenth embodiment, the disclosure provides a compound according toany of the foregoing embodiments wherein R¹ is optionally substituted byone or more substituents independently selected from —CF₃, —CN,—C(O)NH₂, —OCHF₂, —OCH₃, or (C₁-C₃)alkyl.

In an eleventh embodiment, the disclosure provides a compound accordingto any of the foregoing embodiments wherein R¹ is optionally substitutedby one or more substituents independently selected from —CH₃ or —OCHF₂.

In a twelfth embodiment, the disclosure provides a compound according toany of the foregoing embodiments wherein R^(2a) is optionallysubstituted pyrimidinyl or optionally substituted dihydropyranyl.

In a thirteenth embodiment, the disclosure provides a compound accordingany of the foregoing embodiments wherein R^(2a) is 1,2,4-oxadiazolyl,optionally substituted pyrazolyl, optionally substituted pyridinyl,optionally substituted pyrimidinyl, or optionally substituted1,2,4-thiadiazolyl.

In a fourteenth embodiment, the disclosure provides a compound accordingto any of the foregoing embodiments wherein R^(2b) is N(R^(a))(R^(b)),optionally substituted (C₁-C₄)alkyl, optionally substituted morpholinyl,optionally substituted piperazinyl, optionally substituted piperidinyl,1,1-dioxidothiomorpholinyl, optionally substitutedhexahydroimidazo[1,5-a]pyrazin-3(2H)-one, optionally substituted7-azaspiro[3.5]nonane, or optionally substituted pyrrolidinyl.

In a fifteenth embodiment, the disclosure provides a compound accordingto any of the foregoing embodiments wherein R^(2b) is —N(R^(a))(R^(b)),optionally substituted (C₁-C₃)alkyl, optionally substituted7-azaspiro[3.5]nonanyl, optionally substituted morpholinyl,1,1-dioxidothiomorpholinyl, optionally substituted piperazinyl,optionally substituted piperidinyl,hexahydroimidazo[1,5-a]pyrazin-3(2H)-one, or optionally substitutedpyrrolidinyl; wherein R^(a) is H or (C₁-C₃)alkyl, and R^(b) isoptionally substituted (C₁-C₃)alkyl, methoxypropyl,-5-oxopyrrolidin-3-ylmethyl, or tetrahydrofuranyl.

In a sixteenth embodiment, the disclosure provides a compound accordingto any of the foregoing embodiments wherein R^(2b) is optionallysubstituted (C₁-C₃)alkyl, —CH₂-pyrazolyl or —CH₂-triazolyl.

In a seventeenth embodiment, the disclosure provides a compoundaccording any of the foregoing embodiments wherein R^(2b) is optionallysubstituted (C₁-C₃)alkyl, optionally substituted 7-azaspiro[3.5]nonanyl,optionally substituted morpholinyl, orhexahydroimidazo[1,5-a]pyrazin-3(2H)-one.

In a eighteenth embodiment, the disclosure provides a compound accordingto any of the foregoing embodiments wherein R^(2b) is optionallysubstituted by —CH₂OH, —C(OH)(CH₃)₂, —C(O)CH₃, —C(O)OH, —OH, oralkoxyalkyl

In a nineteenth embodiment, the disclosure provides a compound accordingto any of the foregoing embodiments wherein R^(2b) is optionallysubstituted by one or more substituents independently selected from CH₃,—C(O)CH₂OH, —C(O)CH₃.

In a twentieth embodiment, the disclosure provides a compound accordingto any of the foregoing embodiments, wherein the compound is:

-   3-(2-(Difluoromethoxy)phenyl)-6-(2-morpholinopyrimidin-5-yl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one;-   (R)-3-(2-(difluoromethoxy)phenyl)-6-(2-morpholinopyrimidin-5-yl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one;-   (S)-3-(2-(difluoromethoxy)phenyl)-6-(2-morpholinopyrimidin-5-yl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one;-   1-(5-(3-(2-(difluoromethoxy)phenyl)-9-oxo-1,2,3,9-tetrahydropyrazolo[1,2-a]indazol-6-yl)pyrimidin-2-yl)piperidine-4-carboxylic    acid;-   (S)-3-(2-(difluoromethoxy)phenyl)-6-(2-((R)-2-(methoxymethyl)pyrrolidin-1-yl)pyrimidin-5-yl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one;-   (R)-3-(2-(difluoromethoxy)phenyl)-6-(2-((R)-2-(methoxymethyl)pyrrolidin-1-yl)pyrimidin-5-yl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one;-   (R)-3-(2-(difluoromethoxy)phenyl)-6-(2-(((R)-tetrahydrofuran-3-yl)amino)pyrimidin-5-yl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one;-   (S)-3-(2-(difluoromethoxy)phenyl)-6-(2-(((R)-tetrahydrofuran-3-yl)amino)pyrimidin-5-yl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one;-   (R)-3-(2-(difluoromethoxy)phenyl)-6-(2-((R)-2-(hydroxymethyl)morpholino)pyrimidin-5-yl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one;-   (S)-3-(2-(difluoromethoxy)phenyl)-6-(2-((R)-2-(hydroxymethyl)morpholino)pyrimidin-5-yl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one;-   (S)-3-(2-(difluoromethoxy)phenyl)-6-(2-((S)-2-(hydroxymethyl)morpholino)pyrimidin-5-yl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one;-   (R)-3-(2-(difluoromethoxy)phenyl)-6-(2-((S)-2-(hydroxymethyl)morpholino)pyrimidin-5-yl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one;-   (R)-3-(2-(Difluoromethoxy)phenyl)-6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one;-   (S)-3-(2-(difluoromethoxy)phenyl)-6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one;-   3-(2-(difluoromethoxy)phenyl)-6-(2-(4-hydroxypiperidin-1-yl)pyrimidin-5-yl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one;-   (R)-3-(2-(difluoromethoxy)phenyl)-6-(2-((((S)-5-oxopyrrolidin-3-yl)methyl)amino)pyrimidin-5-yl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one;-   (S)-3-(2-(difluoromethoxy)phenyl)-6-(2-((((S)-5-oxopyrrolidin-3-yl)methyl)amino)pyrimidin-5-yl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one;-   (R)-3-(2-(difluoromethoxy)phenyl)-6-(2-((((R)-5-oxopyrrolidin-3-yl)methyl)amino)pyrimidin-5-yl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one;-   (S)-3-(2-(difluoromethoxy)phenyl)-6-(2-((((R)-5-oxopyrrolidin-3-yl)methyl)amino)pyrimidin-5-yl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one;-   (R)-3-(2-(difluoromethoxy)phenyl)-6-(2-(2-hydroxy-7-azaspiro[3.5]nonan-7-yl)pyrimidin-5-yl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one;-   (S)-3-(2-(difluoromethoxy)phenyl)-6-(2-(2-hydroxy-7-azaspiro[3.5]nonan-7-yl)pyrimidin-5-yl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one;-   (S)-3-(2-(difluoromethoxy)phenyl)-6-(2-((S)-3-oxohexahydroimidazo[1,5-a]pyrazin-7(1H)-yl)pyrimidin-5-yl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one;-   (S)-3-(2-(difluoromethoxy)phenyl)-6-(2-((R)-3-oxohexahydroimidazo[1,5-a]pyrazin-7(1H)-yl)pyrimidin-5-yl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one;-   (R)-3-(2-(difluoromethoxy)phenyl)-6-(2-((S)-3-oxohexahydroimidazo[1,5-a]pyrazin-7(1H)-yl)pyrimidin-5-yl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one;-   (R)-3-(2-(difluoromethoxy)phenyl)-6-(2-((R)-3-oxohexahydroimidazo[1,5-a]pyrazin-7(1H)-yl)pyrimidin-5-yl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one;-   (R)-3-(2-(Difluoromethoxy)phenyl)-6-(2-((3-methoxypropyl)amino)pyrimidin-5-yl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one;-   (S)-3-(2-(Difluoromethoxy)phenyl)-6-(2-((3-methoxypropyl)amino)pyrimidin-5-yl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one;-   (S)-6-(2-(4-Acetylpiperazin-1-yl)pyrimidin-5-yl)-3-(2-(difluoromethoxy)phenyl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one;-   (R)-6-(2-(4-Acetylpiperazin-1-yl)pyrimidin-5-yl)-3-(2-(difluoromethoxy)phenyl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one;-   6-(2-(difluoromethoxy)phenyl)-3-(2-morpholinopyrimidin-5-yl)-8,9-dihydro-6H-pyridazino[1,2-a]indazol-11(7H)-one;-   6-(2-(difluoromethoxy)phenyl)-3-(2-(4-hydroxypiperidin-1-yl)pyrimidin-5-yl)-8,9-dihydro-6H-pyridazino[1,2-a]indazol-11(7H)-one;-   6-(2-(difluoromethoxy)phenyl)-3-(2-(1,1-dioxidothiomorpholino)pyrimidin-5-yl)-8,9-dihydro-6H-pyridazino[1,2-a]indazol-11(7H)-one;-   3-(2-methoxyphenyl)-6-(2-morpholinopyrimidin-5-yl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one;-   (R)-6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-3-(2-methoxyphenyl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one;-   (S)-6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-3-(2-methoxyphenyl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one;-   2-methyl-6-(6-(2-morpholinopyrimidin-5-yl)-9-oxo-1,2,3,9-tetrahydropyrazolo[1,2-a]indazol-3-yl)benzonitrile;-   6-(2-morpholinopyrimidin-5-yl)-3-phenyl-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one;-   4-methoxy-3-(6-(2-morpholinopyrimidin-5-yl)-9-oxo-1,2,3,9-tetrahydropyrazolo[1,2-a]indazol-3-yl)benzonitrile;-   2-methoxy-3-(6-(2-morpholinopyrimidin-5-yl)-9-oxo-1,2,3,9-tetrahydropyrazolo[1,2-a]indazol-3-yl)benzonitrile;-   3-(1-isopropyl-1H-pyrazol-5-yl)-6-(2-morpholinopyrimidin-5-yl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one;-   2-methyl-6-(6-(2-morpholinopyrimidin-5-yl)-9-oxo-1,2,3,9-tetrahydropyrazolo[1,2-a]indazol-3-yl)benzamide;-   rac-(1R,9bR)-1-(2-(difluoromethoxy)phenyl)-8-(2-morpholinopyrimidin-5-yl)-2,3-dihydro-1H-pyrrolo[2,1-a]isoindol-5(9bH)-one;-   rac-(1R,9bS)-1-(2-(difluoromethoxy)phenyl)-8-(2-morpholinopyrimidin-5-yl)-2,3-dihydro-1H-pyrrolo[2,1-a]isoindol-5(9bH)-one;-   rac-(1R,10bR)-1-(2-(difluoromethoxy)phenyl)-9-(2-morpholinopyrimidin-5-yl)-3,4-dihydro-1H-[1,4]oxazino[3,4-a]isoindol-6(10bH)-one;-   (1S,9bS)-1-(2-(difluoromethoxy)phenyl)-8-(2-morpholinopyrimidin-5-yl)-2,3-dihydro-1H-pyrrolo[2,1-a]isoindol-5(9bH)-one;-   (1R,9bR)-1-(2-(difluoromethoxy)phenyl)-8-(2-morpholinopyrimidin-5-yl)-2,3-dihydro-1H-pyrrolo[2,1-a]isoindol-5(9bH)-one;-   (1S,9bS)-1-(2-(difluoromethoxy)phenyl)-8-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2,3-dihydro-1H-pyrrolo[2,1-a]isoindol-5(9bH)-one;-   (1R,9bR)-1-(2-(difluoromethoxy)phenyl)-8-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2,3-dihydro-1H-pyrrolo[2,1-a]isoindol-5(9bH)-one;-   (1S,9bS)-1-(2-(difluoromethoxy)phenyl)-8-(2-((R)-2-(methoxymethyl)pyrrolidin-1-yl)pyrimidin-5-yl)-2,3-dihydro-1H-pyrrolo[2,1-a]isoindol-5(9bH)-one;-   (1R,9bR)-1-(2-(difluoromethoxy)phenyl)-8-(2-((R)-2-(methoxymethyl)pyrrolidin-1-yl)pyrimidin-5-yl)-2,3-dihydro-1H-pyrrolo[2,1-a]isoindol-5(9bH)-one;-   (1R,9bR)-1-(2-(difluoromethoxy)phenyl)-8-(2-((R)-3-oxohexahydroimidazo[1,5-a]pyrazin-7(1H)-yl)pyrimidin-5-yl)-2,3-dihydro-1H-pyrrolo[2,1-a]isoindol-5(9bH)-one;-   (1R,9bR)-1-(2-(difluoromethoxy)phenyl)-8-(2-((S)-3-oxohexahydroimidazo[1,5-a]pyrazin-7(1H)-yl)pyrimidin-5-yl)-2,3-dihydro-1H-pyrrolo[2,1-a]isoindol-5(9bH)-one;-   (1R)-1-(2-(difluoromethoxy)phenyl)-8-(2-(2-hydroxypropan-2-yl)-4-methylpyrimidin-5-yl)-2,3-dihydro-1H-pyrrolo[2,1-a]isoindol-5(9bH)-one;-   (R)-6-(2-((R)-4-acetyl-2-methylpiperazin-1-yl)pyrimidin-5-yl)-3-(2-(difluoromethoxy)phenyl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one;-   (S)-3-(2-(difluoromethoxy)phenyl)-6-(2-((S)-3-oxohexahydroimidazo[1,5-a]pyrazin-7(1H)-yl)pyrimidin-5-yl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one;-   (R)-3-(2-(difluoromethoxy)-5-methylphenyl)-6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one;-   (R)-6-(2-((R)-4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-3-(2-(difluoromethoxy)phenyl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one;-   (R)-3-(2-(difluoromethoxy)-5-methylphenyl)-6-(2-((S)-3-oxohexahydroimidazo[1,5-a]pyrazin-7(1H)-yl)pyrimidin-5-yl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one;-   (R)-3-(2-(difluoromethoxy)phenyl)-6-(2-((R)-4-(2-hydroxyacetyl)-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one;-   (R)-3-(2-(difluoromethoxy)-5-methylphenyl)-6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one;-   (S)-3-(2-(difluoromethoxy)phenyl)-6-(2-((S)-3-oxohexahydroimidazo[1,5-a]pyrazin-7(1H)-yl)pyrimidin-5-yl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one;-   (S)-3-(2-(difluoromethoxy)phenyl)-6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one;-   (R)-3-(2-(difluoromethoxy)phenyl)-6-(2-((R)-3-hydroxy-4-(2-hydroxyacetyl)piperazin-1-yl)pyrimidin-5-yl)-2,3-dihydro-1H,9H-pyrazolo[1,2-a]indazol-9-one;-   is    (1R)-1-(2-(difluoromethoxy)phenyl)-8-(2-(2-hydroxypropan-2-yl)-4-methylpyrimidin-5-yl)-2,3-dihydro-1H-pyrrolo[2,1-a]isoindol-5(9bH)-one;-   (S)-3-(2-(difluoromethoxy)-5-methylphenyl)-7-fluoro-6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one;-   (R)-3-(2-(difluoromethoxy)-5-methylphenyl)-7-fluoro-6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one;-   (R)-3-(2-(difluoromethoxy)phenyl)-7-fluoro-6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one;-   (S)-3-(2-(difluoromethoxy)phenyl)-7-fluoro-6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one;-   3-(5-(hydroxymethyl)-2-methoxyphenyl)-6-(2-morpholinopyrimidin-5-yl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one;-   (R)-3-(2-(difluoromethoxy)-5-methylphenyl)-7-fluoro-6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2,3-dihydro-1H,9H-pyrazolo[1,2-a]indazol-9-one;-   (S)-3-(2-(difluoromethoxy)-5-methylphenyl)-7-fluoro-6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2,3-dihydro-1H,9H-pyrazolo[1,2-a]indazol-9-one;-   (S)-3-(2-(difluoromethoxy)phenyl)-6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2,3-dihydro-1H,9H-pyrazolo[1,2-a]indazol-9-one;-   (R)-3-(2-(difluoromethoxy)-5-methylphenyl)-6-(2-((S)-3-oxohexahydroimidazo[1,5-a]pyrazin-7(1H)-yl)pyrimidin-5-yl)-2,3-dihydro-1H,9H-pyrazolo[1,2-a]indazol-9-one;-   (R)-3-(2-(difluoromethoxy)-5-methylphenyl)-6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2,3-dihydro-1H,9H-pyrazolo[1,2-a]indazol-9-one;-   (R)-6-(2-((R)-4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-3-(2-(difluoromethoxy)phenyl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one;-   (R)-3-(2-(difluoromethoxy)phenyl)-6-(2-((R)-3-hydroxy-4-(2-hydroxyacetyl)piperazin-1-yl)pyrimidin-5-yl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one;-   9b-(2-methoxyphenyl)-8-(2-morpholinopyrimidin-5-yl)-2,3-dihydro-1H-pyrrolo[2,1-a]isoindol-5(9bH)-one;    or-   3-(5-(hydroxymethyl)-2-methoxyphenyl)-6-(2-morpholinopyrimidin-5-yl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one.

In a twenty-first embodiment, the disclosure provides a pharmaceuticalcomposition comprising a compound of Formula (I) and pharmaceuticallyacceptable excipients.

In a twenty-second embodiment, the disclosure provides a method oftreating a disease comprising administering a therapeutically effectiveamount of a compound of Formula (I).

In a twenty-third embodiment, the disclosure provides a method accordingto the twenty-second embodiment wherein the disease is rheumatoidarthritis, juvenile rheumatoid arthritis, psoriasis, psoriaticarthritis, Crohn's disease, inflammatory bowel disease, ulcerativecolitis, psoriatic arthritis, psoriasis, ankylosing spondylitis,systemic lupus erythematosus, lupus nephritis, multiple sclerosis,uveitis, or hidraenitis suppurativa.

In a twenty-fourth embodiment, the disclosure provides a kit comprisinga packaged product comprising components with which to administer acompound according to any of the first through twenty-eighth embodimentsfor treatment of an autoimmune disorder.

In a twenty-fifth embodiment, the disclosure provides a kit according tothe thirty-sixth embodiment, wherein the packaged product comprises acompound according to any of the first through twentieth embodiment andinstructions for use.

In a twenty-sixth embodiment, the disclosure provides a pharmaceuticalcomposition comprising a compound according to any of the first throughtwentieth embodiments and one or more pharmaceutically acceptableexcipients.

DETAILED DESCRIPTION OF THE DISCLOSURE

Many autoimmune diseases and disease associated with chronicinflammation, as well as acute responses, have been linked to excessiveor unregulated production or activity of one or more cytokines.

The compounds of the disclosure are also useful in the treatment ofrheumatoid arthritis, asthma, allergic asthma, osteoarthritis, juvenilearthritis, ankylosing spondylitis, hidradenitis supportive, juvenilerheumatoid arthritis, ankylosing spondylitis associated lung disease,Sjögren's syndrome,

Compounds of Formula (I) of the disclosure can be used alone or incombination with an additional agent, e.g., a therapeutic agent, saidadditional agent being selected by the skilled artisan for its intendedpurpose. For example, the additional agent can be a therapeutic agentart-recognized as being useful to treat the disease or condition beingtreated by the compound of the present disclosure. The additional agentalso can be an agent that imparts a beneficial attribute to thetherapeutic composition e.g., an agent that affects the viscosity of thecomposition.

It should further be understood that the combinations which are to beincluded within this disclosure are those combinations useful for theirintended purpose. The agents set forth below are illustrative forpurposes and not intended to be limited. The combinations, which arepart of this disclosure, can be the compounds of the present disclosureand at least one additional agent selected from the lists below. Thecombination can also include more than one additional agent, e.g., twoor three additional agents if the combination is such that the formedcomposition can perform its intended function.

Preferred combinations are non-steroidal anti-inflammatory drug(s) alsoreferred to as NSAIDS which include drugs like ibuprofen. Otherpreferred combinations are corticosteroids including prednisolone; thewell known side-effects of steroid use can be reduced or even eliminatedby tapering the steroid dose required when treating patients incombination with the compounds of this disclosure. Non-limiting examplesof therapeutic agents for rheumatoid arthritis with which a compound ofFormula (I) of the disclosure can be combined include the following:cytokine suppressive anti-inflammatory drug(s) (CSAIDs); antibodies toor antagonists of other human cytokines or growth factors, for example,LT, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-12, IL-15, IL-16,IL-21, IL-23, interferons, EMAP-II, GM-CSF, FGF, MMP-13 and PDGF.Compounds of the disclosure can be combined with antibodies to cellsurface molecules such as CD2, CD3, CD4, CD8, CD25, CD28, CD30, CD40,CD45, CD69, CD80 (B7.1), CD86 (B7.2), CD90, CTLA or their ligandsincluding CD154 (gp39 or CD40L).

Preferred combinations of therapeutic agents may interfere at differentpoints in the autoimmune and subsequent inflammatory cascade; preferredexamples include IL-1 inhibitors (Interleukin-1-converting enzymeinhibitors, IL-1RA etc.) may be effective for the same reason. Otherpreferred combinations include Interleukin 11. Yet other preferredcombinations are the other key players of the autoimmune response whichmay act parallel to, dependent on or in concert with IL-18 function;especially preferred are IL-12 antagonists including IL-12 antibodies orsoluble IL-12 receptors, or IL-12 binding proteins. It has been shownthat IL-12 and IL-18 have overlapping but distinct functions and acombination of antagonists to both may be most effective. Yet anotherpreferred combination is non-depleting anti-CD4 inhibitors. Yet otherpreferred combinations include antagonists of the co-stimulatory pathwayCD80 (B7.1) or CD86 (B7.2) including antibodies, soluble receptors orantagonistic ligands.

A compound of Formula (I) of the disclosure may also be combined withagents, such as methotrexate, 6-mercaptopurine, azathioprinesulphasalazine, mesalazine, olsalazine chloroquinine/hydroxychloroquine,pencillamine, aurothiomalate (intramuscular and oral), azathioprine,cochicine, corticosteroids (oral, inhaled and local injection), beta-2adrenoreceptor agonists (salbutamol, terbutaline, salmeteral), xanthines(theophylline, aminophylline), cromoglycate, nedocromil, ketotifen,ipratropium and oxitropium, cyclosporin, FK506, rapamycin, mycophenolatemofetil, leflunomide, NSAIDs, for example, ibuprofen, corticosteroidssuch as prednisolone, phosphodiesterase inhibitors, adensosine agonists,antithrombotic agents, complement inhibitors, adrenergic agents, agentswhich interfere with signalling by proinflammatory cytokines such asIL-1 (e.g., NIK, IKK, JAK1, JAK2, JAK3, p38 or MAP kinase inhibitors),IL-1β converting enzyme inhibitors, T-cell signalling inhibitors such askinase inhibitors, metalloproteinase inhibitors, sulfasalazine,6-mercaptopurines, angiotensin converting enzyme inhibitors, solublecytokine receptors and derivatives thereof (e.g. sIL-1RI, sIL-1RII,sIL-6R), antiinflammatory cytokines (e.g. IL-4, IL-10, IL-11, IL-13),celecoxib, folic acid, hydroxychloroquine sulfate, rofecoxib, naproxen,valdecoxib, sulfasalazine, methylprednisolone, meloxicam,methylprednisolone acetate, gold sodium thiomalate, aspirin,triamcinolone acetonide, propoxyphene napsylate/apap, folate,nabumetone, diclofenac, piroxicam, etodolac, diclofenac sodium,oxaprozin, oxycodone HCl, hydrocodone bitartrate/apap, diclofenacsodium/misoprostol, fentanyl, anakinra, tramadol HCl, salsalate,sulindac, cyanocobalamin/fa/pyridoxine, acetaminophen, alendronatesodium, prednisolone, morphine sulfate, lidocaine hydrochloride,indomethacin, glucosamine sulf/chondroitin, amitriptyline HCl,sulfadiazine, oxycodone HCl/acetaminophen, olopatadine HCl misoprostol,naproxen sodium, omeprazole, cyclophosphamide, rituximab, tofacitinib,IL-1 TRAP, MRA, CTLA4-IG, IL-18 BP, anti-IL-12, Anti-IL15, BIRB-796,SCIO-469, VX-702, AMG-548, VX-740, Roflumilast, IC-485, CDC-801, S1P1agonists (such as FTY720), PKC family inhibitors (such as Ruboxistaurinor AEB-071) and Mesopram. Preferred combinations include methotrexate orleflunomide and in moderate or severe rheumatoid arthritis cases, andcyclosporine.

Non-limiting examples of therapeutic agents for inflammatory boweldisease with which a compound of Formula (I) of the disclosure can becombined include the following: budenoside; epidermal growth factor;corticosteroids; cyclosporin, sulfasalazine; aminosalicylates;6-mercaptopurine; azathioprine; metronidazole; lipoxygenase inhibitors;mesalamine; olsalazine; balsalazide; antioxidants; thromboxaneinhibitors; IL-1 receptor antagonists; anti-IL-1 monoclonal antibodies;anti-IL-6 monoclonal antibodies; growth factors; elastase inhibitors;pyridinyl-imidazole compounds; antibodies to or antagonists of otherhuman cytokines or growth factors, for example, LT, IL-1, IL-2, IL-6,IL-7, IL-8, IL-12, IL-15, IL-16, IL-23, EMAP-II, GM-CSF, FGF, and PDGF;cell surface molecules such as CD2, CD3, CD4, CD8, CD25, CD28, CD30,CD40, CD45, CD69, CD90 or their ligands; methotrexate; cyclosporine;FK506; rapamycin; mycophenolate mofetil; leflunomide; NSAIDs, forexample, ibuprofen; corticosteroids such as prednisolone;phosphodiesterase inhibitors; adenosine agonists; antithrombotic agents;complement inhibitors; adrenergic agents; agents which interfere withsignalling by proinflammatory cytokines such as IL-1 (e.g. NIK, IKK, p38or MAP kinase inhibitors); IL-1β converting enzyme inhibitors; T-cellsignalling inhibitors such as kinase inhibitors; metalloproteinaseinhibitors; sulfasalazine; azathioprine; 6-mercaptopurines; angiotensinconverting enzyme inhibitors; soluble cytokine receptors and derivativesthereof (e.g. sIL-1RI, sIL-1RII, sIL-6R) and antiinflammatory cytokines(e.g. IL-4, IL-10, IL-11, IL-13). Preferred examples of therapeuticagents for Crohn's disease with which a compound of Formula (I) can becombined include PDE4 inhibitors. A compound of Formula (I) can becombined with corticosteroids, for example, budenoside anddexamethasone; sulfasalazine, 5-aminosalicylic acid; olsalazine; andagents which interfere with synthesis or action of proinflammatorycytokines such as IL-1, for example, IL-1β converting enzyme inhibitorsand IL-1ra; T cell signaling inhibitors, for example, tyrosine kinaseinhibitors; 6-mercaptopurine; IL-11; mesalamine; prednisone;azathioprine; mercaptopurine; infliximab; methylprednisolone sodiumsuccinate; diphenoxylate/atrop sulfate; loperamide hydrochloride;methotrexate; omeprazole; folate; ciprofloxacin/dextrose-water;hydrocodone bitartrate/apap; tetracycline hydrochloride; fluocinonide;metronidazole; thimerosal/boric acid; cholestyramine/sucrose;ciprofloxacin hydrochloride; hyoscyamine sulfate; meperidinehydrochloride; midazolam hydrochloride; oxycodone HCl/acetaminophen;promethazine hydrochloride; sodium phosphate;sulfamethoxazole/trimethoprim; celecoxib; polycarbophil; propoxyphenenapsylate; hydrocortisone; multivitamins; balsalazide disodium; codeinephosphate/apap; colesevelam HCl; cyanocobalamin; folic acid;levofloxacin; methylprednisolone; natalizumab and interferon-gamma.

Non-limiting examples of therapeutic agents for multiple sclerosis withwhich a compound of Formula (I) can be combined include the following:corticosteroids; prednisolone; methylprednisolone; azathioprine;cyclophosphamide; cyclosporine; methotrexate; 4-aminopyridine;tizanidine; interferon-β1a (AVONEX®; Biogen); interferon-β1b(BETASERON®; Chiron/Berlex); interferon α-n3) (InterferonSciences/Fujimoto), interferon-α (Alfa Wassermann/J&J), interferonβ1A-IF (Serono/Inhale Therapeutics), Peginterferon α 2b(Enzon/Schering-Plough), Copolymer 1 (Cop-1; COPAXONE®; TevaPharmaceutical Industries, Inc.); hyperbaric oxygen; intravenousimmunoglobulin; cladribine; antibodies to or antagonists of other humancytokines or growth factors and their receptors, for example, LT, IL-1,IL-2, IL-6, IL-7, IL-8, IL-12, IL-23, IL-15, IL-16, EMAP-II, GM-CSF,FGF, and PDGF. A compound of Formula (I) can be combined with antibodiesto cell surface molecules such as CD2, CD3, CD4, CD8, CD19, CD20, CD25,CD28, CD30, CD40, CD45, CD69, CD80, CD86, CD90 or their ligands. Acompound of Formula (I) may also be combined with agents such asmethotrexate, cyclosporine, FK506, rapamycin, mycophenolate mofetil,leflunomide, an S1P1 agonist, NSAIDs, for example, ibuprofen,corticosteroids such as prednisolone, phosphodiesterase inhibitors,adensosine agonists, antithrombotic agents, complement inhibitors,adrenergic agents, agents which interfere with signalling byproinflammatory cytokines such as IL-1 (e.g., NIK, IKK, p38 or MAPkinase inhibitors). IL-1β converting enzyme inhibitors, TACE inhibitors,T-cell signaling inhibitors such as kinase inhibitors, metalloproteinaseinhibitors, sulfasalazine, azathioprine, 6-mercaptopurines, angiotensinconverting enzyme inhibitors, soluble cytokine receptors and derivativesthereof (e.g. sIL-1RI, sIL-1RII, sIL-6R) and antiinflammatory cytokines(e.g. IL-4, IL-10, IL-13 and TGFβ).

Non-limiting examples of therapeutic agents for ankylosing spondylitiswith which a compound of Formula (I) can be combined include thefollowing: ibuprofen, diclofenac, misoprostol, naproxen, meloxicam,indomethacin, diclofenac, celecoxib, rofecoxib, sulfasalazine,methotrexate, azathioprine, minocyclin, and prednisone

Non-limiting examples of therapeutic agents for psoriasis with which acompound of Formula (I) can be combined include the following:calcipotriene, clobetasol propionate, triamcinolone acetonide,halobetasol propionate, tazarotene, methotrexate, fluocinonide,betamethasone diprop augmented, fluocinolone acetonide, acitretin, tarshampoo, betamethasone valerate, mometasone furoate, ketoconazole,pramoxine/fluocinolone, hydrocortisone valerate, flurandrenolide, urea,betamethasone, clobetasol propionate/emoll, fluticasone propionate,azithromycin, hydrocortisone, moisturizing formula, folic acid,desonide, pimecrolimus, coal tar, diflorasone diacetate, etanerceptfolate, lactic acid, methoxsalen, hc/bismuth subgal/znox/resor,methylprednisolone acetate, prednisone, sunscreen, halcinonide,salicylic acid, anthralin, clocortolone pivalate, coal extract, coaltar/salicylic acid, coal tar/salicylic acid/sulfur, desoximetasone,diazepam, emollient, fluocinonide/emollient, mineral oil/castor oil/nalact, mineral oil/peanut oil, petroleum/isopropyl myristate, psoralen,salicylic acid, soap/tribromsalan, thimerosal/boric acid, celecoxib,infliximab, cyclosporine, alefacept, efalizumab, tacrolimus,pimecrolimus, PUVA, UVB, sulfasalazine, ABT-874 and ustekinamab.

Non-limiting examples of therapeutic agents for psoriatic arthritis withwhich a compound of Formula (I) can be combined include the following:methotrexate, etanercept, rofecoxib, celecoxib, folic acid,sulfasalazine, naproxen, leflunomide, methylprednisolone acetate,indomethacin, hydroxychloroquine sulfate, prednisone, sulindac,betamethasone diprop augmented, infliximab, methotrexate, folate,triamcinolone acetonide, diclofenac, dimethylsulfoxide, piroxicam,diclofenac sodium, ketoprofen, meloxicam, methylprednisolone,nabumetone, tolmetin sodium, calcipotriene, cyclosporine, diclofenacsodium/misoprostol, fluocinonide, glucosamine sulfate, gold sodiumthiomalate, hydrocodone bitartrate/apap, ibuprofen, risedronate sodium,sulfadiazine, thioguanine, valdecoxib, and alefacept

In this disclosure, the following definitions are applicable:

A “therapeutically effective amount” is an amount of a compound ofFormula (I) or a combination of two or more such compounds, whichinhibits, totally or partially, the progression of the condition oralleviates, at least partially, one or more symptoms of the condition. Atherapeutically effective amount can also be an amount which isprophylactically effective. The amount which is therapeuticallyeffective will depend upon the patient's size and gender, the conditionto be treated, the severity of the condition and the result sought. Fora given patient, a therapeutically effective amount can be determined bymethods known to those of skill in the art.

“Pharmaceutically acceptable salts” refers to those salts which retainthe biological effectiveness and properties of the free bases and whichare obtained by reaction with inorganic acids, for example, hydrochloricacid, hydrobromic acid, sulfuric acid, nitric acid, and phosphoric acidor organic acids such as sulfonic acid, carboxylic acid, organicphosphoric acid, methanesulfonic acid, ethanesulfonic acid,p-toluenesulfonic acid, citric acid, fumaric acid, maleic acid, succinicacid, benzoic acid, salicylic acid, lactic acid, tartaric acid (e.g. (+)or (−)-tartaric acid or mixtures thereof), amino acids (e.g. (+) or(−)-amino acids or mixtures thereof), and the like. These salts can beprepared by methods known to those skilled in the art.

Certain compounds of Formula (I) which have acidic substituents mayexist as salts with pharmaceutically acceptable bases. The presentdisclosure includes such salts. Examples of such salts include sodiumsalts, potassium salts, lysine salts and arginine salts. These salts maybe prepared by methods known to those skilled in the art.

Certain compounds of Formula (I) and their salts may exist in more thanone crystal form and the present disclosure includes each crystal formand mixtures thereof.

Certain compounds of Formula (I) and their salts may also exist in theform of solvates, for example hydrates, and the present disclosureincludes each solvate and mixtures thereof.

Certain compounds of Formula (I) may contain one or more chiral centers,and exist in different optically active forms. When compounds of Formula(I) contain one chiral center, the compounds exist in two enantiomericforms and the present disclosure includes both enantiomers and mixturesof enantiomers, such as racemic mixtures. The enantiomers may beresolved by methods known to those skilled in the art, for example byformation of diastereoisomeric salts which may be separated, forexample, by crystallization; formation of diastereoisomeric derivativesor complexes which may be separated, for example, by crystallization,gas-liquid or liquid chromatography; selective reaction of oneenantiomer with an enantiomer-specific reagent, for example enzymaticesterification; or gas-liquid or liquid chromatography in a chiralenvironment, for example on a chiral support for example silica with abound chiral ligand or in the presence of a chiral solvent. It will beappreciated that where the desired enantiomer is converted into anotherchemical entity by one of the separation procedures described above, afurther step is required to liberate the desired enantiomeric form.Alternatively, specific enantiomers may be synthesized by asymmetricsynthesis using optically active reagents, substrates, catalysts orsolvents, or by converting one enantiomer into the other by asymmetrictransformation.

When a compound of Formula (I) contains more than one chiral center, itmay exist in diastereoisomeric forms. The diastereoisomeric compoundsmay be separated by methods known to those skilled in the art, forexample chromatography or crystallization and the individual enantiomersmay be separated as described above. The present disclosure includeseach diastereoisomer of compounds of Formula (I) (and mixtures thereof.

Certain compounds of Formula (I) may exist in different tautomeric formsor as different geometric isomers, and the present disclosure includeseach tautomer and/or geometric isomer of compounds of Formula (I) andmixtures thereof.

Certain compounds of Formula (I) may exist in different stableconformational forms which may be separable. Torsional asymmetry due torestricted rotation about an asymmetric single bond, for example becauseof steric hindrance or ring strain, may permit separation of differentconformers. The present disclosure includes each conformational isomerof compounds of Formula (I) and mixtures thereof.

Certain compounds of Formula (I) may exist in zwitterionic form and thepresent disclosure includes each zwitterionic form of compounds ofFormula (I) (and mixtures thereof.

As used herein the term “pro-drug” refers to an agent which is convertedinto the parent drug in vivo by some physiological chemical process(e.g., a prodrug on being brought to the physiological pH is convertedto the desired drug form). Pro-drugs are often useful because, in somesituations, they may be easier to administer than the parent drug. Theymay, for instance, be bioavailable by oral administration whereas theparent drug is not. The pro-drug may also have improved solubility inpharmacological compositions over the parent drug. An example, withoutlimitation, of a pro-drug would be a compound of the present disclosurewherein it is administered as an ester (the “pro-drug”) to facilitatetransmittal across a cell membrane where water solubility is notbeneficial, but then it is metabolically hydrolyzed to the carboxylicacid once inside the cell where water solubility is beneficial.

Pro-drugs have many useful properties. For example, a pro-drug may bemore water soluble than the ultimate drug, thereby facilitatingintravenous administration of the drug. A pro-drug may also have ahigher level of oral bioavailability than the ultimate drug. Afteradministration, the prodrug is enzymatically or chemically cleaved todeliver the ultimate drug in the blood or tissue.

Exemplary pro-drugs upon cleavage release the corresponding free acid,and such hydrolyzable ester-forming residues of the compounds of thisdisclosure include but are not limited to carboxylic acid substituentswherein the free hydrogen is replaced by (C₁-C₄)alkyl,(C₁-C₁₂)alkanoyloxymethyl, (C₄-C₉)1-(alkanoyloxy)ethyl,1-methyl-1-(alkanoyloxy)-ethyl having from 5 to 10 carbon atoms,alkoxycarbonyloxymethyl having from 3 to 6 carbon atoms,1-(alkoxycarbonyloxy)ethyl having from 4 to 7 carbon atoms,1-methyl-1-(alkoxycarbonyloxy)ethyl having from 5 to 8 carbon atoms.N-(alkoxycarbonyl)aminomethyl having from 3 to 9 carbon atoms,1-(N-(alkoxycarbonyl)amino)ethyl having from 4 to 10 carbon atoms,3-phthalidyl, 4-crotonolactonyl, gamma-butyrolacton-4-yl,di-N,N—(C₁-C₂)alkylamino(C₂-C₃)alkyl (such as β-dimethylaminoethyl),carbamoyl-(C₁-C₂)alkyl, N,N-di(C₁-C₂)-alkylcarbamoyl-(C₁-C₂)alkyl andpiperidino-, pyrrolidino- or morpholino(C₂-C₃)alkyl.

Other exemplary pro-drugs release an alcohol of Formula (I) wherein thefree hydrogen of the hydroxyl substituent (e.g., R¹ contains hydroxyl)is replaced by (C₁-C₆)alkanoyloxymethyl, 1-((C₁-C₆)alkanoyloxy)ethyl,1-methyl-1-((C₁-C₆)alkanoyloxy)ethyl, (C₁-C₁₂)alkoxycarbonyloxymethyl,N—(C₁-C₆)alkoxycarbonylamino-methyl, succinoyl, (C₁-C₆)alkanoyl,α-amino(C₁-C₄)alkanoyl, arylactyl and α-aminoacyl, orα-aminoacyl-α-aminoacyl wherein said α-aminoacyl moieties areindependently any of the naturally occurring L-amino acids found inproteins, P(O)(OH)₂, —P(O)(O(C₁-C₆)alkyl)₂ or glycosyl (the radicalresulting from detachment of the hydroxyl of the hemiacetal of acarbohydrate).

The term “heterocyclic,” “heterocyclyl” or “heterocyclylene,” as usedherein, include non-aromatic, ring systems, including, but not limitedto, monocyclic, bicyclic, tricyclic and spirocyclic rings, which can becompletely saturated or which can contain one or more units ofunsaturation, for the avoidance of doubt, the degree of unsaturationdoes not result in an aromatic ring system) and have 5 to 12 atomsincluding at least one heteroatom, such as nitrogen, oxygen, or sulfur.For purposes of exemplification, which should not be construed aslimiting the scope of this disclosure, the following are examples ofheterocyclic rings: azepinyl, azetidinyl, indolinyl, isoindolinyl,morpholinyl, piperazinyl, piperidinyl, pyrrolidinyl, quinucludinyl,thiomorpholinyl, tetrahydropyranyl, tetrahydrofuranyl,tetrahydroindolyl, thiomorpholinyl and tropanyl.

The term “heteroaryl” or “heteroarylene” as used herein, includearomatic ring systems, including, but not limited to, monocyclic,bicyclic and tricyclic rings, and have 5 to 12 atoms including at leastone heteroatom, such as nitrogen, oxygen, or sulfur. For purposes ofexemplification, which should not be construed as limiting the scope ofthis disclosure: azaindolyl, benzo(b)thienyl, benzimidazolyl,benzofuranyl, benzoxazolyl, benzothiazolyl, benzothiadiazolyl,benzoxadiazolyl, furanyl, imidazolyl, imidazopyridinyl, indolyl,indazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, oxazolyl, purinyl,pyranyl, pyrazinyl, pyrazolyl, pyridinyl, pyrimidinyl, pyrrolyl,pyrrolo[2,3-d]pyrimidinyl, pyrazolo[3,4-d]pyrimidinyl, quinolinyl,quinazolinyl, triazolyl, thiazolyl, thiophenyl, tetrazolyl,thiadiazolyl, thienyl, 6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyrazinyl,6H-imidazo[1,5-a]pyrrolo[2,3-e]pyrazinyl,1,6-dihydropyrazolo[3,4-d]pyrrolo[2,3-b]pyridine,3H-3,4,6,8a-tetraaza-asindacenyl,3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazinyl,pyrazolo[3,4-d]pyrrolo[2,3-b]pyridinyl,1,6-dihydro-1,2,5,6-tetraza-as-indacenyl, 3H-3,4,8a-triaza-as-indacenyl,6H-3-oxa-2,5,6-triaza-as-indacenyl,3,6-dihydro-2,3,6-tetraaza-as-indacenyl,1,6-dihydro-dipyrrolo[2,3-b;2′3′-d]pyridinyl,6H-3-thia-2,5,6-triaza-as-indacenyl,4,5-dihydro-1H-benzo[b]azepin-2(3H)-one, 3,4-dihydroquinolin-2(1H)-one,2H-benzo[b][1,4]oxazin-3(4H)-one, or6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazinyl or1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine.

As used herein, “alkyl,” “alkylene” or notations such as “(C₁-C₈)”include straight chained or branched hydrocarbons which are completelysaturated. Examples of alkyls are methyl, ethyl, propyl, isopropyl,butyl, pentyl, hexyl and isomers thereof. As used herein, “alkenyl,”“alkenylene,” “alkynylene” and “alkynyl” means C₂-C₈ and includesstraight chained or branched hydrocarbons which contain one or moreunits of unsaturation, one or more double bonds for alkenyl and one ormore triple bonds for alkynyl.

As used herein, “aromatic” groups (or “aryl” or “arylene” groups)include aromatic carbocyclic ring systems (e.g. phenyl) and fusedpolycyclic aromatic ring systems (e.g. naphthyl, biphenyl and1,2,3,4-tetrahydronaphthyl).

As used herein, “cycloalkyl” or “cycloalkylene” means C₃-C₁₂ monocyclicor multicyclic (e.g., bicyclic, tricyclic, spirocyclic, etc.)hydrocarbons that is completely saturated. Examples of a cycloalkylgroup are cyclopropyl, cyclobutyl, cyclopentyl, bicyclo[1.1.1]pentyl,and cyclohexyl.

As used herein, “cycloalkenyl” means C₃-C₁₂ monocyclic or multicyclic(e.g., bicyclic, tricyclic, spirocyclic, etc.) hydrocarbons that has oneor more unsaturated bonds but does not amount to an aromatic group.Examples of a cycloalkenyl group are cyclopentenyl and cyclohexenyl.

As used herein, many moieties or substituents are termed as being either“substituted” or “optionally substituted”. When a moiety is modified byone of these terms, unless otherwise noted, it denotes that any portionof the moiety that is known to one skilled in the art as being availablefor substitution can be substituted, which includes one or moresubstituents, where if more than one substituent then each substituentis independently selected. Such means for substitution are well-known inthe art and/or taught by the instant disclosure. For purposes ofexemplification, which should not be construed as limiting the scope ofthis disclosure, some examples of groups that are substituents are:(C₁-C₈)alkyl groups, (C₂-C₈)alkenyl groups, (C₂-C₈)alkynyl groups,(C₃-C₁₀)cycloalkyl groups, halogen (F, Cl, Br or I), halogenated(C₁-C₈)alkyl groups (for example but not limited to —CF₃),—O—(C₁-C₈)alkyl groups, ═O, ═CH₂, —OH, —CH₂OH, —CH₂OCH₃, —CH₂NH₂,(C₁-C₄)alkyl-OH, —CH₂CH₂OCH₂CH₃, —S—(C₁-C₈)alkyl groups, —SH,—NH(C₁-C₈)alkyl groups, —N((C₁-C₈)alkyl)₂ groups, —NH₂, —C(O)NH₂,—CH₂NHC(O)(C₁-C₄)alkyl, —CH₂NHC(O)CH₂Cl, —CH₂NHC(O)CH₂CN,—CH₂NHC(O)CH₂CH₂N(CH₃)₂, —CH₂NHC(O)C(═CH₂)CH₃, —CH₂NHC(O)(C₂-C₄)alkynyl,—CH₂NHC(O)CH₂CH₂-piperidinyl, —(C₁-C₄)alkyl-morpholinyl,—CH₂NHC(O)CH₂O-phenyl wherein the phenyl is optionally substituted withhalogen, (C₁-C₄)alkoxy, —C(O)(C₁-C₄)alkyl, —C(O)(C₁-C₄)alkoxy,—C(O)N(H)₂, —C(O)N(CH₃)₂, —C(O)(C₁-C₆)heteroaryl, —N(CH₃)₂,—NHC(O)(C₁-C₄)alkyl, —NHC(O)(C₂-C₄)alkenyl, —NHC(O)CH₂CN,—S(O)₂(C₁-C₄)alkyl, —S(O)₂(C₁-C₆)heteroaryl, —S(O)₂(C₁-C₆)(C₁-C₆)heterocyclyl, 4-methylpiperazinecarbonyl, —(C₁-C₄)alkylC(O)NH₂,—C(O)NH(C₁-C₈)alkyl groups, —C(O)N((C₁-C₈)alkyl)₂,—C(O)N(H)(C₃-C₈)cycloalkyl groups, —C(O)(C₁-C₄)alkyl-OH,—(C₁-C₄)alkyl(C₁-C₄)alkoxy, —NHC(O)H, —NHC(O)(C₁-C₈)alkyl groups,—NHC(O)(C₃-C₈)cycloalkyl groups, —N((C₁-C₈)alkyl)C(O)H,—N((C₁-C₈)alkyl)C(O)(C₁-C₈)alkyl groups, —NHC(O)NH₂,—NHC(O)NH(C₁-C₈)alkyl groups, —N((C₁-C₈)alkyl)C(O)NH₂ groups.—NHC(O)N((C₁-C₈)alkyl)₂ groups, —N((C₁-C₈)alkyl)C(O)N((C₁-C₈)alkyl)₂groups, —N((C₁-C₈)alkyl)C(O)NH((C₁-C₈)alkyl), —NHCH₂-heteroaryl, benzyl,—OCH₂-heteroaryl, —C(O)H, —C(O)(C₁-C₈)alkyl groups, —CN, —NO₂,—S(O)(C₁-C₈)alkyl groups, —S(O)₂(C₁-C₈)alkyl groups,—S(O)₂N((C₁-C₈)alkyl)₂ groups, —S(O)₂NH(C₁-C₈)alkyl groups,—S(O)₂NH(C₃-C₈)cycloalkyl groups, —S(O)₂NH₂ groups, —NHS(O)₂(C₁-C₈)alkylgroups, —N((C₁-C₈)alkyl)S(O)₂(C₁-C₈)alkyl groups,—(C₁-C₈)alkyl-O—(C₁-C₈)alkyl groups-, —O—(C₁-C₈)alkyl-O—(C₁-C₈)alkylgroups, —C(O)OH, —C(O)O(C₁-C₈)alkyl groups, NHOH, NHO(C₁-C₈)alkylgroups, —O-halogenated (C₁-C₈)alkyl groups (for example but not limitedto —OCF₃), —S(O)₂-halogenated (C₁-C₈)alkyl groups (for example but notlimited to —S(O)₂CF₃), —S-halogenated (C₁-C₈)alkyl groups (for examplebut not limited to —SCF₃), —(C₁-C₆)heterocyclyl (for example but notlimited to pyrrolidine, tetrahydrofuran, pyran or morpholine),—(C₁-C₆)heteroaryl (for example but not limited to tetrazole, imidazole,furan, pyrazine or pyrazole), -phenyl, optionally substituted benzyl,—NHC(O)O—(C₁-C₆)alkyl groups, —N((C₁-C₆)alkyl)C(O)O—(C₁-C₆)alkyl groups,—C(═NH)—(C₁-C₆)alkyl groups, —C(═NOH)—(C₁-C₆)alkyl groups, or—C(═N—O—(C₁-C₈)alkyl)-(C₁-C₆)alkyl groups.

The term “kit” as used herein refers to a packaged product comprisingcomponents with which to administer a compound of Formula (I) of thedisclosure for treatment of an autoimmune disorder. The kit preferablycomprises a box or container that holds the components of the kit. Thebox or container is affixed with a label or a Food and DrugAdministration approved protocol. The box or container holds componentsof the disclosure which are preferably contained within plastic,polyethylene, polypropylene, ethylene, or propylene vessels. The vesselscan be capped-tubes or bottles. The kit can also include instructionsfor administering a compound of Formula (I).

One or more compounds of this disclosure can be administered to a humanpatient by themselves or in pharmaceutical compositions where they aremixed with biologically suitable carriers or excipient(s) at doses totreat or ameliorate a disease or condition as described herein. Mixturesof these compounds can also be administered to the patient as a simplemixture or in suitable formulated pharmaceutical compositions. Atherapeutically effective dose refers to that amount of the compound orcompounds sufficient to result in the prevention or attenuation of adisease or condition as described herein. Techniques for formulation andadministration of the compounds of the instant application may be foundin references well known to one of ordinary skill in the art, such as“Remington's Pharmaceutical Sciences,” Mack Publishing Co., Easton, Pa.,latest edition.

Suitable routes of administration may, for example, include oral,eyedrop, rectal, transmucosal, topical, or intestinal administration;parenteral delivery, including intramuscular, subcutaneous,intramedullary injections, as well as intrathecal, directintraventricular, intravenous, intraperitoneal, intranasal, orintraocular injections.

Alternatively, one may administer the compound in a local rather than asystemic manner, for example, via injection of the compound directlyinto an edematous site, often in a depot or sustained releaseformulation.

Furthermore, one may administer the drug in a targeted drug deliverysystem, for example, in a liposome coated with endothelial cell-specificantibody.

The pharmaceutical compositions of the present disclosure may bemanufactured in a manner that is itself known, e.g., by means ofconventional mixing, dissolving, granulating, dragee-making, levigating,emulsifying, encapsulating, entrapping or lyophilizing processes.

Pharmaceutical compositions for use in accordance with the presentdisclosure thus may be formulated in a conventional manner using one ormore physiologically acceptable carriers comprising excipients andauxiliaries which facilitate processing of the active compounds intopreparations which can be used pharmaceutically. Proper formulation isdependent upon the route of administration chosen.

For injection, the agents of the disclosure may be formulated in aqueoussolutions, preferably in physiologically compatible buffers such asHanks' solution, Ringer's solution, or physiological saline buffer. Fortransmucosal administration, penetrants appropriate to the barrier to bepermeated are used in the formulation. Such penetrants are generallyknown in the art.

For oral administration, the compounds can be formulated readily bycombining the active compounds with pharmaceutically acceptable carrierswell known in the art. Such carriers enable the compounds of thedisclosure to be formulated as tablets, pills, dragees, capsules,liquids, gels, syrups, slurries, suspensions and the like, for oralingestion by a patient to be treated. Pharmaceutical preparations fororal use can be obtained by combining the active compound with a solidexcipient, optionally grinding a resulting mixture, and processing themixture of granules, after adding suitable auxiliaries, if desired, toobtain tablets or dragee cores. Suitable excipients are, in particular,fillers such as sugars, including lactose, sucrose, mannitol, orsorbitol; cellulose preparations such as, for example, maize starch,wheat starch, rice starch, potato starch, gelatin, gum tragacanth,methyl cellulose, hydroxypropylmethyl-cellulose, sodiumcarboxymethylcellulose, and/or polyvinylpyrrolidone (PVP). If desired,disintegrating agents may be added, such as the cross-linked polyvinylpyrrolidone, agar, or alginic acid or a salt thereof such as sodiumalginate.

Dragee cores are provided with suitable coatings. For this purpose,concentrated sugar solutions may be used, which may optionally containgum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethyleneglycol, and/or titanium dioxide, lacquer solutions, and suitable organicsolvents or solvent mixtures. Dyestuffs or pigments may be added to thetablets or dragee coatings for identification or to characterizedifferent combinations of active compound doses.

Pharmaceutical preparations that can be used orally include push-fitcapsules made of gelatin, as well as soft, sealed capsules made ofgelatin and a plasticizer, such as glycerol or sorbitol. The push-fitcapsules can contain the active ingredients in admixture with fillersuch as lactose, binders such as starches, and/or lubricants such astalc or magnesium stearate and, optionally, stabilizers. In softcapsules, the active compounds may be dissolved or suspended in suitableliquids, such as fatty oils, liquid paraffin, or liquid polyethyleneglycols. In addition, stabilizers may be added. All formulations fororal administration should be in dosages suitable for suchadministration.

For buccal administration, the compositions may take the form of tabletsor lozenges formulated in conventional manner.

For administration by inhalation, the compounds for use according to thepresent disclosure are conveniently delivered in the form of an aerosolspray presentation from pressurized packs or a nebuliser, with the useof a suitable propellant, e.g., dichlorodifluoromethane,trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide orother suitable gas. In the case of pressurized aerosol the dosage unitmay be determined by providing a valve to deliver a metered amount.Capsules and cartridges of e.g. gelatin for use in an inhaler orinsufflator may be formulated containing a powder mix of the compoundand a suitable powder base such as lactose or starch.

The compounds can be formulated for parenteral administration byinjection, e.g. bolus injection or continuous infusion. Formulations forinjection may be presented in unit dosage form, e.g. in ampoules or inmulti-dose containers, with an added preservative. The compositions maytake such forms as suspensions, solutions or emulsions in oily oraqueous vehicles, and may contain formulatory agents such as suspending,stabilizing and/or dispersing agents.

Pharmaceutical formulations for parenteral administration includeaqueous solutions of the active compounds in water-soluble form.Additionally, suspensions of the active compounds may be prepared asappropriate oily injection suspensions. Suitable lipophilic solvents orvehicles include fatty oils such as sesame oil, or synthetic fatty acidesters, such as ethyl oleate or triglycerides, or liposomes. Aqueousinjection suspensions may contain substances which increase theviscosity of the suspension, such as sodium carboxymethyl cellulose,sorbitol, or dextran. Optionally, the suspension may also containsuitable stabilizers or agents which increase the solubility of thecompounds to allow for the preparation of highly concentrated solutions.

Alternatively, the active ingredient may be in powder form forconstitution with a suitable vehicle, e.g., sterile pyrogen-free water,before use.

The compounds may also be formulated in rectal compositions such assuppositories or retention enemas, e.g., containing conventionalsuppository bases such as cocoa butter or other glycerides.

In addition to the formulations described previously, the compounds mayalso be formulated as a depot preparation. Such long acting formulationsmay be administered by implantation (for example subcutaneously orintramuscularly or by intramuscular injection). Thus, for example, thecompounds may be formulated with suitable polymeric or hydrophobicmaterials (for example as an emulsion in an acceptable oil) or ionexchange resins, or as sparingly soluble derivatives, for example, as asparingly soluble salt.

An example of a pharmaceutical carrier for the hydrophobic compounds ofthe disclosure is a cosolvent system comprising benzyl alcohol, anonpolar surfactant, a water-miscible organic polymer, and an aqueousphase. The cosolvent system may be the VPD co-solvent system. VPD is asolution of 3% w/v benzyl alcohol, 8% w/v of the nonpolar surfactantpolysorbate 80, and 65% w/v polyethylene glycol 300, made up to volumein absolute ethanol. The VPD co-solvent system (VPD:5W) consists of VPDdiluted 1:1 with a 5% dextrose in water solution. This co-solvent systemdissolves hydrophobic compounds well, and itself produces low toxicityupon systemic administration. Naturally, the proportions of a co-solventsystem may be varied considerably without destroying its solubility andtoxicity characteristics. Furthermore, the identity of the co-solventcomponents may be varied: for example, other low-toxicity nonpolarsurfactants may be used instead of polysorbate 80; the fraction size ofpolyethylene glycol may be varied; other biocompatible polymers mayreplace polyethylene glycol, e.g. polyvinyl pyrrolidone; and othersugars or polysaccharides may substitute for dextrose.

Alternatively, other delivery systems for hydrophobic pharmaceuticalcompounds may be employed. Liposomes and emulsions are well knownexamples of delivery vehicles or carriers for hydrophobic drugs. Certainorganic solvents such as dimethylsulfoxide also may be employed,although usually at the cost of greater toxicity. Additionally, thecompounds may be delivered using a sustained-release system, such assemipermeable matrices of solid hydrophobic polymers containing thetherapeutic agent. Various sustained-release materials have beenestablished and are well known by those skilled in the art.Sustained-release capsules may, depending on their chemical nature,release the compounds for a few weeks up to over 100 days. Depending onthe chemical nature and the biological stability of the therapeuticreagent, additional strategies for protein stabilization may beemployed.

The pharmaceutical compositions also may comprise suitable solid or gelphase carriers or excipients. Examples of such carriers or excipientsinclude but are not limited to calcium carbonate, calcium phosphate,various sugars, starches, cellulose derivatives, gelatin, and polymerssuch as polyethylene glycols.

Many of the compounds of the disclosure may be provided as salts withpharmaceutically compatible counter ions. Pharmaceutically compatiblesalts may be formed with many acids, including but not limited tohydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic, etc.Salts tend to be more soluble in aqueous or other protonic solvents thanare the corresponding free base forms.

Pharmaceutical compositions suitable for use in the present disclosureinclude compositions wherein the active ingredients are contained in aneffective amount to achieve its intended purpose. More specifically, atherapeutically effective amount means an amount effective to preventdevelopment of or to alleviate the existing symptoms of the subjectbeing treated. Determination of the effective amounts is well within thecapability of those skilled in the art.

For any compound used in a method of the present disclosure, thetherapeutically effective dose can be estimated initially from cellularassays. For example, a dose can be formulated in cellular and animalmodels to achieve a circulating concentration range that includes theIC₅₀ as determined in cellular assays (e.g., the concentration of thetest compound which achieves a half-maximal inhibition of a givenprotein kinase activity). In some cases it is appropriate to determinethe IC₅₀ in the presence of 3 to 5% serum albumin since such adetermination approximates the binding effects of plasma protein on thecompound. Such information can be used to more accurately determineuseful doses in humans. Further, the most preferred compounds forsystemic administration effectively inhibit protein kinase signaling inintact cells at levels that are safely achievable in plasma.

A therapeutically effective dose refers to that amount of the compoundthat results in amelioration of symptoms in a patient. Toxicity andtherapeutic efficacy of such compounds can be determined by standardpharmaceutical procedures in cell cultures or experimental animals,e.g., for determining the maximum tolerated dose (MTD) and the ED₅₀(effective dose for 50% maximal response). The dose ratio between toxicand therapeutic effects is the therapeutic index and it can be expressedas the ratio between MTD and ED₅₀. Compounds which exhibit hightherapeutic indices are preferred. The data obtained from these cellculture assays and animal studies can be used in formulating a range ofdosage for use in humans. The dosage of such compounds lies preferablywithin a range of circulating concentrations that include the ED₅₀ withlittle or no toxicity. The dosage may vary within this range dependingupon the dosage form employed and the route of administration utilized.The exact formulation, route of administration and dosage can be chosenby the individual physician in view of the patient's condition (see,e.g., Fingl et al., 1975, in The Pharmacological Basis of Therapeutics,Ch. 1, p. 1). In the treatment of crises, the administration of an acutebolus or an infusion approaching the MTD may be required to obtain arapid response.

Dosage amount and interval may be adjusted individually to provideplasma levels of the active moiety which are sufficient to maintain thekinase modulating effects, or minimal effective concentration (MEC). TheMEC will vary for each compound but can be estimated from in vitro data;e.g. the concentration necessary to achieve 50-90% inhibition of proteinkinase using the assays described herein. Dosages necessary to achievethe MEC will depend on individual characteristics and route ofadministration. However, HPLC assays or bioassays can be used todetermine plasma concentrations.

Dosage intervals can also be determined using the MEC value. Compoundsshould be administered using a regimen which maintains plasma levelsabove the MEC for 10-90% of the time, preferably between 30-90% and mostpreferably between 50-90% until the desired amelioration of symptoms isachieved. In cases of local administration or selective uptake, theeffective local concentration of the drug may not be related to plasmaconcentration.

The amount of composition administered will, of course, be dependent onthe subject being treated, on the subject's weight, the severity of theaffliction, the manner of administration and the judgment of theprescribing physician.

The compositions may, if desired, be presented in a pack or dispenserdevice which may contain one or more unit dosage forms containing theactive ingredient. The pack may for example comprise metal or plasticfoil, such as a blister pack. The pack or dispenser device may beaccompanied by instructions for administration. Compositions comprisinga compound of the disclosure formulated in a compatible pharmaceuticalcarrier may also be prepared, placed in an appropriate container, andlabelled for treatment of an indicated condition.

In some formulations it may be beneficial to use the compounds of thepresent disclosure in the form of particles of very small size, forexample as obtained by fluid energy milling.

The use of compounds of the present disclosure in the manufacture ofpharmaceutical compositions is illustrated by the following description.In this description the term “active compound” denotes any compound ofthe disclosure but particularly any compound which is the final productof one of the following Examples.

a) Capsules

In the preparation of capsules, 10 parts by weight of active compoundand 240 parts by weight of lactose can be de-aggregated and blended. Themixture can be filled into hard gelatin capsules, each capsulecontaining a unit dose or part of a unit dose of active compound.

b) Tablets

Tablets can be prepared, for example, from the following ingredients.

Parts by weight Active compound 10 Lactose 190 Maize starch 22Polyvinylpyrrolidone 10 Magnesium stearate 3

The active compound, the lactose and some of the starch can bede-aggregated, blended and the resulting mixture can be granulated witha solution of the polyvinylpyrrolidone in ethanol. The dry granulate canbe blended with the magnesium stearate and the rest of the starch. Themixture is then compressed in a tabletting machine to give tablets eachcontaining a unit dose or a part of a unit dose of active compound.

c) Enteric Coated Tablets

Tablets can be prepared by the method described in (b) above. Thetablets can be enteric coated in a conventional manner using a solutionof 20% cellulose acetate phthalate and 3% diethyl phthalate inethanol:dichloromethane (1:1).

d) Suppositories

In the preparation of suppositories, for example, 100 parts by weight ofactive compound can be incorporated in 1300 parts by weight oftriglyceride suppository base and the mixture formed into suppositorieseach containing a therapeutically effective amount of active ingredient.

In the compositions of the present disclosure the active compound may,if desired, be associated with other compatible pharmacologically activeingredients. For example, the compounds of this disclosure can beadministered in combination with another therapeutic agent that is knownto treat a disease or condition described herein. For example, with oneor more additional pharmaceutical agents that inhibit or prevent theproduction of VEGF or angiopoietins, attenuate intracellular responsesto VEGF or angiopoietins, block intracellular signal transduction,inhibit vascular hyperpermeability, reduce inflammation, or inhibit orprevent the formation of edema or neovascularization. The compounds ofthe disclosure can be administered prior to, subsequent to orsimultaneously with the additional pharmaceutical agent, whichevercourse of administration is appropriate. The additional pharmaceuticalagents include, but are not limited to, anti-edemic steroids, NSAIDS,ras inhibitors, anti-IL1 agents, antihistamines, PAF-antagonists, COX-1inhibitors, COX-2 inhibitors, NO synthase inhibitors, Akt/PTBinhibitors, IGF-1R inhibitors, PKC inhibitors, PI3 kinase inhibitors,calcineurin inhibitors and immunosuppressants. The compounds of thedisclosure and the additional pharmaceutical agents act eitheradditively or synergistically. Thus, the administration of such acombination of substances that inhibit angiogenesis, vascularhyperpermeability and/or inhibit the formation of edema can providegreater relief from the deletrious effects of a hyperproliferativedisorder, angiogenesis, vascular hyperpermeability or edema than theadministration of either substance alone. In the treatment of malignantdisorders combinations with antiproliferative or cytotoxicchemotherapies or radiation are included in the scope of the presentdisclosure.

The present disclosure also comprises the use of a compound of Formula(I) as a medicament.

A further aspect of the present disclosure provides the use of acompound of Formula (I) or a salt thereof in the manufacture of amedicament for treating vascular hyperpermeability,angiogenesis-dependent disorders, proliferative diseases and/ordisorders of the immune system in mammals, particularly human beings.

The present disclosure also provides a method of treating vascularhyperpermeability, inappropriate neovascularization, proliferativediseases and/or disorders of the immune system which comprises theadministration of a therapeutically effective amount of a compound ofFormula (I) to a mammal, particularly a human being, in need thereof.

ABBREVIATIONS

-   Ac Acetyl-   AcOH Glacial acetic acid-   Aq Aqueous-   9-BBN 9-Borabicyclo[3.3.1]nonane-   Boc t-Butoxycarbonyl-   d Doublet-   DEA Diethylamine-   DIEA N,N-Diisopropylethylamine-   DCM Dichloromethane (methylene chloride)-   dd Doublet of doublets-   DMA N,N-Dimethylacetamide-   DMAP 4-Dimethylaminopyridine-   DMF N,N-Dimethylformamide-   DMSO Dimethyl sulfoxide-   dppf 1,1′-Bis(diphenylphosphino)ferrocene-   EDTA Ethylene diamine tetraacetic acid-   Et₂O Diethyl ether-   EtOAc Ethyl acetate-   EtOH Ethanol-   g Gram(s)-   h Hour(s)-   HATU    1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium    3-oxid hexafluorophosphate-   HEPES N-2-Hydroxyethylpiperazine-N′-2-ethanesulfonic acid-   HPLC High-pressure liquid chromatography-   IPA Isopropyl alcohol-   KOAc Potassium acetate-   LC/MS Liquid chromatography/mass spectrometry-   LiHMDS Lithium bis(trimethylsilyl)amide-   m Multiplet-   M Molar-   m-CPBA 3-Chloroperoxybenzoic acid-   MeCN Acetonitrile-   MeI Iodomethane-   MeOH Methyl alcohol-   min Minute(s)-   mmol Millimole-   MS Mass spectrometry-   MsCl Methanesulfonyl chloride-   n- Normal (nonbranched)-   N Normal-   NA Not obtained or not applicable-   NaBH(OAc)₃ Sodium triacetoxyhydroborate-   NBS N-Bromosuccinimide-   NH₄OAc Ammonium acetate-   NMO 4-Methylmorpholine N-oxide-   NMP N-Methyl-2-pyrrolidinone-   NMR Nuclear magnetic resonance-   pH −log [H⁺]-   PdCl₂(PPh₃)₂ Bis(triphenylphosphine)palladium(II) dichloride-   Pd(OAc)₂ Palladium(II) acetate-   Pd(PPh₃)₄ Tetrakis(triphenylphosphine)palladium(0)-   PPh₃ Triphenylphosphine-   ppm Parts per million-   q Quartet-   R_(t) Retention time-   rt Room temperature-   s Singlet-   SFC Supercritical fluid chromatography-   SPE Solid phase extraction-   Soln Solution-   SM Small molecule-   t Triplet-   TEA Triethylamine-   tert- Tertiary-   TNFα Tumor necrosis factor alpha-   TFA Trifluoroacetic acid-   THF Tetrahydrofuran-   UV Ultraviolet-   wt weight

TNFα FP Competitive Binding Assay

Solution Preparation

-   1. Assay Buffer: Prepare 1× Assay Buffer (Water with 47 mM HEPES, 47    mM NaCl, 0.9 mM EDTA, 0.0071% Triton X-100) by adding 25 mL of 1 M    HEPES, 5 mL of 5 M NaCl, 1 mL of 0.5 M EDTA, and 375 μL of a 10%    Triton X-100 stock to a fresh 500 mL bottle of water.-   2. Assay Mixture: Prepare fresh Assay Mixture containing 20 nM TNFα    trimer (60 nM protein) and 1 nM    2′,7′-difluoro-3′,6′-dihydroxy-N-(2-(2-(2-((4-(isoquinolin-8-yl)-3-(4-(isoquinolin-8-yl)phenethoxy)benzyl)oxy)ethoxy)ethoxy)ethyl)-3-oxo-3H-spiro[isobenzofuran-1,9′-xanthene]-5-carboxamide    probe in 1× Assay Buffer.    Compound Plate Preparation    Manual 12-Point 1:3 Dilution Plates: (384 Well Polypropylene Plates)

Top concentration of compounds, 10 mM in DMSO, dispensed in rows A-O incolumns 1 and 13. Compounds are serially diluted 1:3 with DMSO incolumns 2-12 or 14-24 using a 16-channel Matrix pipettor. Plates storedat −20° C.

Discovery Preps 12-Point 1:3 Dilution Plates: (384 Well Assay Plates)

Top concentration, 5 mM in DMSO, of compounds placed in rows A-O incolumns 1 and 13. Compounds are serially diluted 1:3 with DMSO incolumns 2-12 or 14-24. Compound solutions are dispensed into replicateassay plates at 410 nL per well. Plates stored at 4° C.

TNFα FP Competitive Binding Assay Protocol

-   1. Compound plates warmed to rt.-   2. Fresh Assay Mixture is prepared.-   3. Assay Mixture (20 μL) is dispensed each well of 384 assay plates    using a Thermo Multidrop Combi or 16-channel Matrix pipettor. If    Manual 12-point 1:3 Dilution Plates are to be tested, Assay Mix is    dispensed into empty plates. Discovery Preps 12-point 1:3 Dilution    Plates already contain 410 nL compound solution in DMSO.-   4. For Manual 12-point 1:3 Dilution Plates, 0.7 μL is manually    transferred using a 16-channel Matrix pipettor to replicate assay    plates containing 20 μL Assay Mixture for a final top compound    concentration of 338 μM (3.4% DMSO).-   5. For Discovery Preps 12-point 1:3 Dilution Plates, 20 μL Assay    Mixture added the 410 nL compound solution already in the plates    yields a final top compound concentration of 100 μM (2.0% DMSO).-   6. Background subtraction controls are wells P1-P8 containing only    Assay Buffer. The low % inhibition controls are wells P9-P16    containing only Assay Mix. The high % inhibition are wells P17-P24    containing only 1 nM    2′,7′-difluoro-3′,6′-dihydroxy-N-(2-(2-(2-((4-(isoquinolin-8-yl)-3-(4-(isoquinolin-8-yl)phenethoxy)benzyl)oxy)ethoxy)ethoxy)ethyl)-3-oxo-3H-spiro[isobenzofuran-1,9′-xanthene]-5-carboxamide    probe in 1× Assay Buffer.-   7. Plates are incubated at rt for 18-24 h in 37° C. incubator (CO₂    is off).-   8. Prior to reading the assay, the plates are placed in a dark    cabinet to equilibrate at rt for one hour.-   9. Background-subtracted fluorescence polarization (mP) is measured    using a PerkinElmer Envision plate reader.-   10. Raw data is entered into Assay Explorer and dose-response curves    are generated using a variable slope curve.    Supplies, Materials, and Reagents

Item Vendor Catalog # HEPES (1M) Invitrogen 15630-080 EDTA (0.5M)Invitrogen 15575-038 NaCl (5M) Sigma S5150 Triton X-100 Sigma T8787Water Invitrogen 10977-015 SM-antiTNFα Abbvie2′,7′-difluoro-3′,6′-dihydroxy-N- OregonGreen488(2-(2-(2-((4-(isoquinolin-8-yl)-3- probe (4-(isoquinolin-8-yl)pheneth-oxy)benzyl)oxy)ethoxy)ethoxy)eth- yl)-3-oxo-3H-spiro[isobenzofuran-1,9′-xanthene]-5-carboxamide Corning 3676 Compound Corning 3676 Plate:384 Well Low Volume Black Round Bottom Polystyrene NBS

For the purpose of the Tables and Examples below, the FP binding assayIC₅₀ of each compound is expressed as follows: A=a compound with IC₅₀less than 1 μM, B=a compound with IC₅₀ within the range of 1 μM to 10μM, and C=a compound with a TNFα IC₅₀ greater than 10 μM.

SM-antiTNFα OregonGreen488 Probe

Preparation A: 2-(4-(Isoquinolin-8-yl)phenyl)ethanol

Step 1: 2-(4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethanol

Potassium acetate (4.88 g, 49.7 mmol),4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (7.6 g, 30mmol) and PdCl₂(dppf) (0.91 g, 1.2 mmol) were added to a solution of2-(4-bromophenyl)ethanol (5.0 g, 25 mmol) in 1,4-dioxane (100 mL) underN₂. The mixture was purged with N₂ then stirred under N₂ at about 85° C.for about 12 h. After cooling to rt, water (100 mL) was added and themixture was extracted with EtOAc (2×100 mL). The combined organic layerswere washed with saturated aqueous NaCl (100 mL) and dried over Na₂SO₄,filtered and concentrated under reduced pressure. The residue waspurified via flash chromatography on silica gel (17% EtOAc/petroleumether). The appropriate fractions were collected and concentrated underreduced pressure to give the title compound (6.2 g, 100%). ¹H NMR (400MHz, CDCl₃) δ 7.78 (d, J=7.9 Hz, 2H), 7.29-7.23 (m, 2H), 3.87 (t, J=6.6Hz, 2H), 2.90 (t, J=6.6 Hz, 2H), 1.36 (s, 12H).

Step 2: 2-(4-(Isoquinolin-8-yl)phenyl)ethanol

1,1′-Bis(diphenylphosphino)ferrocenepalladium(II) dichloridedichloromethane complex (0.30 g, 0.40 mmol) was added to a mixture of2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethanol (6.15g, 24.8 mmol), 8-bromoisoquinoline (5.67 g, 27.3 mmol), cesium carbonate(16.6 g, 50.8 mmol), and 1,4-dioxane (60 mL) under N₂. The mixture waspurged with N₂ and then stirred at about 95° C. for about 2 h. Aftercooling to rt, water (200 mL), chloroform (450 mL), and isopropylalcohol (150 mL) were added then the layers were separated. The organiclayer was dried over Na₂SO₄, filtered, and concentrated under reducedpressure. The residue was purified via flash chromatography on silicagel (0-100% EtOAc/heptane). The appropriate fractions were collected andconcentrated under reduced pressure to give the title compound (3.72 g,60%). MS m/z: 250 (M+H)⁺.

Preparation B: Methyl 3-hydroxy-4-(isoquinolin-8-yl)benzoate

Step 1: Methyl3-hydroxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate

Potassium acetate (1.27 g, 13.0 mmol) was added to a solution of methyl4-bromo-3-hydroxybenzoate (1.0 g, 4.3 mmol) in 1,4-dioxane (20 mL) underN₂ followed by addition of4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (2.2 g, 8.7mmol) and 1,1′-bis(diphenylphosphino)ferrocenepalladium(II) dichloride(0.18 g, 0.22 mmol). The mixture was purged with N₂ then stirred atabout 80° C. for about 3 h. The reaction mixture was cooled to rt andwater (50 mL) was added. The mixture was extracted with EtOAc (3×50 mL).The combined organics were dried over Na₂SO₄, filtered, and concentratedunder reduced pressure. The residue was purified via flashchromatography on silica gel (0-10% MeOH/DCM). The appropriate fractionswere combined and concentrated under reduced pressure to give the titlecompound (1.13 g, 94%). ¹H NMR (400 MHz, CDCl₃) δ 7.81 (s, 1H), 7.60 (d,J=8.1 Hz, 1H), 7.50-7.40 (m, 2H), 3.84 (s, 3H), 1.31 (s, 12H).

Step 2: Methyl 3-hydroxy-4-(isoquinolin-8-yl)benzoate

EtOH (100 mL) was added to a mixture of sodium carbonate (2.04 g, 19.2mmol), Pd(OAc)₂ (0.022 g, 0.096 mmol), 8-bromoisoquinoline (2.00 g, 9.61mmol), methyl3-hydroxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate (2.67g, 9.61 mmol), anddicyclohexyl(2′,6′-dimethoxy-[1,1′-biphenyl]-2-yl)phosphine (0.079 g,0.19 mmol) under N₂. The mixture was degassed with N₂ and then heated toabout 80° C. for about 16 h. Water (200 mL) was added and the resultingsolid was collected by filtration then dried to give the title compound(1.27 g, 47%). MS m/z: 280 (M+H)⁺.

Preparation C: SM-antiTNFα OregonGreen488 Probe(2′,7′-difluoro-3′,6′-dihydroxy-N-(2-(2-(2-((4-(isoquinolin-8-yl)-3-(4-(isoquinolin-8-yl)phenethoxy)benzyl)oxy)ethoxy)ethoxy)ethyl)-3-oxo-3H-spiro[isobenzofuran-1,9′-xanthene]-5-carboxamide)

Step 1: Methyl4-(isoquinolin-8-yl)-3-(4-(isoquinolin-8-yl)phenethoxy)benzoate

Cyanomethylenetributylphosphorane (0.90 mL, 3.4 mmol) was added to amixture of methyl 3-hydroxy-4-(isoquinolin-8-yl)benzoate (800 mg, 2.86mmol) (Preparation B), 2-(4-(isoquinolin-8-yl)phenyl)ethanol (714 mg,2.86 mmol) (Preparation A), and toluene (30 mL). After stirring forabout 4 h at about 100° C., the reaction mixture was allowed to cool tort. Tri-n-butylphosphine (0.71 mL, 2.9 mmol) and(E)-N1,N1,N2,N2-tetramethyldiazene-1,2-dicarboxamide (493 mg, 2.86 mmol)were added respectively. After stirring at rt for about 18 h, theorganic volatiles were removed under reduced pressure. The residue waspurified via flash chromatography on silica gel (20% acetone/hexanes).The appropriate fractions were collected and concentrated under reducedpressure to give the title compound (1.07 g, 73%). MS m/z: 511 (M+H)⁺.

Step 2:(4-(Isoquinolin-8-yl)-3-(4-(isoquinolin-8-yl)phenethoxy)phenyl)methanol

Lithium aluminum hydride (1 M solution in THF, 0.4 mL, 0.4 mmol) wasadded to a solution of methyl 4-(isoquinolin-8-yl)phenethoxy)benzoate(204 mg, 0.400 mmol) and THF (3.6 mL) under N₂ at about 0° C. Afterabout 1 h, 10% aqueous sodium potassium tartrate (6 mL) was added. Thereaction was allowed to warm to t. After about 10 min at rt, EtOAc (10mL) was added. The layers were separated and the aqueous layer wasextracted with EtOAc (10 mL). The combined organics were washed withsaturated aqueous NaCl (10 mL), dried over MgSO₄, filtered andconcentrated under reduced pressure. The residue was purified via flashchromatography on silica gel (0-5% McOH/CHCl₃). The appropriatefractions were collected and concentrated under reduced pressure to givethe title compound (169 mg, 88%). MS m/z: 483 (M+H)⁺.

Step 3:2-(2-(2-((4-(Isoquinolin-8-yl)-3-(4-(isoquinolin-8-yl)phenethoxy)benzyl)oxy)ethoxy)ethoxy)ethanamine

(4-(Isoquinolin-8-yl)-3-(4-(isoquinolin-8-yl)phenethoxy)phenyl)methanol(31 mg, 0.064 mmol) and2,2-dimethyl-4-oxo-3,8,11-trioxa-5-azatridecan-13-yl methanesulfonate(32 mg, 0.096 mmol) were combined in DMF (1 mL). Sodium hydride (10 mg,0.26 mmol) was added in one portion. The reaction was stirred at rt forabout 16 h. 50% MeCN/water (1 mL) was added and the resulting mixturewas lyophilized to dryness. The residue was diluted with 90% DMSO/water(3 mL) and purified in one injection using RP-HPLC (Waters Deltapak C18200×25 mm column) with time collection. The appropriate peak wascollected and lyophilized. The residue was dissolved in TFA (2 mL) andshaken at rt for about 1 min. The volatiles were evaporated under astream of dry nitrogen gas. The film was dissolved in 50% MeCN/water (1mL) and lyophilized to give a trifluoroacetate salt of the titlecompound (10 mg, 19%). MS m/z: 614 (M+H)⁺.

Step 4:2′,7′-difluoro-3′,6′-dihydroxy-N-(2-(2-(2-((4-(isoquinolin-8-yl)-3-(4-(isoquinolin-8-yl)phenethoxy)benzyl)oxy)ethoxy)ethoxy)ethyl)-3-oxo-3H-spiro[isobenzofuran-1,9′-xanthene]-5-carboxamide

2-(2-(2-((4-(Isoquinolin-8-yl)-3-(4-(isoquinolin-8-yl)phenethoxy)benzyl)oxy)ethoxy)ethoxy)ethanamine(9.38 mg, 9.82 μmol) and 2,5-dioxopyrrolidin-1-yl2′,7′-difluoro-3′,6′-dihydroxy-3-oxo-3H-spiro[isobenzofuran-1,9′-xanthene]-5-carboxylate(5 mg, 10 μmol) were combined in 1% DIEA/DMF (1 mL) and shaken at rt.After completion, the reaction mixture was diluted with 90% DMSO/water(2 mL) and purified in one injection using RP-HPLC (Waters Deltapak C18200×25 mm column) with slope collection. The appropriate peak wascollected and lyophilized to give the title compound (4.1 mg, 41%). MSm/z: 1008 (M+H)⁺.

Analytical Methods

Analytical data was included within the procedures below or in thetables of examples. Unless otherwise stated, all ¹H NMR data werecollected on a Varian 400 MHz Mercury Plus, Inova, or 400-MR instrumentand chemical shifts are quoted in parts per million (ppm). LC/MS andHPLC data are referenced to the table of LC/MS and HPLC conditions usingthe lower case method letter provided in Table A.

TABLE A LC/MS methods Method Conditions a LC/MS: The gradient was 5-60%B in 1.5 min then 60-95% B to 2.5 min with a hold at 95% B for 1.2 min(1.3 mL/min flow rate). Mobile phase A was 10 mM NH₄OAc, mobile phase Bwas HPLC grade MeCN. The column used for the chromatography is a 4.6 ×50 mm MAC-MOD Halo C18 column (2.7 μm particles). Detection methods arediode array (DAD) and evaporative light scattering (ELSD) detection aswell as positive/negative electrospray ionization. b LC/MS: The gradientwas 5-60% B in 1.50 min then 60-95% B to 2.5 min with a hold at 95% Bfor 1.2 min (1.3 mL/min flow rate). Mobile phase A was 10 mM NH₄OAc,mobile phase B was HPLC grade MeCN. The column used for thechromatography was a 4.6 × 50 mm MAC-MOD Halo C8 column (2.7 μmparticles). Detection methods were diode array (DAD) and evaporativelight scattering (ELSD) detection as well as positive/negativeelectrospray ionization. c LC/MS: The gradient was 5-60% B in 1.6 minthen 60-95% B to 2.2 min with a hold at 95% B for 0.1 min (1.0 mL/minflow rate). Mobile phase A was 10 mM NH₄OAc, mobile phase B was HPLCgrade MeCN. The column used for the chromatography is a 2.1 × 30 mmWaters Cortecs C18 column (1.6 μm particles). Detection methods arediode array (DAD) and evaporative light scattering (ELSD) detection aswell as positive/negative electrospray ionization. d LC/MS: The gradientwas 5-60% B in 1.6 min then 60-95% B to 2.2 min with a hold at 95% B for0.1 min (1.0 mL/min flow rate). Mobile phase A was 10 mM NH₄OAc, mobilephase B was HPLC grade MeCN. The column used for the chromatography is a2.1 × 30 mm Waters Cortecs C18 column (1.6 μm particles). Detectionmethods are diode array (DAD) and evaporative light scattering (ELSD)detection as well as positive/negative electrospray ionization.)

TABLE B Chiral HPLC Methods Method Conditions 1 70-95% B in heptane in20 min then step to 100% B for 6 min (20 mL/min flow rate). Mobile phaseB was EtOH (200 proof), mobile phase A was HPLC grade heptane with 0.2%diethylamine modifier added. The column used for the chromatography wasa WhelkO1 R,R 21 × 250 mm column from Regis Technologies (5 μmparticles). 2 65-84% B in heptane over 19 min (20 mL/min flow rate).Mobile phase B was EtOH (200 proof), mobile phase A was HPLC gradeheptane with 0.2% diethylamine modifier added. The column used for thechromatography was a WhelkO1 R,R 21 × 250 mm column from RegisTechnologies (5 μm particles). 3 Isocratic 50% B for 25 min (20 mL/minflow rate). Mobile phase B was 1:1 MeOH/EtOH, mobile phase A was HPLCgrade heptane with 0.125% diethylamine added. The column used for thechromatography was a Daciel IC 20 × 250 mm column (5 μm particles). 450-60% B for 20 min (20 mL/min flow rate). Mobile phase B was EtOH (200proof), mobile phase A was HPLC grade heptane with 0.2% diethylamineadded. The column used for the chromatography was a Daciel IC 20 × 250mm column (5 μm particles). 5 65-75% B for 3 min, then 75-85% B for 17min (20 mL/min flow rate). Mobile phase B was 20% EtOAc/EtOH (200proof), mobile phase A was HPLC grade heptane with 0.2% diethylamineadded. The chromatography used a WhelkO1 R,R 21 × 250 mm column fromRegis Technologies (5 μm particles). 6 50-62% B in heptane over 25 min(20 mL/min flow rate). Mobile phase B was EtOH (200 proof), mobile phaseA was HPLC grade heptane with 0.2% diethylamine modifier added. Thecolumn used for the chromatography was a Daciel IC 20 × 250 mm column (5μm particles). 7 Gradient separation method wherein mobile phase A wasEtOH (200 proof), mobile phase B was HPLC grade heptane with 0.2% DEA.Flow rate was 20 mL/min. Gradient was held at 30% A for 12.4 min, thenramp to 60% A in 0.2 min, hold for 5.4 min. The column used for thechromatography was a YMC SA column (20 × 250 mm). 8 5-25% B in heptanefor the first 3 min then held at 25% B for the next 24 min thenincreased to 40% B and held for 8 min then equilibrated back down to 5%B (20 mL/min flow rate). Mobile phase B was EtOH (EtOH is 200 proof),mobile phase A was HPLC grade heptane with 0.2% diethylamine modifieradded. The column used for the chromatography was a Daicel ID 20 × 250mm column from Chiral Technologies (5 μm particles). 9 20-65% B inheptane in the first 3 min then 65%-75% B in 30 min then 75%-85% B inthe next 10 min then held at 85% B for 5 min, then after equilibratedback down to 20% B (20 mL/min flow rate). Mobile phase B was EtOH (200proof) with 0.1% diethylamine added, mobile phase A was HPLC gradeheptane with 0.2% diethylamine modifier added. The column used for thechromatography was a WhelkO1 R,R 21 × 250 mm column from RegisTechnologies (5 μm particles). 10 19% B in heptane for 50 min (20 mL/minflow rate). Mobile phase B was a 1:1 mixture of HPLC grade MeOH and EtOH(200 proof), mobile phase A was HPLC grade heptane with 0.2%diethylamine modifier added. The column used for the chromatography wasa PCAP- DP, 21 × 250 mm column from Supelco (5 μm particles). 11 70-87%B in heptane in 17 min then 87-100% B in 4 min and hold at 100% for 4min (20 mL/min flow rate). Mobile phase B was EtOH (200 proof), mobilephase A was HPLC grade heptane with 0.2% diethylamine modifier added.The column used for the chromatography was a WhelkO1 RR, 21 × 250 mmcolumn from Regis Technologies (5 μm particles). 12 Isocratic 25% B for32 min (20 mL/min flow rate). Mobile phase B was EtOH (200 proof),mobile phase A was HPLC grade heptane with 0.20% diethylamine added. Thecolumn used for the chromatography was a WhelkO1 R,R 21 × 250 mm columnfrom Regis Technologies (5 μm particles) 13 65-75% B in heptane for 3min then 75%-85% B for 20 min., held at 85% for the next 5 min., thenstepped gradient down to 75% and held for additional 13 min., thenequilibrated back down to 65% B (20 mL/min flow rate). Mobile phase Bwas MeOH:EtOH 1:1 mixture (EtOH is 200 proof), mobile phase A was HPLCgrade heptane with 0.2% diethylamine modifier added. The column used forthe chromatography was a WhelkO1 R,R 21 × 250 mm column from RegisTechnologies (5 μm particles). 14 Gradient separation method 50-80% B inheptane over 25 min, hold at 80% for 5 min (20 mL/min flow rate). Mobilephase B was EtOH (200 proof), mobile phase A was HPLC grade heptane with0.2% diethylamine modifier added. The column used for the chromatographywas a WhelkO1 RR column (21 × 250 mm) 15 Gradient separation methodwherein mobile phase A was isopropanol, mobile phase B was HPLC gradeheptane with 0.1% DEA. Flow rate was 20 mL/min. Gradient was 5-12% Aover 24.0 min. The column used for the chromatography was a Daicel IDcolumn (20 × 250 mm) 16 Isocratic separation method wherein mobile phaseA was HPLC grade isopropanol, mobile phase B was HPLC grade heptane.Flow rate was 20 mL/min. 35% A for 27 min. The column used for thechromatography was a Daicel ID (20 × 250 mm column). 17 Gradientseparation method wherein mobile phase A was isopropanol, mobile phase Bwas HPLC grade heptane with 0.125% DEA. Flow rate was 20 mL/min.Gradient was 15-30% A over 21.0 min then 30-34% A over 11.0 min. Thecolumn used for the chromatography was a Daicel ID column (20 × 250 mm).18 Gradient separation method wherein mobile phase A was isopropanol,mobile phase B was HPLC grade heptane with 0.2% DEA. Flow rate was 20mL/min. Gradient was 15-30% A over 21.0 min then 30-32% A over 9.0 min.The column used for the chromatography was a Daicel ID column (20 × 250mm). 19 Gradient separation method used with WhelkO1 RR column (30 × 250mm) 20% B for 0.5 min then 20-60% B in 0.5 min then hold at 60% B for17.5 min then 60-85% B over 4.5 min. Note: used 0.2% DEA modifier inheptane (solvent A). No modifier in solvent B (EtOH. Flow was adjustedto achieve measured 30 mL/min effluent at the different compositions inthe run. 20 Isocratic 30% B for 32 min (20 mL/min flow rate). Mobilephase B was EtOH (200 proof) with 0.1% DEA, mobile phase A was HPLCgrade heptane with 0.20% DEA added. The column used for thechromatography was a Whelko S,S 20 × 250 mm column from RegisTechnologies (5 μm particles)

TABLE C Reverse Phase Preparative HPLC methods Method Conditions 1Hypersil HS C18 column, 250 mm × 21.2 mm, 8 μm particle size, flow rate21 mL/min, detection 335 nm, A = 0.05N NH₄OAc pH 4.5 buffer, B = MeCN,10 to 100% B over 25 min 2 50 × 150 mm C-18 Atlantis T3 prep column, 30to 70% MeCN/Water (0.1% TFA), 20 mL/min) over 12 min. 3 Hypersil HS C18column, 250 mm × 21.2 mm, 8 μm particle size, flow rate 21 mL/min,detection 254 nm, A = 0.05N NH₄OAc pH 4.5 buffer, B = MeCN, 5 to 100% Bover 25 min

TABLE D SFC methods Method Conditions 1 12% EtOH in CO₂ (70 mL/min, 130bar, 35° C.). Cycle time was 3.2 min, with single run time of 10 min.200 proof EtOH was used with SFC grade CO₂. The chromatography used aYMC-SA, 21 × 250 mm column (5 μm particles).

PREPARATIONS AND EXAMPLES

Starting materials are commercially available, may be prepared by theprocedures described herein, by literature procedures, or by proceduresthat would be well known to one skilled in the art of organic chemistry.Reagent/reactant names given are as named on the commercial bottle or asgenerated by IUPAC conventions, PerkinElmer ChemDraw® Professional 15.0,CambridgeSoft® ChemDraw Ultra 12.0, CambridgeSoft® Chemistry E-Notebook11, or AutoNom 2000. None of the specific conditions and reagents notedherein are to be construed as limiting the scope of the disclosure andare provided for illustrative purposes only. Compounds designated assalts (e.g. hydrochloride, trifluoroacetate) may contain more than onemolar equivalent of the salt or may contain the acid as an excipient.Compounds of the disclosure where the absolute stereochemistry has beendetermined by the use of a commercially available enantiomerically purestarting material or a stereochemically defined intermediate or by X-raydiffraction are denoted by an asterisk after the example number.Otherwise the absolute stereochemistry is unknown and assigned randomlyas drawn.

Compounds of the disclosure may be prepared using synthetictransformations shown herein. For groups of compounds that have beenprepared in a similar fashion, a representative example is givenfollowed by a table of these similarly prepared compounds. It should beappreciated by one skilled in the art that minor modifications to therepresentative example may be necessary to successfully execute thesesyntheses. Prepared compounds may be purified by any technique orcombination of techniques known to one skilled in the art. Some examplesthat are not limiting include column chromatography with a solid phase(i.e. silica gel, alumina, etc.) and a solvent (or combination ofsolvents) that elutes the desired compounds (i.e. hexanes, heptane,EtOAc, DCM, MeOH, EtOH, MeCN, water, etc.); preparatory TLC with a solidphase (i.e. silica gel, alumina etc.) and a solvent (or combination ofsolvents) that elutes the desired compounds (i.e. hexanes, heptane,EtOAc, DCM, MeOH, EtOH, MeCN, water, etc.); reverse phase HPLC (seeTable 1 for some non-limiting conditions); recrystalization from anappropriate solvent (i.e. MeOH, EtOH, IPA, EtOAc, toluene, etc.) orcombination of solvents (i.e. EtOAc/heptane, EtOAc/MeOH, etc.); chiralLC with a solid phase and an appropriate solvent (i.e. EtOH/heptane,MeOH/heptane, IPA/heptane, etc. with or without a modifier such asdiethylamine, TFA, etc.) to elute the desired compound; chiral SFC witha solid phase and CO₂ with an appropriate modifier (i.e. MeOH, EtOH, IPAwith or without additional modifier such as diethylamine, TFA, etc.);precipitation from a combination of solvents (i.e. DMF/water, DMSO/DCM,EtOAc/heptane, etc.); trituration with an appropriate solvent (i.e.EtOAc, DCM, MeCN, MeOH, EtOH, IPA, n-PrOH, etc.); extractions bydissolving a compound in a liquid and washing with an appropriatelyimmiscible liquid (i.e. DCM/water, EtOAc/water, DCM/saturated NaHCO₃,EtOAc/saturated NaHCO₃, DCM/10% aqueous HCl, EtOAc/10% aqueous HCl,etc.); distillation (i.e. simple, fractional, Kugelrohr, etc.); gaschromatography using an appropriate temperature, carrier gas and flowrate; sublimation at an appropriate temperature and pressure; filtrationthrough a media (i.e. Florosil®, alumina, Celite®, silica gel, etc.)with a solvent (i.e. heptane, hexanes, EtOAc, DCM, MeOH, etc.) orcombination of solvents; salt formation with solid support (resin based,i.e. ion exchange) or without. Some descriptions of these techniques canbe found in the following references, Gordon, A. J. and Ford, R. A. “TheChemist's Companion”, 1972; Palleros, D. R. “Experimental OrganicChemistry”, 2000; Still, W. C., Kahn, M. and Mitra, A. J. Org. Chem.1978, 43, 2923; Yan, B. “Analysis and Purification Methods inCombinatorial Chemistry” 2003; Harwood, L. M., Moody, C. J. and Percy,J. M. “Experimental Organic Chemistry: Standard and Microscale, 2^(nd)Edition”, 1999; Stichlmair, J. G. and Fair, J. R. “Distillation;Principles and Practices” 1998; Beesley T. E. and Scott, R. P. W.“Chiral Chromatography”, 1999; Landgrebe, J. A. “Theory and Practice inthe Organic Laboratory, 4^(th) Edition”, 1993; Skoog, D. A. and Leary,J. J. “Principles of Instrumental Analysis, 4^(th) Edition” 1992;Subramanian, G. “Chiral Separation Techniques 3^(rd) Edition” 2007;Kazakevich, Y. and Lobrutto, R. “HPLC for Pharmaceutical Scientists”2007.

Preparation #1:6-Bromo-3-(2-(difluoromethoxy)phenyl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one

Step 1: 1-(2-(Difluoromethoxy)phenyl)but-3-en-1-ol

2-(Difluoromethoxy)benzaldehyde (20.1 g, 117 mmol) was dissolved in dryTHF (350 mL) under N₂. The reaction mixture was cooled to about −78° C.and then allylmagnesium bromide (1 M solution in Et₂O) (152 mL, 152mmol) was added dropwise, keeping the internal temperature below about−65° C. The mixture was stirred at about −65° C. for about 1 h thenallowed to warm to about 5° C. over about 1 h. The mixture was cooled toabout 0° C. then quenched with saturated aqueous ammonium chloridesolution (200 mL). The mixture was extracted with EtOAc (2×200 mL) thenthe combined organics were dried over MgSO₄, filtered and concentratedunder reduced pressure to give the title compound (24.05 g, 96%); ¹H NMR(400 MHz, DMSO) δ 7.53 (dd, J=7.5, 1.7 Hz, 1H), 7.31-7.19 (m, 2H), 7.17(t, J=76 Hz, 1H), 7.10 (d, J=8.0 Hz, 1H), 5.84-5.71 (m, 1H), 5.26 (d,J=4.7 Hz, 1H), 5.01-4.85 (m, 3H), 2.41-2.25 (m, 2H).

Step 2: 1-(1-Bromobut-3-en-1-yl)-2-(difluoromethoxy)benzene

1-(2-(Difluoromethoxy)phenyl)but-3-en-1-ol (16.43 g, 77 mmol) wasstirred in DCM (384 mL) then PBr₃ (18.09 mL, 192 mmol) was added and themixture stirred at rt for about 2 h. The mixture was cooled to about 0°C. in an ice bath then aqueous saturated sodium bicarbonate was addedslowly until a neutral pH was achieved. The mixture was stirred anadditional 30 min then the layers were separated and the organicsolution was dried over MgSO₄, filtered and concentrated under reducedpressure. The residue was purified via flash chromatography on silicagel (0-15% EtOAc/heptane) to give the title compound (15.49 g, 73%); ¹HNMR (400 MHz, DMSO) δ 7.68 (dd, J=7.8, 1.7 Hz, 1H), 7.43-7.37 (m, 1H),7.32-7.27 (m, 1H), 7.26 (t, J=75 Hz, 1H), 7.20-7.16 (m, 1H), 5.78-5.66(m, 1H), 5.43-5.37 (m, 1H), 5.18-5.05 (m, 2H), 3.10-2.93 (m, 2H).

Step 3:6-Bromo-1-(1-(2-(difluoromethoxy)phenyl)but-3-en-1-yl)-1H-indazol-3(2H)-one

6-Bromo-1H-indazol-3(2H)-one (7.44 g, 34.9 mmol) in DMF (50 mL) wastreated with powdered potassium carbonate (5.31 g, 38.4 mmol) then themixture was warmed to about 50° C.1-(1-Bromobut-3-en-1-yl)-2-(difluoromethoxy)benzene (15.5 g, 55.9 mmol)in DMF (80 mL) was added over about 45 min. After about 2 h, the mixturewas added to ice water (200 mL) with stirring. The solids were collectedby filtration, rinsed with DCM (20 mL) and dried to constant weight in avacuum oven to give the title compound. (1.05 g, 7%); LC/MS (Table A,Method b) R_(t)=2.54 min; MS m/z: 409, 411 (M+H)⁺.

Step 4:6-Bromo-1-(1-(2-(difluoromethoxy)phenyl)-3-hydroxypropyl)-1H-Indazol-3(2H)-one

A suspension of6-bromo-1-(1-(2-(difluoromethoxy)phenyl)but-3-en-1-yl)-1H-indazol-3(2H)-one(5.44 g, 13.3 mmol) and 4-methylmorpholine 4-oxide (4.67 g, 39.9 mmol)in THF (66 mL) was cooled to about 0° C. in an ice/water bath for about5 min. The mixture was treated with osmium (VIII) oxide (4 wt % inwater) (4.23 g, 0.665 mmol). The mixture was warmed to rt for about 2.5h then a 10% aqueous sodium bisulfite solution (60 mL) was added. Themixture was stirred at rt for about 1 h. The mixture was extracted withEtOAc (3×40 mL), filtering the mixture to remove emulsive material. Thecombined organics were dried over MgSO₄, filtered then the filtrate wasconcentrated under reduced pressure to give6-bromo-1-(1-(2-(difluoromethoxy)phenyl)-3,4-dihydroxybutyl)-1H-indazol-3(2H)-one(5.89 g, 100%). A solution of6-bromo-1-(1-(2-(difluoromethoxy)phenyl)-3,4-dihydroxybutyl)-1H-indazol-3(2H)-one(5.89 g, 13.3 mmol) in THF (100 mL) and water (25 mL) was treated at rtwith sodium periodate (4.26 g, 19.9 mmol). After about 1 h, the reactionmixture was partitioned between water (30 mL) and DCM (100 mL). Afterseparating the layers, the aqueous phase was extracted with additionalDCM (100 mL). The combined organic phases were washed with saturatedaqueous NaCl (70 mL), dried over MgSO₄ and filtered. The filtrate wasconcentrated under reduced pressure to give3-(6-bromo-3-oxo-2,3-dihydro-1H-indazol-1-yl)-3-(2-(difluoromethoxy)phenyl)propanal(5.46 g, 100%). A suspension of3-(6-bromo-3-oxo-2,3-dihydro-1H-indazol-1-yl)-3-(2-(difluoromethoxy)phenyl)propanal(4.80 g, 11.7 mmol) in MeOH (100 mL) was cooled to about 0° C. thentreated with NaBH₄ (0.442 g, 11.67 mmol. After about 30 min, additionalNaBH₄ (0.050 g, 1.32 mmol) was added. The mixture was stirred for about15 min then the reaction mixture was partitioned between EtOAc (100 mL)and saturated aqueous NH₄Cl (50 mL). After separating the layers theaqueous phase was extracted with EtOAc (2×40 mL). The combined organicphases were washed with saturated aqueous NaCl (100 mL), dried overMgSO₄, filtered, and concentrated under reduced pressure. The materialwas purified via flash chromatography on silica gel (0-100% EtOAc/DCM).The appropriate fractions were concentrated to give the title compound(3.1 g, 64%); LC/MS (Table A, Method b) R_(t)=2.09 min; MS m/z: 413, 415(M+H)⁺.

Step 5:6-Bromo-3-(2-(difluoromethoxy)phenyl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one

A flask was charged with6-bromo-1-(1-(2-(difluoromethoxy)phenyl)-3-hydroxypropyl)-1H-indazol-3(2H)-one(0.830 g, 2.009 mmol) in DCM (9 mL). 2,6-Dimethylpyridine (0.702 mL,6.03 mmol) and XtalFluor-E® (0.736 g, 3.21 mmol) were each addedsequentially in one portion. The resulting solution was allowed to stirat rt for about 45 min. The mixture was quenched with saturated aqueoussodium bicarbonate (10 mL) then extracted with DCM (2×20 mL). Theorganic solution was dried over MgSO₄, filtered and the filtrate wasconcentrated under reduced pressure. The residue was purified via flashchromatography on silica gel (0-100% EtOAc/DCM). The appropriatefractions were concentrated to give the title compound (0.596 g, 75%);LC/MS (Table A, Method b) R_(t)=2.20 min; MS m/z: 395, 397 (M+H)⁺.

Preparation #2:(S)-6-Bromo-3-(2-(difluoromethoxy)phenyl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one

6-Bromo-3-(2-(difluoromethoxy)phenyl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one(0.650 g, 1.645 mmol) (Preparation t#1) was submitted for chiralpurification (Table B, Method 12). Fractions from the first elutingcomponent were combined and concentrated under reduced pressure thentaken into water, frozen and lyophilized to give the title compound(0.255 g, 39%) with negative (−) optical rotation. LC/MS (Table A,Method a) R_(t)=2.19 min; MS m/z: 397, 395 (M+H)⁺.

Preparation #3:(R)-6-Bromo-3-(2-(difluoromethoxy)phenyl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one

6-Bromo-3-(2-(difluoromethoxy)phenyl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one(0.650 g, 1.645 mmol) (Preparation #1) was submitted for chiralpurification (Table B, Method 12). Fractions from the second elutingcomponent were combined and concentrated under reduced pressure thentaken into water, frozen and lyophilized to give the title compound(0.250 g, 39%) with positive (+) optical rotation. LC/MS (Table A,Method a) R_(t)=2.19 min; MS m/z: 397, 395 (M+H)⁺.

Preparation #4:(R)-2-(2-(Methoxymethyl)pyrrolidin-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine

(R)-5-Bromo-2-(2-(methoxymethyl)pyrrolidin-1-yl)pyrimidine (0.220 g,0.808 mmol) (Preparation #10) was dissolved in DMF (2 mL) then degassedand flushed with N₂. Potassium acetate (0.167 g, 1.70 mmol) and4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (0.308 g,1.21 mmol) were added followed by an additional degas and flush with N₂.PdCl₂(dppf) (0.041 g, 0.057 mmol) was then added, degassed then heatedunder N₂ to 85° C. for about 1 h. The mixture was cooled to rt, filteredthrough Celite®, then concentrated under reduced pressure. The residuewas purified via flash chromatography on silica gel (0-50% EtOAc/DCM) togive the title compound. (0.099 g, 38%); LC/MS (Table A, Method b)R_(t)=2.43 min; MS m/z: 320 (M+H)⁺.

Preparation #5:(R)—N-(Tetrahydrofuran-3-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine

2-Chloro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine(0.331 g, 1.376 mmol), (R)-tetrahydrofuran-3-amine (0.132 g, 1.514mmol), and TEA (0.211 mL, 1.514 mmol) were mixed in EtOH (3 mL) at 80°C. for about 1 h. The mixture was cooled to rt under N₂. The mixture wasconcentrated under reduced pressure and then purified via flashchromatography on silica gel (10-100% EtOAc/DCM) to give the titlecompound (0.296 g, 74%); LC/MS (Table A, Method b) R_(t)=1.89 min; MSm/z: 292 (M+H)⁺.

Preparation #6:(R)-(2-(2-(Hydroxymethyl)morpholino)pyrimidin-5-yl)boronic acid

Step 1: (R)-Morpholin-2-ylmethanol TFA Salt

(R)-tert-Butyl 2-(hydroxymethyl)morpholine-4-carboxylate (0.200 g, 0.921mmol) was dissolved in DCM (3 mL) followed by the addition of TFA (0.355mL, 4.60 mmol). The mixture was stirred at rt for about 17 h. AdditionalTFA (0.355 mL, 4.60 mmol) was added and the mixture was stirred anadditional 17 h. The mixture was concentrated under reduced pressure tofurnish the title compound (0.108 g, 100%); ¹H NMR (400 MHz, CDCl₃) δ9.47 (br, 1H), 7.41 (br, 1H), 4.52-4.45 (m, 1H), 4.41-4.35 (m, 1H),4.21-4.08 (m, 2H), 4.02-3.93 (m, 1H), 3.45-3.30 (m, 2H), 3.21-3.10 (m,1H), 3.07-2.96 (m, 1H).

Step 2: (R)-(2-(2-(Hydroxymethyl)morpholino)pyrimidin-5-yl)boronic acid

(2-Chloropyrimidin-5-yl)boronic acid (0.122 g, 0.768 mmol), EtOH (2 mL),TEA (0.13 mL, 0.92 mmol) and (R)-morpholin-2-ylmethanol TFA salt (0.108g, 0.922 mmol) were heated to about 80° C. for about 1 h. The reactionmixture was cooled to rt and then concentrated under reduced pressure.The residue was purified via flash chromatography on silica gel (50-100%EtOAc/DCM then 0-6% MeOH/DCM). The appropriate fractions wereconcentrated to give the title compound (0.139 g, 76%); LC/MS (Table A,Method b) R_(t)=0.91 min; MS m/z: 240 (M+H)⁺.

Preparation #7:7-(5-Bromopyrimidin-2-yl)hexahydroimidazo[1,5-a]pyrazin-3(2H)-one

A mixture of hexahydroimidazo[1,5-a]pyrazin-3(2H)-one hydrochloride(0.441 g, 2.48 mmol), 5-bromo-2-chloropyrimidine (0.542 g, 2.80 mmol),TEA (1.20 mL, 8.61 mmol), and EtOH (20 mL) was warmed to about 78° C.After about 4 h, the solution was allowed to cool to rt. After stirringabout 20 h, the volatiles were removed under reduced pressure. Theresidue was partitioned between 5% MeOH/DCM (50 mL) and water (25 mL).The aqueous layer was extracted with 5% MeOH/DCM (2×25 mL). The combinedorganics were dried over Na₂SO₄, filtered, and concentrated underreduced pressure. The residue was purified via flash chromatography onsilica gel (0-5% McOH/DCM) to give the title compound (0.714 g, 96%);LC/MS (Table A, Method b) R_(t)=1.61 min; MS m/z: 298, 300 (M+H)⁺.

Preparation #8:(S)-7-(5-Bromopyrimidin-2-yl)hexahydroimidazo[1,5-a]pyrazin-3(2H)-one

7-(5-Bromopyrimidin-2-yl)hexahydroimidazo[1,5-a]pyrazin-3(2H)-one (0.714g, 2.40 mmol) (Preparation #7) was submitted for chiral purification(Table B, Method 7). Fractions from the first eluting component werecombined and concentrated under reduced pressure then dried to give thetitle compound (0.320 g, 43%) with positive (+) optical rotation. LC/MS(Table A, Method b) R_(t)=1.61 min; MS m/z: 298, 300 (M+H)⁺.

Preparation #9:(R)-7-(5-Bromopyrimidin-2-yl)hexahydroimidazo[1,5-a]pyrazin-3(2H)-one

7-(5-Bromopyrimidin-2-yl)hexahydroimidazo[1,5-a]pyrazin-3(2H)-one (0.714g, 2.40 mmol) (Preparation #7) was submitted for chiral purification(Table B, Method 7). Fractions from the second eluting component werecombined and concentrated under reduced pressure then dried to give thetitle compound (0.335 g, 44%) with negative (−) optical rotation. LC/MS(Table A, Method b) R_(t)=1.61 min; MS m/z: 298, 300 (M+H)⁺.

Preparation #10:(R)-5-Bromo-2-(2-(methoxymethyl)pyrrolidin-1-yl)pyrimidine

NMP (10.0 mL), DIEA (5.00 mL, 28.6 mmol), and(R)-2-(methoxymethyl)pyrrolidine (2.00 mL, 16.2 mmol) were addedrespectively to 5-bromo-2-chloropyrimidine (2.00 g, 10.3 mmol). Afterabout 4 h at about 120° C., the solution was allowed to cool to rt andthe volatiles were removed under reduced pressure at about 90° C. Water(20 mL), saturated aqueous NH₄Cl (20 mL) and EtOAc (50 mL) were added.The layers were separated and the organics were washed with water (50mL). The aqueous layers were extracted with EtOAc (25 mL). The combinedorganics were dried over Na₂SO₄, filtered and concentrated under reducedpressure. The residue was purified via flash chromatography on silicagel (0-20% EtOAc/heptane) to give the title compound (2.66 g, 95%);LC/MS (Table A, Method b) R_(t)=2.27 min; MS m/z: 272, 274 (M+H)⁺.

Preparation #11:4-(((5-Bromopyrimidin-2-yl)amino)methyl)pyrrolidin-2-one

The title compound was synthesized using methods similar to Preparation#10 from 4-(aminomethyl)pyrrolidin-2-one and 5-bromo-2-chloropyrimidine;LC/MS (Table A, Method b) R_(t)=1.36 min; MS m/z: 271, 273 (M+H)⁺.

Preparation #12:(S)-4-(((5-Bromopyrimidin-2-yl)amino)methyl)pyrrolidin-2-one

4-(((5-Bromopyrimidin-2-yl)amino)methyl)pyrrolidin-2-one (0.603 g, 2.22mmol) (Preparation #11) was submitted for chiral purification (Table B,Method 8). Fractions from the first eluting component were combined andconcentrated under reduced pressure then dried in a vacuum oven at about65° C. for about 24 h to give the title compound (0.228 g, 38%) LC/MS(Table A, Method b) R_(t)=1.34 min; MS m/z: 271, 273 (M+H)⁺.

Preparation #13:(R)-4-(((5-Bromopyrimidin-2-yl)amino)methyl)pyrrolidin-2-one

4-(((5-Bromopyrimidin-2-yl)amino)methyl)pyrrolidin-2-one (0.603 g, 2.22mmol) (Preparation #11) was submitted for chiral purification (Table B,Method 8). Fractions from the second eluting component were combined andconcentrated under reduced pressure then dried in a vacuum oven at about65° C. for about 24 h to give the title compound (0.237 g, 39%) LC/MS(Table A, Method b) R_(t)=1.34 min; MS m/z: 271, 273 (M+H)⁺.

Preparation #14:6-(2-(4-Acetylpiperazin-1-yl)pyrimidin-5-yl)-3-(2-(difluoromethoxy)phenyl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one

Step 1:3-(2-(Difluoromethoxy)phenyl)-6-(2-(piperazin-1-yl)pyrimidin-5-yl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-onehydrochloride

To a solution of tert-butyl4-(5-(3-(2-(difluoromethoxy)phenyl)-9-oxo-1,2,3,9-tetrahydropyrazolo[1,2-a]indazol-6-yl)pyrimidin-2-yl)piperazine-1-carboxylate(0.135 g, 0.196 mmol) (synthesized from tert-butyl4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-yl)piperazine-1-carboxylateand6-bromo-3-(2-(difluoromethoxy)phenyl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one(Preparation #1) in a manner similar to Example #1, step 1) in1,4-dioxane (2.8 mL) was added 4 M HCl in 1,4-dioxane (1.9 mL, 7.60mmol) dropwise and stirred at ambient temperature for about 5 h. Thesolvent was removed under reduced pressure. The residue was dissolved inEtOAc (15 mL) and then concentrated under reduced pressure to give thetitle compound (0.101 g, 100%). LC/MS (Table A, Method b) R_(t)=1.47min; MS m/z: 479 (M+H)⁺.

Step 2:6-(2-(4-Acetylpiperazin-1-yl)pyrimidin-5-yl)-3-(2-(difluoromethoxy)phenyl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one

To a mixture of3-(2-(difluoromethoxy)phenyl)-6-(2-(piperazin-1-yl)pyrimidin-5-yl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-onehydrochloride (0.101 g, 0.196 mmol) in DCM (2.0 mL) was addedtriethylamine (0.11 mL, 0.789 mmol) and acetyl chloride (0.015 mL, 0.211mmol). The reaction was stirred at ambient temperature for about 2 hthen acetyl chloride (0.005 mL, 0.070 mmol) was added. The mixture wasstirred for about 5 min then saturated aqueous NaHCO₃ (10 mL) and DCM (8mL) were added and the layers were separated. The organic layer wasdried over MgSO₄, filtered and concentrated under reduced pressure. Thematerial was purified via flash chromatography on silica gel (0-10%MeOH/DCM). The appropriate fractions were combined and concentratedunder reduced pressure to give the title compound (0.095 g, 93%). LC/MS(Table A, Method b) R_(t)=1.89 min; MS m/z: 521 (M+H)⁺.

Preparation #15:3-Bromo-6-(2-(difluoromethoxy)phenyl)-8,9-dihydro-6H-pyridazino[1,2-a]indazol-11(7H)-one

Step 1:6-Bromo-1-(1-(2-(difluoromethoxy)phenyl)-4-hydroxybutyl)-1H-indazol-3(2H)-one

A solution of6-bromo-1-(1-(2-(difluoromethoxy)phenyl)but-3-en-1-yl)-1H-indazol-3(2H)-one(1.33 g, 3.25 mmol) (Preparation #1, Step 3) in THF (32.5 mL) wastreated at rt with 9-BBN dimer (0.787 g, 3.25 mmol) and the resultingsuspension was stirred for about 10 min. The reaction mixture was thenheated at about 55° C. After about 1 h, additional 9-BBN dimer (0.35 g,1.4 mmol) was added, and again after about 1 h (0.30 g, 1.2 mmol). About5 min after the final addition, the reaction was cooled in an ice bath.EtOH (2 mL) was added, followed by careful addition of 2.5 M aqueousNaOH (2 mL) and 30% aqueous H₂O₂(2 mL). The mixture was partitionedbetween EtOAc (75 mL) and water (50 mL). After separating the layers,the aqueous phase was extracted with EtOAc (3×50 mL). The combinedorganic phases were washed with saturated aqueous NaCl (125 mL), driedover Na₂SO₄, filtered, and concentrated under reduced pressure. Thematerial was purified via flash chromatography on silica gel (0-10%EtOAc/heptane) to give the title compound (1.26 g, 90%); LC/MS (Table A,Method b) R_(t)=2.13 min; MS m/z: 427 and 429 (M+H)⁺.

Step 2:3-Bromo-6-(2-(difluoromethoxy)phenyl)-8,9-dihydro-6H-pyridazino[1,2-a]indazol-11(7H)-one

To a stirred solution of6-bromo-1-(1-(2-(difluoromethoxy)phenyl)-4-hydroxybutyl)-1H-indazol-3(2H)-one(0.85 g, 2.0 mmol) in DCM (20 mL) was added XtalFluor-E® (0.683 g, 2.98mmol). The resulting solution was stirred at about rt for about 45 min.The reaction mixture was quenched by addition of saturated aqueousNaHCO₃ (20 mL). After separating the layers, the aqueous phase wasextracted with DCM (20 mL). The combined organics were washed withsaturated aqueous NaCl (25 mL), dried over Na₂SO₄, filtered, andconcentrated under reduced pressure. The material was purified via flashchromatography on silica (0-50% EtOAc/heptane) to give the titlecompound (0.353 g, 43%); LC/MS (Table A, Method b) R_(t)=2.33 min; MSm/z: 409, 411 (M+H)⁺.

Preparation #16:6-(2-(Difluoromethoxy)phenyl)-3-(2-thiomorpholinopyrimidin-5-yl)-8,9-dihydro-6H-pyridazino[1,2-a]indazol-11(7H)-one

A mixture of3-bromo-6-(2-(difluoromethoxy)phenyl)-8,9-dihydro-6H-pyridazino[1,2-a]indazol-11(7H)-one(0.085 g, 0.21 mmol) (Preparation #15),(2-thiomorpholinopyrimidin-5-yl)boronic acid (0.118 g, 0.415 mmol)(synthesized from thiomorpholine and 2-chloropyrimidine-5-boronic acidusing methods similar to Preparation #6, step 2), Pd(Ph₃P)₄ (0.024 g,0.021 mmol), and cesium carbonate (0.203 g, 0.623 mmol) in 1,4-dioxane(1 mL)/water (0.25 mL) was heated at about reflux for about 16 h. Aftercooling to rt the reaction mixture was partitioned between EtOAc (5 mL)and saturated aqueous NaCl (1 mL). The layers were separated then theorganic phase was dried over Na₂SO₄, filtered, and concentrated underreduced pressure. The residue was purified via flash chromatography onsilica gel (0-5% MeOH/DCM) to give the title compound (0.118 g, 100%);LC/MS (Table A, Method b) R_(t)=2.49 min; MS m/z: 510 (M+H)⁺.

Preparation #17:6-Bromo-3-(2-methoxyphenyl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one

Step 1: 1-(2-Methoxyphenyl)but-3-en-1-ol

A solution of 2-methoxybenzaldehyde (11 g, 81 mmol) in THF (300 mL) wascooled to below −70° C. in a dry ice bath. Allylmagnesium bromide (1 Min Et₂O, 121 mL, 121 mmol) was added dropwise while keeping thetemperature at or below −70° C. Once the addition was complete (about 2h) the cooling bath was removed and the reaction mixture was allowed towarm to rt. The reaction mixture was then cooled to about 0° C. in anice/water bath then saturated aqueous NH₄Cl (125 mL) was slowly added.Water (25 mL) was added and the layers were separated. The aqueous phasewas extracted with EtOAc (125 mL) and the combined organics were washedwith saturated aqueous NaCl (250 mL), dried over Na₂SO₄, filtered, andconcentrated under reduced pressure to give the title compound (14.4 g,100%); ¹H NMR (400 MHz, Chloroform-d) δ 7.39-7.30 (m, 1H), 7.29-7.18 (m,1H), 7.03-6.92 (m, 1H), 6.91-6.84 (m, 1H), 5.97-5.74 (m, 1H), 5.23-5.04(m, 2H), 5.04-4.91 (m, 1H), 3.85 (s, 3H), 2.69-2.34 (m, 2H).

Step 2: 1-(1-Chlorobut-3-en-1-yl)-2-methoxybenzene

A flask containing cyanuric chloride (7.76 g, 42.1 mmol) was cooled inan ice water bath after which DMF (22 mL) was added, and the resultingsuspension was stirred for about 30 min.1-(2-Methoxyphenyl)but-3-en-1-ol (5.0 g, 28 mmol) in DCM (110 mL) wasadded and the ice bath was removed. After stirring for 1 h, diethylether (250 mL) was added and the resulting suspension was stirred at rtovernight. The suspension was filtered to remove precipitated solids,and the filtrate was then washed with saturated aqueous Na₂CO₃ (2×100mL). The organic phase was washed with saturated aqueous NaCl (150 mL),dried over Na₂SO₄, filtered, and concentrated under reduced pressure togive a mixture of yellow solid and reddish oil. The oil was isolated bydecantation to give the title compound (2.6 g, 47%); ¹H NMR (400 MHz,Chloroform-d) δ 7.48 (dd, J=7.7, 1.8 Hz, 1H), 7.32-7.21 (m, 1H), 6.98(d, J=1.1 Hz, 1H), 6.87 (dd, J=8.2, 1.1 Hz, 1H), 5.92-5.72 (m, 1H), 5.45(dd, J=7.9, 6.3 Hz, 1H), 5.17-5.02 (m, 2H), 3.85 (s, 3H), 2.87-2.76 (m,2H).

Step 3:6-Bromo-1-(1-(2-methoxyphenyl)but-3-en-1-yl)-1H-indazol-3(2H)-one

A suspension of potassium carbonate (1.86 g, 13.4 mmol) and6-bromo-1H-indazol-3-ol (2.6 g, 12 mmol) in DMF (18 mL) was heated atabout 50° C. A solution of 1-(1-chlorobut-3-en-1-yl)-2-methoxybenzene(3.84 g, 19.5 mmol) in DMF (30 mL) was added drop-wise over about 20min. The resulting suspension was allowed to stir at about 50° C. forabout 2 days. After cooling to rt, the reaction mixture was poured intoice water (100 mL) and extracted with EtOAc (3×75 mL). The combinedorganics were washed with water (100 mL) and saturated aqueous NaCl (100mL), and then dried over Na₂SO₄, filtered and concentrated. The materialwas purified via flash chromatography on silica (0-100% EtOAc/DCM) togive the title compound (1.7 g, 37%); LC/MS (Table A, Method b)R_(t)=2.59 min; MS m/z: 373, 375 (M+H)⁺.

Step 4:6-Bromo-1-(3,4-dihydroxy-1-(2-methoxyphenyl)butyl)-1H-indazol-3(2H)-one

A mixture of6-bromo-1-(1-(2-methoxyphenyl)but-3-en-1-yl)-1H-indazol-3(2H)-one (1.7g, 4.6 mmol) and NMO (1.60 g, 13.7 mmol) in THF (23 mL) was cooled in anice water bath, and osmium tetroxide (4% in H₂O) (2.89 g, 0.455 mmol)was added drop-wise. The resulting suspension was stirred for about 2 h,after which the ice bath was removed and stirring was continued for anadditional 2 h. The reaction was then quenched with 10% aqueous Na₂S₂O₃(20 mL) and stirred for about 1 h. The mixture was partitioned betweenEtOAc (50 mL) and water (10 mL). After separating the layers, theaqueous phase was extracted with EtOAc (2×25 mL). The combined organicphases were washed with saturated aqueous NaCl (75 mL), dried overNa₂SO₄, filtered, and concentrated under reduced pressure to give thetitle compound (1.76 g, 95%); LC/MS (Table A, Method b) R_(t)=1.83 and1.87 min; MS m/z: 407, 409 (M+H)⁺.

Step 5:3-(6-Bromo-3-oxo-2,3-dihydro-1H-indazol-1-yl)-3-(2-methoxyphenyl)propanal

A solution of6-bromo-1-(3,4-dihydroxy-1-(2-methoxyphenyl)butyl)-1H-indazol-3(2H)-one(1.99 g, 4.89 mmol) in THF (39 mL)/water (9.8 mL) was treated withsodium periodate (1.57 g, 7.33 mmol) while stirring at rt. After about 3h, the reaction mixture was partitioned between EtOAc (100 mL) and water(50 mL). The layers were separated, and then the aqueous phase wasextracted with EtOAc (100 mL). The combined organic phases were washedwith saturated aqueous NaCl (125 mL), dried over Na₂SO₄, filtered, andconcentrated under reduced pressure to give the title compound (1.67 g,91%); LC/MS (Table A, Method b) R_(t)=2.11 min; MS m/z: 375, 377 (M+H)⁺.

Step 6:6-Bromo-1-(3-hydroxy-1-(2-methoxyphenyl)propyl)-1H-indazol-3(2H)-one

A solution of3-(6-bromo-3-oxo-2,3-dihydro-1H-indazol-1-yl)-3-(2-methoxyphenyl)propanal(1.67 g, 4.45 mmol) in THF (44.5 mL) was cooled at about 0° C. in an icewater bath for about 10 min, after which was treated with NaBH₄ (0.168g, 4.45 mmol) and then allowed to stir at about 0° C. for about 1.5 h.The reaction mixture was quenched at 0° C. by careful addition ofsaturated aqueous NH₄Cl (50 mL) and then diluted with EtOAc (50 mL).After separating the layers, the aqueous phase was extracted with EtOAc(2×25 mL), and the combined organic phases were washed with saturatedaqueous NaCl (75 mL), dried over Na₂SO₄, filtered, and concentratedunder reduced pressure. The material was purified via flashchromatography on silica gel (0-100% EtOAc/DCM) to give the titlecompound (1.39 g, 83%); LC/MS (Table A, Method b) R_(t)=2.03 min; MSm/z: 377, 379 (M+H)⁺.

Step 7:6-Bromo-3-(2-methoxyphenyl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one

A mixture of6-bromo-1-(3-hydroxy-1-(2-methoxyphenyl)propyl)-1H-indazol-3(2H)-one(1.4 g, 3.7 mmol) and 2,6-lutidine (1.3 mL, 11 mmol) in DCM (37.1 mL)was treated with XtalFluor-E® (1.28 g, 5.57 mmol) and the resultingsolution was stirred at rt for about 20 min. The reaction mixture wasthen quenched at rt by addition of saturated aqueous NaHCO₃ (50 mL) anddiluted with DCM (25 mL). The aqueous phase was extracted with DCM (15mL), and then the combined organic phases were washed with 1M Aq HCl (50mL) and saturated aqueous NaCl (50 mL), dried over Na₂SO₄, filtered, andconcentrated under reduced pressure. The material was purified via flashchromatography on silica gel (0-100% EtOAc/DCM) to give the titlecompound (0.80 g, 60%); LC/MS (Table A, Method b) R_(t)=2.22 min; MSm/z: 359, 361 (M+H)⁺.

Preparation #18:6-(2-(2-Hydroxypropan-2-yl)pyrimidin-5-yl)-3-(2-methoxyphenyl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one

A mixture of 2-(5-bromopyrimidin-2-yl)propan-2-ol (0.079 g, 0.36 mmol),bis(pinacolato)diboron (0.191 g, 0.752 mmol), PdCl₂(dppf)-CH₂Cl₂ adduct(0.016 g, 0.019 mmol), and KOAc (0.090 g, 0.92 mmol) in 1,4-dioxane(2.25 mL) was heated at reflux for about 1.5 h. The reaction mixture wasallowed to cool and then6-bromo-3-(2-methoxyphenyl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one(0.100 g, 0.278 mmol) (Preparation #17),bis(triphenylphosphine)palladium dichloride (9.8 mg, 0.014 mmol), cesiumcarbonate (0.227 g, 0.696 mmol) and water (0.5 mL) were added. Thereaction mixture was heated at about 80° C. for about 30 min, and thencooled to rt, during which the aqueous and organic portions separated.The organics were filtered through a 0.45 μM GHP Acrodisc syringe filterand then through a pad of Celite®. The sample was purified by reversephase chromatography (Table C, Method 2). The appropriate fractions werecombined and the volatiles evaporated under reduced pressure. Theaqueous mixture was extracted with EtOAc (3×20 mL) and then the combinedorganic phases were washed with saturated aqueous NaCl (50 mL), driedover Na₂SO₄, filtered, and concentrated under reduced pressure. Theresidue was triturated with diethyl ether (10 mL), and the resultingsolid was recovered by vacuum filtration and air dried to give the titlecompound (0.080 g, 69%); LC/MS (Table A, Method b) R_(t)=1.81 min; MSm/z: 417 (M+H)⁺.

Preparation #19: 2-(1-Hydroxybut-3-en-1-yl)-6-methylbenzonitrile

Step 1: 2-Iodo-6-methylbenzonitrile

A flask was charged with concentrated sulfuric acid (100 mL, 1.88 mol).2-Amino-6-methylbenzonitrile (10 g, 76 mmol) was gradually added andthen the mixture was stirred at rt for about 16 h. The mixture wascooled to about −5° C. then sodium nitrite (5.74 g, 83.0 mmol) wasgradually added. The reaction mixture was stirred at about 0° C. forabout 2.5 h then added into mixture of ice/water (200 g) and potassiumiodide (16 g, 96 mmol). The mixture was stirred at about 0° C. for about10 min and then at ambient temperature for about 2.5 h. The mixture wasextracted with Et₂O (400 mL). The aqueous layer was extracted with Et₂O(50 mL). The combined organics were washed with 10% aqueous NaS₂O₃(400mL) then dried over MgSO₄, filtered, and concentrated. The material wastriturated with DCM (25 mL) and the resulting solids were collected byfiltration. The filtrate was concentrated under reduced pressure and theresidue was purified via flash chromatography on silica gel (1-15%EtOAc/heptane) to give the title compound (13.2 g, 72%); ¹H NMR (400MHz, CDCl₃) δ 7.76-7.71 (m, 1H), 7.31-7.27 (m, 1H), 7.18-7.13 (m, 1H),2.59 (s, 3H).

Step 2: 2-Methyl-6-vinylbenzonitrile

A flask was charged with 2-iodo-6-methylbenzonitrile (1.10 g, 4.53mmol), 4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane (1.39 g, 9.05mmol), cesium carbonate (4.42 g, 13.6 mmol), 1,4-dioxane (20 mL) andwater (5.0 mL). The reaction vessel was evacuated then back-filled withN₂ three times. Pd(PPh₃)₄ (0.37 g, 0.32 mmol) was added. The reactionvessel was evacuated then back-filled with N₂ three times. The reactionwas heated at about 90° C. for about 3 h. After cooling to ambienttemperature, the mixture was partitioned between saturated aqueousNaHCO₃ (20 mL) and EtOAc (50 mL). The organic layer was dried overMgSO₄, filtered, and concentrated. DCM (10 mL) was added and the solidwas removed by filtration. The filtrate was concentrated under reducedpressure and the residue was purified via flash chromatography on silicagel (5-10% EtOAc/heptane) to give the title compound (0.85 g, 66%); ¹HNMR (400 MHz, CDCl₃) δ 7.45-7.33 (m, 2H), 7.17-7.11 (m, 1H), 7.08-6.98(m, 1H), 5.88-5.82 (m, 1H), 5.48-5.42 (m, 1H), 2.55 (s, 3H).

Step 3: 2-Formyl-6-methylbenzonitrile

A flask was charged with 2-methyl-6-vinylbenzonitrile (7.00 g, 48.9mmol). Osmium(VIII) oxide (4% water solution, 12.4 g, 1.96 mmol), sodiumperiodate (30.3 g, 142 mmol), acetone (300 mL) and water (50 mL) wereadded. After mixing at ambient temperature for about 2.5 h, the solidswere removed by filtration and rinsed with acetone (50 mL). The organicvolatiles were removed under reduced pressure. The residue was extractedwith EtOAc (200 mL). The organic layer was washed with saturated aqueousNaCl (25 mL). The aqueous layer was extracted with EtOAc (50 mL). Thecombined organics were dried over MgSO₄, filtered and concentrated underreduced pressure. The residue was purified via flash chromatography onsilica gel (5-18% EtOAc/heptane) to give the title compound (4.3 g,61%); ¹H NMR (400 MHz, CDCl₃) δ 10.36 (s, 1H), 7.89-7.85 (m, 1H),7.68-7.58 (m, 2H), 2.66 (s, 3H).

Step 4: 2-(1-Hydroxybut-3-en-1-yl)-6-methylbenzonitrile

A flask was charged with diacetoxypalladium (0.186 g, 0.827 mmol), DMAP(0.404 g, 3.31 mmol) and DMF (30 mL). 2-Formyl-6-methylbenzonitrile(4.00 g, 27.6 mmol), 3-bromoprop-1-ene (2.58 mL, 29.8 mmol) and tin(II)chloride dihydrate (8.71 g, 38.6 mmol) were added successively. Themixture was warmed to about 44° C. for about 30 min. The reaction wascooled to rt, added to water (200 mL) then extracted with Et₂O (200 mL).The aqueous layer was extracted with Et₂O (2×30 mL). The combinedorganics were washed with saturated aqueous NaCl (30 mL), dried overMgSO₄, filtered and concentrated under reduced pressure. The residue waspurified via flash chromatography on silica gel (5-30% EtOAc/heptane) togive the title compound (3.5 g, 68%); LC/MS (Table A, Method b)R_(t)=1.94 min; MS m/z: 188 (M+H)⁺.

Preparation #20:rac-(1R,9bR)-8-Bromo-1-(2-(difluoromethoxy)phenyl)-2,3-dihydro-1H-pyrrolo[2,1-a]isoindol-5(9bH)-one

Step 1: 3-(2-(Difluoromethoxy)phenyl)-4-nitrobutanenitrile

A flask was charged with THF (75 mL) and sodium hydride (60% dispersionin oil) (2.35 g, 58.8 mmol) and then cooled to about 0° C. Diethyl(cyanomethyl)phosphonate (10.3 g, 58.1 mmol) was added over about 45 minthen the mixture was stirred for about 30 min.2-(Difluoromethoxy)benzaldehyde (6 g, 34.9 mmol) in THF (25 mL) wasadded to the mixture while keeping the internal temperature below about5° C. The mixture was warmed to rt for about 1.5 h then diluted withwater (200 mL) and EtOAc (150 mL). The layers were separated then theaqueous layer was extracted with EtOAc (100 mL). The combined organicswere washed with water (200 mL) then saturated aqueous NaCl (˜75 mL),dried over MgSO₄, filtered and the filtrate concentrated under reducedpressure. The material was purified via flash chromatography on silicagel (0-50% EtOAc/heptane). The appropriate fractions were collected andconcentrated under reduced pressure to give(E)-3-(2-(difluoromethoxy)phenyl)acrylonitrile (5.93 g). The(E)-3-(2-(difluoromethoxy)phenyl)acrylonitrile (5.93 g, 30.4 mmol) wasdissolved in acetonitrile (85 mL) and nitromethane (21 mL, 0.39 mol)then the mixture was treated with N,N,N-trimethyl-1-phenylmethanaminiumhydroxide (40 weight % in water) (1.0 mL, 2.2 mmol). The mixture washeated to about 85° C. for about 21 h then cooled to rt and diluted withwater (100 mL) and 10% aqueous HCl (15 mL). The mixture was extractedwith EtOAc (100 mL). The organic layer was washed with saturated aqueousNaCl (˜50 mL) then dried over sodium sulfate, filtered and the filtrateconcentrated under reduced pressure. The material was purified via flashchromatography on silica gel (10-50% EtOAc/heptane). The appropriatefractions were collected and concentrated under reduced pressure to givethe title compound (6.0 g, 67%); LC/MS (Table A, Method b) R_(t)=2.12min; MS m/z: 255 (M−H)⁻

Step 2: 3-(2-(Difluoromethoxy)phenyl)-4,4-diethoxybutanenitrile

A flask was charged with MeOH (210 mL) then cooled to about −30° C.Concentrated sulfuric acid (55.0 mL, 1.03 mol) was slowly added keepingthe internal temperature of the mixture between about −30° C. and −20°C. The resulting solution was cooled to about −35° C. then3-(2-(difluoromethoxy)phenyl)-4-nitrobutanenitrile (6.0 g, 23.42 mmol)dissolved in sodium methoxide (0.5 M solution in MeOH) (55 mL, 27.5mmol) was added over about 15 min keeping the internal temperature ofthe mixture about −35° C. After about 20 min the mixture was poured intoa mixture of CHCl₃ (1 L) and water (200 mL). The separated organic layerwas washed with water (200 mL), 1 N aqueous NaOH (200 mL) then water(200 mL), dried over sodium sulfate, filtered and concentrated underreduced pressure. The material was purified via flash chromatography onsilica gel (10-50% EtOAc/heptane). The appropriate fractions werecollected and concentrated under reduced pressure to give the titlecompound (3.62 g, 57%); ¹H NMR (400 MHz, CDCl₃) δ 7.42 (dd, J=7.7, 1.8Hz, 1H), 7.35-7.29 (m, 1H), 7.26-7.22 (m, 1H), 7.14-7.12 (m, 1H), 6.53(t, J=74 Hz, 1H)), 4.57 (d, J=5.8 Hz, 1H), 3.79-3.71 (m, 1H), 3.41 (s,3H), 3.32 (s, 3H), 2.88-2.72 (m, 2H).

Step 3: 3-(2-(Difluoromethoxy)phenyl)-4,4-dimethoxybutan-1-amine

A flask was charged with3-(2-(difluoromethoxy)phenyl)-4,4-dimethoxybutanenitrile (0.925 g, 3.41mmol), MeOH (40 mL) and cobalt(II) chloride hexahydrate (1.87 g, 7.84mmol). Sodium borohydride (0.645 g, 17.0 mmol) was added then themixture was stirred for about 15 min. The mixture was filtered through abed of Celite® then the pad was washed with McOH (30 mL). The filtratewas concentrated to give the crude title compound (3.15 g); LC/MS (TableA, Method b) R_(t)=1.38 min; MS m/z: 276 (M+H)⁺.

Step 4:N-(3-(2-(Difluoromethoxy)phenyl)-4,4-dimethoxybutyl)-2-iodo-4-nitrobenzamide

A flask was charged with 2-iodo-4-nitrobenzoic acid (1.0 g, 3.41 mmol)in DCM (25 mL), oxalyl chloride (0.597 mL, 6.83 mmol) and a drop of DMF.After about 20 min the mixture was concentrated under reduced pressure,dissolved in DCM (25 mL) then added to the crude3-(2-(difluoromethoxy)phenyl)-4,4-dimethoxybutan-1-amine (3.15 g fromstep 3, assumed 3.41 mmol) in DCM (25 mL) with TEA (5 mL, 35.9 mmol).The mixture was stirred for about 15 min at rt then water (50 mL) wasadded and stirring continued for about 5 min. The solvent layers wereseparated then the aqueous layer was extracted with DCM (20 mL). Thecombined organics were washed with saturated sodium bicarbonate (2×20mL) then dried over MgSO₄, filtered and concentrated under reducedpressure. The material was purified via flash chromatography on silicagel (0-25% EtOAc/DCM). The appropriate fractions were collected andconcentrated under reduced pressure to give the title compound (1.23 g,66%); LC/MS (Table A, Method b) R_(t)=2.37 min; MS m/z: 549 (M−H)⁻

Step 5:(4-(2-(Difluoromethoxy)phenyl)-2,3-dihydro-1H-pyrrol-1-yl)(2-iodo-4-nitrophenyl)methanone

A flask was charged withN-(3-(2-(difluoromethoxy)phenyl)-4,4-dimethoxybutyl)-2-iodo-4-nitrobenzamide(1.23 g, 2.23 mmol) and DCM (25 mL). Trifluoromethanesulfonic acid(0.444 mL, 5.00 mmol) was added and then the mixture was stirred forabout 15 min. Water (20 mL) was added then the solvent layers wereseparated. The organic layer was washed with saturated sodiumbicarbonate, dried over MgSO₄, filtered and the filtrate concentrated togive the title compound (1.09 g, 100%); LC/MS (Table A, Method b)R_(t)=2.41 min; MS m/z: 487 (M+H)⁺

Step 6:1-(2-(Difluoromethoxy)phenyl)-8-nitro-5H-pyrrolo[2,1-a]isoindol-5-one

A mixture of(4-(2-(difluoromethoxy)phenyl)-2,3-dihydro-1H-pyrrol-1-yl)(2-iodo-4-nitrophenyl)methanone(2.37 g, 4.87 mmol), silver phosphate (2.65 g, 6.34 mmol), PdCl₂(PPh₃)₂(0.342 g, 0.487 mmol), and DMA (50.0 mL) was evacuated then back-filledwith N₂ three times. After purging with N₂ for about 45 min, the mixturewas warmed to about 100° C. for about 1 h. After cooling to rt, themixture was filtered rinsing with EtOAc (75 mL). The volatiles wereremoved under reduced pressure. The residue was via flash chromatographyon silica gel (DCM) to give the title compound (0.982 g, 56%); ¹H NMR(400 MHz, CDCl₃) δ 8.06 (dd, J=8.2, 2.0 Hz, 1H), 8.00 (dd, J=2.0, 0.6Hz, 1H), 7.83 (dd, J=8.2, 0.6 Hz, 1H), 7.56 (ddd, J=7.6, 1.8, 0.4 Hz,1H), 7.47 (ddd, J=8.2, 7.5, 1.8 Hz, 1H), 7.40-7.31 (m, 2H), 7.18 (d,J=3.3 Hz, 1H), 6.47 (t, J=73.5 Hz, 1H), 6.45 (d, J=3.4 Hz, 1H).

Step 7:8-Amino-1-(2-(difluoromethoxy)phenyl)-2,3-dihydro-1H-pyrrolo[2,1-a]isoindol-(9bH)-one

EtOH (34.0 mL) was added to Pd/C (10 wt % on activated carbon, 0.723 g,0.679 mmol) under N₂.1-(2-(Difluoromethoxy)phenyl)-8-nitro-5H-pyrrolo[2,1-a]isoindol-5-one(1.21 g, 3.40 mmol) was added. The mixture was shaken under about 50 psiof hydrogen for about 2.5 h. The hydrogen atmosphere was evacuated usinghouse vacuum for about 10 min then the mixture was filtered throughCelite® rinsing with MeOH (80 mL). The volatiles were removed underreduced pressure to give the title compound (1.12 g, 100%); LC/MS (TableA, Method b) R_(t)=1.85 min; MS m/z: 331 (M+H)⁺.

Step 8:rac-(1R,9bR)-1-Bromo-1-(2-(difluoromethoxy)phenyl)-2,3-dihydro-1H-pyrrolo[2,1-a]isoindol-5(9bH)-one

A solution of HBr (48 wt % in water, 1.20 mL, 10.61 mmol) and water(3.00 mL) was added to a solution of8-amino-1-(2-(difluoromethoxy)phenyl)-2,3-dihydro-1H-pyrrolo[2,1-a]isoindol-5(9bH)-one(1.19 g, 3.60 mmol) and acetonitrile (30.0 mL) under N₂ at about 0° C. Asolution of sodium nitrite (0.300 g, 4.35 mmol) and water (3.00 mL) wasadded dropwise over about 2 min. After about 30 min, copper(II) bromide(1.22 g, 5.46 mmol) was added. After about 30 min, the ice bath wasremoved. After about 40 min at rt, water (50 mL) and EtOAc (100 mL) wereadded. The layers were separated and the organics were washed with water(50 mL) and saturated aqueous NaHCO₃ (50 mL) then dried over Na₂SO₄,filtered, and concentrated under reduced pressure. The residue waspurified via flash chromatography on silica gel (1-10% EtOAc/DCM) togive a light tan solid (1.25 g). The material was dissolved in refluxingMeOH (5 mL) then allowed to cool to rt. After stirring for about 1 h,the solid was collected by filtration rinsing with MeOH (2×1 mL). Asecond crop was obtained from the residue of the mother liquor usingrefluxing MeOH (0.75 mL) and rinsing with MeOH (2×0.5 mL). The two cropswere combined then dried to give the title compound (0.942 g, 69%);LC/MS (Table A, Method b) R_(t)=2.34 min; MS m/z: 394 and 396 (M+H)⁺.

Preparation #21:(1S,9bS)-8-Bromo-1-(2-(difluoromethoxy)phenyl)-2,3-dihydro-1H-pyrrolo[2,1-a]isoindol-5(9bH)-one

rac-(1R,9bR)-8-Bromo-1-(2-(difluoromethoxy)phenyl)-2,3-dihydro-1H-pyrrolo[2,1-a]isoindol-5(9bH)-one(0.947 g, 2.40 mmol) (Preparation #20) was submitted for chiralpurification (Table B, Method 15). Fractions from the first eludingcomponent were combined and concentrated under reduced pressure thendried to give the title compound (0.372 g, 39%) with negative (−)optical rotation; LC/MS (Table A, Method a) R_(t)=2.31 min; MS m/z: 394and 396 (M+H)⁺

Preparation #22:(1R,9bR)-8-Bromo-1-(2-(difluoromethoxy)phenyl)-2,3-dihydro-1H-pyrrolo[2,1-a]isoindol-5(9bH)-one

rac-(1R,9bR)-8-Bromo-1-(2-(difluoromethoxy)phenyl)-2,3-dihydro-1H-pyrrolo[2,1-a]isoindol-5(9bH)-one(0.947 g, 2.40 mmol) (Preparation #20) was submitted for chiralpurification (Table B, Method 15). Fractions from the second eludingcomponent were combined and concentrated under reduced pressure thendried to give the title compound (0.356 g, 37%) with positive (+)optical rotation; LC/MS (Table A, Method a) R_(t)=2.31 min; MS m/z: 394and 396 (M+H)⁺

Preparation #23: 6-Bromo-5-fluoro-1H-indazol-3(2H)-one

To a mixture of 4-bromo-2,5-difluorobenzoic acid (5.0 g, 21 mmol) in DCM(80 mL) was slowly added oxalyl chloride (2.8 mL, 32 mmol) at rt. DMF(0.02 mL, 0.258 mmol) was added then the mixture was stirred for about2.5 h. The mixture was concentrated under reduced pressure then theresidue was dissolved in DCM (40 mL). The solution was slowly added tohydrazine (3.3 mL, 150 mmol) in DCM (40 mL) at about −35 to −50° C. Themixture was warmed to about 5° C. then the solids were collected byfiltration and washed with DCM (50 mL) then Et₂O (50 mL). The materialwas dried under vacuum to yield 4.9 g of tan solid. The material wasadded to n-butanol (130 mL) with hydrazine hydrate (10 mL, 205 mmol)then heated to about 120° C. for about 22 h. The mixture wasconcentrated under reduced pressure to about one half volume. Solidswere collected by filtration and discarded. The filtrate wasconcentrated to dryness then triturated with EtOAc (50 mL). Solids werecollected by filtration and dried under vacuum to give the titlecompound (1.2 g, 25%); ¹H NMR (400 MHz, DMSO-d₆) δ 11.23 (bs, 2H), 7.64(d, J=5.5 Hz, 1H), 7.52 (dd, J=8.7, 1.2 Hz, 1H).

Preparation #24:6-Bromo-1-(1-(2-(difluoromethoxy)phenyl)-3-hydroxypropyl)-5-fluoro-1H-indazol-3(2H)-one

6-Bromo-1-(1-(2-(difluoromethoxy)phenyl)-3-hydroxypropyl)-5-fluoro-1H-indazol-3(2H)-onewas synthesized in a manner similar to Preparation #1, steps 1 through 5from 2-(difluoromethoxy)benzaldehyde and6-bromo-5-fluoro-1H-indazol-3(2H)-one (Preparation #23); LC/MS (Table A,Method d) R_(t)=1.44 min; MS m/z: 413 and 415 (M+H)⁺

Preparation #25:(R)-1-(4-(5-Bromopyrimidin-2-yl)-2-methylpiperazin-1-yl)ethanone

Step 1: (R)-tert-Butyl4-(5-bromopyrimidin-2-yl)-2-methylpiperazine-1-carboxylate

EtOH (250 mL) was added to a mixture of 5-bromo-2-chloropyrimidine (10.1g, 52.2 mmol) and (R)-1-N-Boc-2-methylpiperazine (10.0 g, 49.9 mmol).TEA (21.0 mL, 151 mmol) was added. The solution was warmed to about 75°C. for about 8 h. The mixture was cooled and concentrated under reducedpressure then the mixture was partitioned between water (100 ml), Et₂O(100 mL) and EtOAc (100 mL). The layers were separated then the organiclayer was washed with water (100 mL). The aqueous layers were extractedwith EtOAc (50 mL). The combined organic layers were dried over Na₂SO₄,filtered, and concentrated. The material was purified via flashchromatography on silica gel (0-25% EtOAc/heptane) to give the titlecompound (16.6 g, 94%); LC/MS (Table A, Method d) R_(t)=1.86 min; MSm/z: 301 and 303 (M+H)⁺

Step 2: (R)-5-Bromo-2-(3-methylpiperazin-1-yl)pyrimidine dihydrochloride

To a solution of (R)-tert-butyl4-(5-bromopyrimidin-2-yl)-2-methylpiperazine-1-carboxylate (4 g, 11.20mmol) in 1,4-dioxane (40 mL) was added hydrogen chloride (28.0 ml, 112mmol) (4N in 1,4-dioxane) at rt. The reaction was stirred at rt forabout 24 h. The solids were collected by filtration and washed withdiethyl ether then dried under vacuum to give the title compound (3.67g, 99%); LC/MS (Table A, Method d) R_(t)=1.86 min; MS m/z: 257 and 259(M+H)⁺

Step 3: (R)-1-(4-(5-Bromopyrimidin-2-yl)-2-methylpiperazin-1-yl)ethanone

(R)-5-Bromo-2-(3-methylpiperazin-1-yl)pyrimidine dihydrochloride (3.67g, 11.12 mmol) in DCM (100 mL) was treated with TEA (5.1 mL, 37 mmol).Acetyl chloride (0.90 mL, 12.8 mmol) was added while maintaining thereaction temperature below 30° C. After complete addition the mixturewas washed with water (50 mL) and brine (50 mL) then dried over sodiumsulfate, filtered and concentrated under reduced pressure to give thetitle compound (3.32 g, 99%) LC/MS (Table A, Method d) R_(t)=0.45 min;MS m/z: 257 and 259 (M+H)⁺

Preparation #26:(R)-1-(4-(5-bromopyrimidin-2-yl)-2-methylpiperazin-1-yl)-2-hydroxyethanone

(R)-5-Bromo-2-(3-methylpiperazin-1-yl)pyrimidine dihydrochloride (2.0 g,6.06 mmol), glycolic acid (0.69 g, 9.1 mmol) and HATU (2.76 g, 7.27mmol) in DMF (30 mL) was treated with TEA (3.4 mL, 24 mmol) then stirredfor about 90 min. The mixture was concentrated under reduced pressurethen water and saturated aqueous sodium bicarbonate were added. Themixture was extracted with EtOAc (75 mL). The organic solution waswashed with brine, dried over magnesium sulfate, filtered andconcentrated. The material was purified via flash chromatography onsilica gel (0-100% EtOAc/DCM) to give the title compound (1.89 g, 99%);LC/MS (Table A, Method d) R_(t)=0.90 min; MS m/z: 315 and 317 (M+H)⁺

Preparation #27: 2-(Difluoromethoxy)-5-methylbenzaldehyde

2-Hydroxy-5-methylbenzaldehyde (20 g, 147 mmol) in MeCN (500 mL) wascooled to about −25° C. A solution of KOH (165 g, 2938 mmol) in water(500 mL) was added over about 30 min keeping the temperature of themixture below about −25° C. The mixture was cooled to an internaltemperature of about −35° C. then diethyl(bromodifluoromethyl)phosphonate (58.8 g, 220 mmol) was added over about5 min. The mixture was warmed to about 5° C. Diethyl ether (1 L) wasadded then the phases were allowed to separate. The organic layer waswashed with water and brine (1 L each) and then dried over sodiumsulfate and filtered. The filtrate was concentrated under reducedpressure then the material was purified via silica gel chromatography(0-30% EtOAc/heptane) to give the title compound (15.2 g, 56%); ¹H NMR(400 MHz, Chloroform-d) δ 10.36 (s, 1H), 7.73 (d, J=1.5 Hz, 1H), 7.41(dd J=8.4, 1.5 Hz, 1H), 7.13 (d, J=8.4 Hz, 1H), 6.61 (J=73.1 Hz, 1H),2.39 (s, 3H).

Preparation #28:6-Bromo-3-(2-(difluoromethoxy)-5-methylphenyl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one

6-Bromo-3-(2-(difluoromethoxy)-5-methylphenyl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-onewas synthesized in a manner similar to Preparation #1, steps 1 through 5from 2-(difluoromethoxy)-5-methylbenzaldehyde (Preparation #27) and6-bromo-1H-indazol-3(2H)-one; LC/MS (Table A, Method d) R_(t)=1.53 min;MS m/z: 409 and 411 (M+H)⁺

Preparation #29:6-Bromo-3-(2-(difluoromethoxy)-5-methylphenyl)-7-fluoro-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one

6-Bromo-3-(2-(difluoromethoxy)-5-methylphenyl)-7-fluoro-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-onewas synthesized in a manner similar to Preparation #1, steps 1 through 5from 2-(difluoromethoxy)-5-methylbenzaldehyde (Preparation #27) and6-bromo-5-fluoro-1H-indazol-3(2H)-one (Preparation #23); LC/MS (Table A,Method d) R_(t)=1.56 min; MS m/z: 427, 429 (M+H)⁺

Preparation #30:(S)-6-Bromo-3-(2-(difluoromethoxy)-5-methylphenyl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one

6-Bromo-3-(2-(difluoromethoxy)-5-methylphenyl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one(0.322 g, 0.787 mmol) (Preparation #28) was submitted for chiralpurification (Table B, Method 20). Fractions from the first elutingcomponent were combined and concentrated under reduced pressure thentaken into water, frozen and lyophilized to give the title compound(0.148 g, 22%) with an inconclusive optical rotation. LC/MS (Table A,Method a) R_(t)=2.34 min; MS m/z: 409, 411 (M+H)⁺.

Preparation #31:(R)-6-Bromo-3-(2-(difluoromethoxy)-5-methylphenyl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one

6-Bromo-3-(2-(difluoromethoxy)-5-methylphenyl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one(0.322 g, 0.787 mmol) (Preparation #28) was submitted for chiralpurification (Table B, Method 20). Fractions from the second elutingcomponent were combined and concentrated under reduced pressure thentaken into water, frozen and lyophilized to give the title compound(0.152 g, 22%) with an inconclusive optical rotation. LC/MS (Table A,Method a) R_(t)=2.34 min; MS m/z: 409, 411 (M+H)⁺.

Example 13-(2-(Difluoromethoxy)phenyl)-6-(2-morpholinopyrimidin-5-yl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one

6-Bromo-3-(2-(difluoromethoxy)phenyl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one(0.400 g, 1.012 mmol) (Preparation #1),4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-yl)morpholine(0.442 g, 1.52 mmol) and cesium carbonate (0.989 g, 3.04 mmol) wereadded to a flask with 1,4-dioxane (3 mL) and water (0.75 mL). The flaskwas purged and flushed with N₂. Pd(Ph₃P)₄ (0.082 g, 0.071 mmol) was thenadded and mixture was purged again and then heated to 90° C. under N₂for about 30 min. The mixture was cooled to rt and aqueous sodiumbicarbonate solution (5 mL) and EtOAc (10 mL) were added. The aqueouslayer was extracted with EtOAc (3×5 mL), then the organics were driedover MgSO₄ and concentrated under reduced pressure. The residue waspurified via flash chromatography on silica gel (0-100% EtOAc/DCM then0-10% MeOH/DCM). The fractions were concentrated then purified furthervia flash chromatography on silica gel (100% EtOAc) to give the titlecompound (0.335 g, 69%). LC/MS (Table A, Method a) R_(t)=2.07 min; MSm/z: 480 (M+H)⁺. TNF IC₅₀=A

The compounds shown in Table 1 were synthesized in a manner similar toExample #1 from6-bromo-3-(2-(difluoromethoxy)phenyl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one(Preparation #1) and the corresponding boronic acid/boronate. Thecorresponding enantiomers were separated by the chiral methods listed inTable B when applicable.

TABLE 1 Method for chiral Exam- R_(t) min m/z separation/ ple (Table A,ESI+ Order of TNF Boronic acid/boronate Product # Method) (M + H)⁺elution/Sign IC₅₀ 4-(5-(4,4,5,5-Tetramethyl- 1,3,2-dioxaborolan-2-yl)pyrimidin-2- yl)morpholine

1.1 2.07 (a) 480 3/1^(st)/+ A 4-(5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2- yl)pyrimidin-2- yl)morpholine

1.2 2.07 (a) 480 3/2^(nd)/− A 1-(5-Boronopyrimidin-2-yl)piperidine-4-carboxylic acid (synthesized as described inWO2014009295A1)

1.3 1.86 (a) 523 NA B (R)-2-(2- (Methoxymethyl) pyrrolidin-1-yl)-5-(4,4,5,5- tetramethyl-1,3,2- dioxaborolan-2- yl)pyrimidine(Preparation #4)

1.4 2.31 (a) 508 4/2^(nd)/NA B (R)-2-(2- (Methoxymethyl) pyrrolidin-1-yl)-5-(4,4,5,5- tetramethyl-1,3,2- dioxaborolan-2- yl)pyrimidine(Preparation #4)

1.5 2.31 (a) 508 4/1^(st)/NA B (R)-N-(Tetrahydrofuran-3-yl)-5-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolan-2- yl)pyrimidin-2-amine(Preparation #5)

1.6 1.80 (a) 480 5/1^(st)/+ B (R)-N-(Tetrahydrofuran-3-yl)-5-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolan-2- yl)pyrimidin-2-amine(Preparation #5)

1.7 1.80 (a) 480 5/2^(nd)/NA B (R)-(2-(2- (Hydroxymethyl) morpholino)pyrimidin-5-yl)boronic acid (Preparation #6)

1.8 1.77 (a) 510 1/1^(st)/+ A (R)-2-(2- (Hydroxymethyl) morpholino)pyrimidin-5-yl)boronic acid (Preparation #6)

1.9 1.77 (a) 510 1/2^(nd)/− A

The compound shown in Table 2 were synthesized in a manner similar toExample #1 from(S)-6-bromo-3-(2-(difluoromethoxy)phenyl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one(Preparation #2) and the corresponding boronic acid/boronate.

TABLE 2 R_(t) min Example (Table A, m/z ESI+ TNF Boronic acid/boronateProduct # Method) (M + H)⁺ IC₅₀ (S)-(2-(2- (Hydroxymethyl)morpholino)pyrimidin-5-yl)boronic acid (synthesized from (S)-tert- butyl 2-(hydroxymethyl)morpholine- 4-carboxylate using methods similar toPreparation #6)

2.1 1.77 (a) 510 A

The compound shown in Table 3 were synthesized in a manner similar toExample #1 from(R)-6-bromo-3-(2-(difluoromethoxy)phenyl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one(Preparation #3) and the corresponding boronic acid/boronate.

TABLE 3 R_(t) min Example (Table A, m/z ESI+ TNF Boronic acid/boronateProduct # Method) (M + H)+ IC₅₀ (S)-(2-(2- (Hydroxymethyl)morpholino)pyrimidin-5-yl)boronic acid (synthesized from (S)-tert-butyl2-(hydroxymethyl)morpholine- 4-carboxylate using methods similar toPreparation #6)

3.1 1.77 (a) 510 A

Example 4(R)-3-(2-(Difluoromethoxy)phenyl)-6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one

Step 1:3-(2-(Difluoromethoxy)phenyl)-6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one

2-(5-Bromopyrimidin-2-yl)propan-2-ol (0.038 g, 0.177 mmol),4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (0.087 g,0.342 mmol), potassium acetate (0.041 g, 0.418 mmol) and 1,4-dioxane (2mL) were combined in a round flask under a N₂ atmosphere. The mixturewas purged and flushed with N₂. PdCl₂(dppf) (6.48 mg, 8.86 μmol) wasadded then the flask was once again purged and flushed with N₂ and thenwas heated to about 95° C. for about 90 min. The mixture was cooled tort and then6-bromo-3-(2-(difluoromethoxy)phenyl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one(0.050 g, 0.127 mmol) (Preparation #1), water (0.500 mL), cesiumcarbonate (0.103 g, 0.316 mmol) and Pd(Ph₃P)₄ (0.0088 g, 0.0076 mmol)were added. After purging and flushing with N₂, the mixture was heatedto about 100° C. for about 30 min. The mixture was cooled to rt, thenwater (10 mL) and DCM (10 mL) were added. The layers were separated thenthe aqueous portion was extracted with DCM (10 mL). The combinedorganics were dried over MgSO₄ filtered and concentrated under reducedpressure. The material was purified via flash chromatography on silicagel (0-100% EtOAc/DCM) to give the title compound (0.025, 44%); LC/MS(Table A, Method b) R_(t)=1.87 min; MS m/z: 453 (M+H)⁺.

Step 2:(R)-3-(2-(Difluoromethoxy)phenyl)-6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one

3-(2-(Difluoromethoxy)phenyl)-6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one(0.051 g, 0.11 mmol) was submitted for chiral purification (Table B,Method 2). The first eluting fractions were concentrated to give thetitle compound (0.017 g, 30%) with undetermined optical rotation. LC/MS(Table A, Method a) R_(t)=1.85 min; MS m/z: 453 (M+H)⁺.

The compounds shown in Table 4 were synthesized in a manner similar toExample #4 from6-bromo-3-(2-(difluoromethoxy)phenyl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one(Preparation #1) and the corresponding bromide. Enantiomers wereseparated by the chiral methods listed in Table B when applicable.

TABLE 4 Method for chiral Exam- R_(t) min separation/ ple (Table A, m/zESI+ Order of TNF Bromide Product # Method) (M + H)⁺ elution/Sign IC₅₀2-(5-Bromopyrimidin-2- yl)propan-2-ol

4.1 1.85 (a) 453 2/2^(nd)/− B 1-(5-Bromopyrimidin-2- yl)piperidin-4-ol

4.2 1.82 (a) 494 NA A (S)-4-(((5-Bromo- pyrimidin-2- yl)amino)methyl)pyrrolidin-2-one (Preparation #12)

4.3 1.61 (b) 507 9/^(2nd)/NA B (S)-4-(((5-Bromo- pyrimidin-2-yl)amino)methyl) pyrrolidin-2-one (Preparation #12)

4.4 1.61 (b) 507 9/1^(st)/NA A (R)-4-(((5-Bromo- pyrimidin-2-yl)amino)methyl) pyrrolidin-2-one (Preparation #13)

4.5 1.62 (b) 507 10/2^(nd)/NA B (R)-4-(((5-Bromo- pyrimidin-2-yl)amino)methyl) pyrrolidin-2-one (Preparation #13)

4.6 1.62 (b) 507 10/1^(st)/NA B 7-(5-Bromo- pyrimidin-2-yl)-7-azaspiro[3.5]nonan- 2-ol (synthesized from 7-azaspiro[3.5]nonan- 2-ol,Hydrochloric Acid and 5-bromo-2- chloropyrimidine using methods similarto Preparation #10)

4.7 2.09 (b) 534 11/1^(st)/NA A 7-(5-Bromopyrimidin-2-yl)-7-azaspiro[3.5] nonan-2-ol (synthesized from 7-azaspiro[3.5]nonan-2-ol, Hydrochloric Acid and 5-bromo-2- chloropyrimidine using methodssimilar to Preparation #10)

4.8 2.09 (b) 534 11/2^(nd)/NA A

The compounds shown in Table 5 were synthesized in a manner similar toExample #4 from(S)-6-bromo-3-(2-(difluoromethoxy)phenyl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one(Preparation #2) and the corresponding bromide.

TABLE 5 Exam- R_(t) min Optical ple (Table A, m/z ESI+ Rota- TNF BromideProduct # Method) (M + H)⁺ tion IC₅₀ (S)-7-(5-Bromopyrimidin-2-yl)hexahydroimidazo [1,5-a]pyrazin-3(2H)-one (Preparation #8)

5.1 1.72 (a) 534 — A (R)-7-(5-Bromopyrimidin- 2-yl)hexahydroimidazo[1,5-a]pyrazin-3(2H)-one (Preparation #9)

5.2 1.72 (a) 534 — A

The compounds shown in Table 6 were synthesized in a manner similar toExample #4 from(R)-6-bromo-3-(2-(difluoromethoxy)phenyl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one(Preparation #3) and the corresponding bromide.

TABLE 6 Exam- R_(t) min Optical ple (Table A, m/z ESI+ Rota- TNF BromideProduct # Method) (M + H)⁺ tion IC₅₀ (S)-7-(5- Bromopyrimidin-2-yl)hexahydroimidazo [1,5-a]pyrazin-3(2H)- one (Preparation #8)

6.1 1.72 (a) 534 + A (R)-7-(5- Bromopyrimidin-2- yl)hexahydroimidazo[1,5-a]pyrazin-3(2H)- one (Preparation #9)

6.2 1.72 (a) 534 NA A (R)-1-(4-(5- Bromopyrimidin-2-yl)-2-methylpiperazin- 1-yl)ethanone (Preparation #25)

6.3 1.85 (a) 535 NA A (R)-1-(4-(5- Bromopyrimidin- 2-yl)-2-methylpiperazin- 1-yl)-2- hydroxyethanone (Preparation #26)

6.4 1.77 (a) 551 NA A (R)-1-(4-(5- Bromopyrimidin- 2-yl)-3-methylpiperazin- 1-yl)ethanone (synthesized in a manner similar toPreparation #25 from 5-bromo-2- chloropyrimidine and (R)-tert-butyl 3-methylpiperazine-1- carboxylate)

6.5 2.00 (b) 535 NA A 2-(5-Bromo-4- methylpyrimidin-2-yl) propan-2-ol(synthesized as described in WO2015/86506A1)

6.6 1.92 (a) 467 NA A

Example 7(R)-3-(2-(Difluoromethoxy)phenyl)-6-(2-((3-methoxypropyl)amino)pyrimidin-5-yl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one

Step 1:3-(2-(Difluoromethoxy)phenyl)-6-(2-((3-methoxypropyl)amino)pyrimidin-5-yl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one

To a solution of (2-((3-methoxypropyl)amino)pyrimidin-5-yl)boronic acid(0.187 g, 0.886 mmol) (synthesized from 3-methoxypropan-1-amine and5-bromo-2-chloropyrimidine using methods similar to Preparation #6 step2 in EtOH (2 mL) was added6-bromo-3-(2-(difluoromethoxy)phenyl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one(0.050 g, 0.127 mmol) (Preparation #1) followed by Cs₂CO₃ (0.124 g,0.380 mmol) and SiliaCat® DPP-Pd (0.053 g, 0.013 mmol). Under anatmosphere of N₂, the mixture was heated to about 90° C. for about 45min. The reaction mixture was cooled to rt and the catalyst was filteredoff and rinsed with excess MeOH. The filtrate was concentrated underreduced pressure and the residue was purified via flash chromatographyon silica gel (50-1000/% EtOAc/DCM then 0-7% MeOH/DCM) to give the titlecompound (0.053 g, 87%); LC/MS (Table A, Method b) R_(t)=1.95 min; MSm/z: 482 (M+H)⁺.

Step 2:(R)-3-(2-(Difluoromethoxy)phenyl)-6-(2-((3-methoxypropyl)amino)pyrimidin-5-yl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one

3-(2-(Difluoromethoxy)phenyl)-6-(2-((3-methoxypropyl)amino)pyrimidin-5-yl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one(0.085 g, 0.177 mmol) was submitted for chiral purification (Table B,Method 6). Fractions from the first eluting component were combined andconcentrated under reduced pressure then taken into water, frozen andlyophilized to give the title compound (0.029 g, 34%) with positive (+)optical rotation. LC/MS (Table A, Method a) R_(t)=1.92 min; MS m/z: 482(M+H)⁺.

Example 8(S)-3-(2-(Difluoromethoxy)phenyl)-6-(2-((3-methoxypropyl)amino)pyrimidin-5-yl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one

3-(2-(Difluoromethoxy)phenyl)-6-(2-((3-methoxypropyl)amino)pyrimidin-5-yl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one(0.085 g, 0.177 mmol) (Example 7, step 1) was submitted for chiralpurification (Table B, Method 6). Fractions from the second elutingcomponent were combined and concentrated under reduced pressure thentaken into water, frozen and lyophilized to give the title compound(0.028 g, 33%) with negative (−) optical rotation. LC/MS (Table A,Method a) R_(t)=1.92 min; MS m/z: 482 (M+H)⁺.

Example 9(S)-6-(2-(4-Acetylpiperazin-1-yl)pyrimidin-5-yl)-3-(2-(difluoromethoxy)phenyl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one

6-(2-(4-Acetylpiperazin-1-yl)pyrimidin-5-yl)-3-(2-(difluoromethoxy)phenyl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one(0.095 g, 0.18 mmol) (Preparation #14) was submitted for chiralpurification (Table B, Method 13). Fractions from the first elutingcomponent were combined and concentrated under reduced pressure thendried in a vacuum oven at about 65° C. for about 24 h to give the titlecompound (0.038 g, 35%), optical rotation (NA); LC/MS (Table A, Methodb) R_(t)=1.89 min; MS m/z: 521 (M+H)⁺.

Example 10(R)-6-(2-(4-Acetylpiperazin-1-yl)pyrimidin-5-yl)-3-(2-(difluoromethoxy)phenyl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one

6-(2-(4-Acetylpiperazin-1-yl)pyrimidin-5-yl)-3-(2-(difluoromethoxy)phenyl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one(Preparation #14) was submitted for chiral purification (Table B, Method13). Fractions from the second eluting component were combined andconcentrated under reduced pressure then dried in a vacuum oven at about65° C. for about 24 h to give the title compound (0.032 g, 31%), opticalrotation (NA); LC/MS (Table A, Method b) R_(t)=1.89 min; MS m/z: 521(M+H)⁺.

The compounds shown in Table 7 were synthesized in a manner similar toExample #1, step 1 from3-bromo-6-(2-(difluoromethoxy)phenyl)-8,9-dihydro-6H-pyridazino[1,2-a]indazol-11(7H)-one(Preparation #15) and the corresponding boronic acid/boronate.

TABLE 7 R_(t) min Example (Table A, m/z ESI+ TNF Boronic acid/boronateProduct # Method) (M + H)⁺ IC₅₀ 2-(4-Morpholino)pyrimidine- 5-boronicacid pinacol ester

7.1 2.19 (a) 494 A 1-(5-(4,4,5,5-Tetramethyl- 1,3,2-dioxaborolan-2-yl)pyrimidin-2-yl)piperidin-4- ol (0.102 g, 0.334 mmol) (synthesizedfrom 1-(5- bromopyrimidin-2- yl)piperidin-4-ol using methods similar toPreparation #4)

7.2 1.93 (a) 508 B

Example 116-(2-(Difluoromethoxy)phenyl)-3-(2-(1,1-dioxidothiomorpholino)pyrimidin-5-yl)-8,9-dihydro-6H-pyridazino[1,2-a]indazol-11(7H)-one

A mixture of6-(2-(difluoromethoxy)phenyl)-3-(2-thiomorpholinopyrimidin-5-yl)-8,9-dihydro-6H-pyridazino[1,2-a]indazol-11(7H)-one(0.118 g, 0.208 mmol) (Preparation #16) in DCM (2 mL) was cooled in anice water bath for about 5 min, after which m-CPBA (˜77%) (0.085 g, 0.38mmol) was added in one portion. The resulting solution was allowed tostir at about 0° C. for about 30 min. The reaction mixture waspartitioned between DCM (20 mL) and saturated aqueous NaHCO₃ (20 mL).After separating the layers, the aqueous phase was extracted with DCM(3×5 mL). The combined organic phases were washed with saturated aqueousNaCl (10 mL), dried over Na₂SO₄, filtered, and concentrated underreduced pressure. The resulting solid was triturated with DCM (3 mL),isolated by vacuum filtration and air dried to give the title compound(0.057 g, 50%); LC/MS (Table A, Method a) R_(t)=2.01 min; MS m/z: 542(M+H)⁺.

Example 123-(2-Methoxyphenyl)-6-(2-morpholinopyrimidin-5-yl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one

A mixture of 2-(4-morpholino)pyrimidine-5-boronic acid pinacol ester(0.063 g, 0.217 mmol),6-bromo-3-(2-methoxyphenyl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one(0.052 g, 0.145 mmol) (Preparation #17), Pd(Ph₃P)₄ (0.017 g, 0.014mmol), and cesium carbonate (0.141 g, 0.434 mmol) in 1,4-dioxane (1.2mL)/water (0.3 mL) was heated at reflux for about 12 min. After cooling,the reaction mixture was partitioned between EtOAc (5 mL) and water (5mL). The layers were separated and the aqueous phase was extracted withEtOAc (2×2 mL). The combined organics were washed with saturated aqueousNaCl (5 mL), dried over Na₂SO₄, filtered, and concentrated under reducedpressure. The material was purified via flash chromatography on silicagel (0-50% of 1:9 MeOH:EtOAc/DCM) to give the title compound (0.056 g,87%); LC/MS (Table A, Method a) R_(t)=2.03 min; MS m/z: 444 (M+H)⁺.

Example 13(R)-6-(2-(2-Hydroxypropan-2-yl)pyrimidin-5-yl)-3-(2-methoxyphenyl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one

6-(2-(2-Hydroxypropan-2-yl)pyrimidin-5-yl)-3-(2-methoxyphenyl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one(0.080 g, 0.19 mmol) (Preparation #14) was submitted for chiralpurification (Table B, Method 18). Fractions from the first elutingcomponent were combined and concentrated under reduced pressure to givethe title compound (0.030 g, 34%) with positive (+) optical rotation.LC/MS (Table A, Method a) R_(t)=1.81 min; MS m/z: 417 (M+H)⁺.

Example #14(S)-6-(2-(2-Hydroxypropan-2-yl)pyrimidin-5-yl)-3-(2-methoxyphenyl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one

6-(2-(2-Hydroxypropan-2-yl)pyrimidin-5-yl)-3-(2-methoxyphenyl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one(0.080 g, 0.19 mmol) (Preparation #14) was submitted for chiralpurification (Table B, Method 18). Fractions from the second elutingcomponent were combined and concentrated under reduced pressure to givethe title compound (0.030 g, 34%) with negative (−) optical rotation.LC/MS (Table A, Method a) R_(t)=1.81 min; MS m/z: 417 (M+H)⁺.

The compounds shown in Table 8 were synthesized in a manner similar toExample #1, step 1 from a3-bromo-6-(2-(aryl)-8,9-dihydro-6H-pyridazino[1,2-a]indazol-11(7H)-oneorbromo-6-(2-(heteroaryl)-8,9-dihydro-6H-pyridazino[1,2-a]indazol-11(7H)-one(Prepared from the appropriate halide and 6-bromo-1H-indazol-3(2H)-onein a manner similar to Preparation 1, steps 3 through 5) and2-(4-morpholino)pyrimidine-5-boronic acid pinacol ester.

TABLE 8 R_(t) min Example (Table A, m/z ESI+ TNF Halide Product #Method) (M + H)⁺ IC₅₀ 2-(1-Chlorobut-3-en-1-yl)-6- methylbenzonitrile(synthesized from Preparation #19 using methods similar to Preparation#17, Step 2)

8.1 1.96 (a) 453 B (1-Bromobut-3-en-1- yl)benzene (synthesized frombenzaldehyde using methods similar to Preparation #1, Steps 1 and 2)

8.2 1.98 (a) 414 B 3-(1-Bromobut-3-en-1-yl)-4- methoxybenzonitrile(synthesized from 3-formyl-4- methoxybenzonitrile (synthesized from5-bromo-2- methoxybenzaldehyde as described in Tetrahedron Letters,46(11), 1815-1818, 2005) using methods similar to Preparation #19, Step4 and Preparation #1, Step 2)

8.3 1.85 (a) 469 B 3-(1-Bromobut-3-en-1-yl)-2- methoxybenzonitrile(synthesized from 3-formyl-2- methoxybenzonitrile (synthesized from3-bromo-2- methoxybenzaldehyde as described in Tetrahedron Letters,46(11), 1815-1818, 2005) using methods similar to Preparation #19, Step4 and Preparation #1, Step 2)

8.4 1.92 (a) 469 B 5-(1-Bromobut-3-en-1-yl)-1- isopropyl-1H-pyrazole(synthesized from 1- isopropyl-1H-pyrazole-5- carbaldehyde using methodssimilar to Preparation #1, Steps 1 and 2)

8.5 1.68 (a) 446 C

Example #152-Methyl-6-(6-(2-morpholinopyrimidin-5-yl)-9-oxo-1,2,3,9-tetrahydropyrazolo[1,2-a]indazol-3-yl)benzamide

A flask was charged with2-methyl-6-(6-(2-morpholinopyrimidin-5-yl)-9-oxo-1,2,3,9-tetrahydropyrazolo[1,2-a]indazol-3-yl)benzonitrile(0.050 g, 0.11 mmol) (Example #8.1),

sodium hydroxide (32 wt % in water, 0.138 g, 1.11 mmol), MeOH (1.0 mL)and water (1.0 mL).

After about 20 h at about 90° C., the reaction mixture was cooled toambient temperature and then partitioned between saturated aqueousNaHCO₃ (5 mL) and DCM (50 mL). The aqueous phase was extracted withEtOAc (30 mL). The combined organics were concentrated under reducedpressure. The residue was dissolved in 10% MeOH/DCM (50 mL). Thesolution was dried over MgSO₄, filtered, and concentrated under reducedpressure. The residue was purified via flash chromatography on silicagel (1-10% MeOH/DCM) to give the title compound (0.018 g, 34%); LC/MS(Table A, Method a) R_(t)=1.62 min; MS m/z: 471 (M+H)⁺.

Example 16rac-(1R,9bR)-1-(2-(Difluoromethoxy)phenyl)-8-(2-morpholinopyrimidin-5-yl)-2,3-dihydro-1H-pyrrolo[2,1-a]isoindol-5(9bH)-one

Step 1:3-(2-(Difluoromethoxy)phenyl)-3-((trimethylsilyl)oxy)propanenitrile

A flask was charged with tris(2,4,6-trimethoxyphenyl)phosphine (0.310 g,0.582 mmol), 2-(difluoromethoxy)benzaldehyde (1.00 g, 5.81 mmol) and2-(trimethylsilyl)acetonitrile (0.905 g, 7.99 mmol). The mixture waswarmed to about 60° C. for about 14 h. The mixture was cooled to rt thendiluted with water (50 mL) and extracted with EtOAc (2×25 mL). Thecombined organics were washed with saturated aqueous NaCl, dried overMgSO₄, filtered and concentrated under reduced pressure. The materialwas purified via flash chromatography on silica gel 75:25 heptane/EtOAc)to give the title compound (1.48 g, 89%); LC/MS (Table A, Method b)R_(t)=2.63 min; MS m/z: 286 (M+H)⁺

Step 2: 3-(2-(Difluoromethoxy)phenyl)-3-hydroxypropanenitrile

A flask was charged with MeOH (25 mL) then hydrogen chloride gas wasbubbled into the solution for about 5 min. The solution was added to3-(2-(difluoromethoxy)phenyl)-3-((trimethylsilyl)oxy)propanenitrile(1.46 g, 5.12 mmol) then the mixture was stirred for about 30 min. Themixture was concentrated on under reduced pressure then the material waspurified via flash chromatography on silica gel (0-40% EtOAc/DCM) togive the title compound (1.05 g, 96%); ¹H NMR (400 MHz, DMSO-d₆) δ 7.61(dd, J=7.7, 1.8 Hz, 1H), 7.42-6.99 (m, 4H), 6.02 (d, J=4.6 Hz, 1H),5.14-5.09 (m, 1H), 2.92-2.72 (m, 2H).

Step 3: 3-Amino-1-(2-(difluoromethoxy)phenyl)propan-1-ol

A flask was charged with THF (12 mL) and lithium aluminum hydride (0.411g, 10.8 mmol). The mixture was cooled to about 0° C. then3-(2-(difluoromethoxy)phenyl)-3-hydroxypropanenitrile (1.05 g, 4.93mmol) in THF (12 mL) was added over about 20 min keeping the internaltemperature of the mixture between about 0° C. and 5° C. After completeaddition the mixture was stirred at about 0° C. for about 15 min thenthe mixture was allowed to warm to rt. After about 1 h the mixture wasdiluted with THF (10 mL) then sodium sulfate decahydrate (3.0 g, 9.3mmol) was added slowly. The mixture was stirred for about 6 h thensodium sulfate decahydrate (1.0 g, 3.1 mmol) was added. The mixture wasstirred for about 12 h then filtered through a bed of Celite® and thepad was washed with EtOAc (25 mL). The filtrate was concentrated underreduced pressure to give the title compound (0.868 g, 81%); LC/MS (TableA, Method b) R_(t)=0.99 min; MS m/z: 218 (M+H)⁺

Step 4:5-Bromo-2-(3-(2-(difluoromethoxy)phenyl)-3-hydroxypropyl)isoindolin-1-one

A flask was charged with3-amino-1-(2-(difluoromethoxy)phenyl)propan-1-ol (0.77 g, 3.5 mmol),McOH (15 mL), methyl 4-bromo-2-(bromomethyl)benzoate (0.863 g, 2.80mmol) and DIEA (0.538 mL, 3.08 mmol). The mixture was warmed to about75° C. for about 3 h then cooled to rt and concentrated under reducedpressure. The material was partitioned between EtOAc (25 mL) water (25mL). Hydrochloric acid (1 N) was added until the aqueous layer wasacidic by pH paper. The organic layer was washed with saturated aqueousNaCl, dried over MgSO₄, filtered and the filtrate concentrated underreduced pressure. The residue was purified via flash chromatography onsilica gel (0-30% EtOAc/DCM). The appropriate fractions were collectedand concentrated under reduced pressure to give the title compound(0.807 g, 70%); LC/MS (Table A, Method b) R_(t)=2.24 min; MS m/z: 412,414 (M+H)⁺

Step 5:5-Bromo-2-(3-bromo-3-(2-(difluoromethoxy)phenyl)propyl)isoindolin-1-one

A flask was charged with5-bromo-2-(3-(2-(difluoromethoxy)phenyl)-3-hydroxypropyl)isoindolin-1-one(0.375 g, 0.910 mmol), DCM (9 mL) and tribromophosphine (1 M in DCM)(1.0 mL, 1.0 mmol). The mixture was stirred for about 1 h then water (2mL) was added and the mixture was then stirred for about 30 min. Themixture was diluted with DCM (25 mL) then cooled to about 0° C. andbasified with saturated aqueous sodium bicarbonate. The organic layerwas washed with saturated aqueous NaCl, dried over MgSO₄, filtered andthe filtrate concentrated under reduced pressure to give the titlecompound (0.328 g, 76%); LC/MS (Table A, Method b) R_(t)=2.51 min; MSm/z: 474, 476, 478 (M+H)⁺

Step 6:8-Bromo-1-(2-(difluoromethoxy)phenyl)-2,3-dihydro-1H-pyrrolo[2,1-a]isoindol-5(9bH)-one

A flask under nitrogen was charged with5-bromo-2-(3-bromo-3-(2-(difluoromethoxy)phenyl)propyl)isoindolin-1-one(0.37 g, 0.78 mmol) and THF (8 mL). The mixture was cooled to about −70°C. then LiHMDS (1M in THF) (0.9 mL, 0.9 mmol) was added over about 5min. After about 45 min acetic acid (0.2 mL) was added. The mixture waswarmed to rt then concentrated under reduced pressure. The material waspartitioned between EtOAc (20 mL) and water (10 mL) then the organiclayer was washed with saturated aqueous NaCl, dried over MgSO₄, filteredand the filtrate concentrated under reduced pressure. The residue waspurified via flash chromatography on silica gel (0-20% EtOAc/DCM). Theappropriate fractions were collected and concentrated under reducedpressure to give the title compound as an approximately 1:1 mixture ofdiastereomers; (0.092 g, 30%); LC/MS (Table A, Method b) R_(t)=2.29,2.38 min; MS m/z: 394, 396 (M+H)⁺

Step 7:rac-(1R,9bR)-1-(2-(Difluoromethoxy)phenyl)-8-(2-morpholinopyrimidin-5-yl)-2,3-dihydro-1H-pyrrolo[2,1-a]isoindol-5(9bH)-one

A flask under nitrogen was charged with8-bromo-1-(2-(difluoromethoxy)phenyl)-2,3-dihydro-1H-pyrrolo[2,1-a]isoindol-5(9bH)-one(0.090 g, 0.228 mmol) as an approximately 1:1 mixture of diastereomers,1,4-dioxane (4 mL) and water (1 mL),4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-yl)morpholine(0.073 g, 0.251 mmol), cesium carbonate (0.149 g, 0.457 mmol) andPdCl₂(PPh₃)₂(0.011 g, 0.016 mmol). The mixture was heated to about 85°C. for about 45 min. The mixture was cooled to rt then concentratedunder reduced pressure. The material was purified by preparative reversephase chromatography (Table C, Method 1). The shorter R, compoundfraction was lyophilized to give the title compound (0.0206 g, 19%);LC/MS (Table A, Method a) R_(t)=2.20 min; MS m/z: 479 (M+H)⁺

Example 17rac-(1R,9bS)-1-(2-(Difluoromethoxy)phenyl)-8-(2-morpholinopyrimidin-5-yl)-2,3-dihydro-1H-pyrrolo[2,1-a]isoindol-5(9bH)-one

The material from Example 16, Step 7 was purified by preparative reversephase chromatography (Table C, method 1). The longer R, compoundfraction was lyophilized to give the title compound (0.0237 g, 22%);LC/MS (Table A, Method a) R_(t)=2.29 min; MS m/z: 479 (M+H)⁺

Example #18rac-(1R,10bR)-1-(2-(Difluoromethoxy)phenyl)-9-(2-morpholinopyrimidin-5-yl)-3,4-dihydro-1H-[1,4]oxazino[3,4-a]isoindol-6(10bH)-one

Step 1: 5-Bromo-2-(2-hydroxyethyl)isoindolin-1-one

A flask was charged with 2-aminoethanol (2.31 g, 37.8 mmol), MeOH (75mL), DIEA (2.80 mL, 16.1 mmol) and methyl4-bromo-2-(bromomethyl)benzoate (2.0 g, 6.5 mmol). The mixture waswarmed in an oil bath heated to about 75° C. After about 90 min, themixture was cooled to rt then concentrated under reduced pressure. Water(50 mL) was added then the mixture was concentrated at a pressure ofabout 50 mbar and a bath temperature of about 40° C. to removevolatiles. The solids formed were collected by filtration then washedwith water (10 mL). The collected solids were dried to give the titlecompound (2.73 g, 85%); LC/MS (Table A, Method b) R_(t)=1.46 min; MSm/z: 256, 258 (M+H)⁺

Step 2: 5-Bromo-2-(2-chloroethyl)isoindolin-1-one

A flask was charged with 5-bromo-2-(2-hydroxyethyl)isoindolin-1-one(2.73 g, 10.7 mmol), DCM (50 mL) and thionyl chloride (1.00 mL, 13.6mmol). The mixture was stirred at rt for about 15 min then warmed toabout 40° C. After about 15 min the mixture was cooled to rt thenthionyl chloride (0.575 mL, 7.86 mmol) was added. The mixture was warmedto about 40° C. for about 8 h then cooled to rt and stirred for about 12h. The mixture was concentrated under reduced pressure then trituratedwith heptane (15 mL). The solids were collected by filtration and washedwith heptane (2×5 mL). The solids were dried under vacuum to give thetitle compound (2.51 g, 86%); LC/MS (Table A, Method b) R_(t)=1.96 min;MS m/z: 274, 276 (M+H)⁺

Step 3:rac-(1R,10bR)-9-Bromo-1-(2-(difluoromethoxy)phenyl)-3,4-dihydro-1H-[1,4]oxazino[3,4-a]isoindol-6(10bH)-one

A flask under nitrogen was charged with5-bromo-2-(2-chloroethyl)isoindolin-1-one (1.0 g, 3.64 mmol) and THF (30mL) then cooled to an internal temperature of about −70° C. Potassiumbis(trimethylsilyl)amide (0.5 M in toluene) (8.0 mL, 4.0 mmol) was addedkeeping the temperature between about −65° C. and −70° C. The mixturewas allowed to warm to about −50° C. over about 15 min. The mixture wascooled to about −60° C. then 2-(difluoromethoxy)benzaldehyde (0.69 g,4.01 mmol) was added. The mixture was warmed to rt over about 45 minthen added to a saturated aqueous ammonium chloride (25 mL) and water(25 mL) mixture. DCM (50 mL) was added then the layers were separated.The aqueous layer was extracted with DCM (25 mL) then the organicsolutions were combined and washed with water (2×50 mL) then saturatedaqueous NaCl (30 mL). The organic layer was dried over MgSO₄, filteredand the filtrate concentrated under reduced pressure. The residue waspurified via flash chromatography on silica gel (50% EtOAc/heptane). Theappropriate fractions were collected and concentrated under reducedpressure to give the title compound (1.35 g, 90%); LC/MS (Table A,Method b) R_(t)=2.29 min; MS m/z: 410, 412 (M+H)⁺

Step 4:rac-(1R,10bR)-1-(2-(Difluoromethoxy)phenyl)-9-(2-morpholinopyrimidin-5-yl)-3,4-dihydro-1H-[1,4]oxazino[3,4-a]isoindol-6(10bH)-one

A flask under nitrogen was charged withrac-(1R,10bR)-9-bromo-1-(2-(difluoromethoxy)phenyl)-3,4-dihydro-1H-[1,4]oxazino[3,4-a]isoindol-6(10bH)-one(0.200 g, 0.488 mmol),4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-yl)morpholine(0.170 g, 0.585 mmol), 1,4-dioxane (8 mL), water (2 mL), cesiumcarbonate (0.238 g, 0.731 mmol) and PdCl₂(PPh₃)₂(0.0342 g, 0.049 mmol).The mixture was warmed to about 80° C. for about 2.5 h then cooled tort, diluted with EtOAc (70 mL) and washed with water (2×10 mL). Theorganic layer was dried over MgSO₄ then filtered and concentrated underreduced pressure. The residue was purified via flash chromatography onsilica gel (5-80% EtOAc/heptane). The appropriate fractions werecollected and concentrated under reduced pressure to give the titlecompound (0.150 g, 59%); LC/MS (Table A, Method a) R_(t)=2.13 min; MSm/z: 495 (M+H)⁺

Example #193-(5-(Hydroxymethyl)-2-methoxyphenyl)-6-(2-morpholinopyrimidin-5-yl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one

Step 1:3-(5-(Aminomethyl)-2-methoxyphenyl)-6-(2-morpholinopyrimidin-5-yl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one

4-Methoxy-3-(6-(2-morpholinopyrimidin-5-yl)-9-oxo-1,2,3,9-tetrahydropyrazolo[1,2-a]indazol-3-yl)benzonitrile(Example #8.2) (0.19 g, 0.406 mmol) was dissolved in MeOH (10 mL). Thematerial was cycled three times through a flow hydrogenation apparatus(H-Cube® Continuous-flow Hydrogenation Reactor, 70° C., 50 bar, 0.9mL/min, Raney Nickel cartridge). The resulting mixture was concentratedunder reduced pressure then purified by reverse phase HPLC (Table C,Method 3) to give the title compound after lyophilzation (0.065 g, 34%);LC/MS (Table A, Method a) R_(t)=1.32 min; MS m/z: 473 (M+H)⁺.

Step 2:3-(5-(Hydroxymethyl)-2-methoxyphenyl)-6-(2-morpholinopyrimidin-5-yl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one

3-(5-(Aminomethyl)-2-methoxyphenyl)-6-(2-morpholinopyrimidin-5-yl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one(0.025 g, 0.053 mmol) was dissolved in AcOH (0.5 mL). Water (0.5 mL) wasadded then the mixture was cooled to about 0° C. Sodium nitrite (0.015g, 0.212 mmol) was added then the mixture was warmed to rt and stirredfor about 1 h. A second portion of sodium nitrite (0.015 g, 0.212 mmol)was added then the mixture was stirred for about 4 h. The mixture wasbasified with saturated sodium bicarbonate then extracted with EtOAc (25mL). The organic solution was dried over magnesium sulfated filtered andconcentrated. The residue was dissolved in 1,4-dioxane (1 mL) and water(0.25 mL). Lithium hydroxide (6.3 mg, 0.265 mmol) was added then themixture was heated to about 80° C. for about 1 hour. The mixture wascooled then partitioned between EtOAc (15 mL) and water (5 mL). Theorganic solution was dried over magnesium sulfate, filtered andconcentrated. The residue was triturated with MeOH then dried to givethe title compound (0.018 g, 71%); LC/MS (Table A, Method b) R_(t)=1.62min; MS m/z: 474 (M+H)⁺ (TNF IC₅₀=B).

The compounds shown in Table 9 were synthesized in a manner similar toExample #16, Step 7 fromrac-(1R,9bR)-8-bromo-1-(2-(difluoromethoxy)phenyl)-2,3-dihydro-1H-pyrrolo[2,1-a]isoindol-5(9bH)-one(Preparation #20) and the corresponding boronic acid/boronate.Enantiomers were separated by the chiral methods listed in Table B whenapplicable.

TABLE 9 Method for chiral R_(t) min separation/ Example (Table A, m/zESI+ Order of TNF Boronic acid/boronate Product # Method) (M + H)⁺elution/Sign IC₅₀ 2-(4-Morpholono)pyrimidine- 5-boronic acid pinacolester

9.1 2.18 (a) 479 16/1^(st)/− C 2-(4-Morpholino)pyrimidine- 5-boronicacid pinacol ester

9.2 2.18 (a) 479 16/2^(nd)/+ A

The compounds shown in Table 10 were synthesized in a manner similar toExample #4, Step 1 fromrac-(1R,9bR)-8-bromo-1-(2-(difluoromethoxy)phenyl)-2,3-dihydro-1H-pyrrolo[2,1-a]isoindol-5(9bH)-one(Preparation #20) and the corresponding aryl halide. Enantiomers wereseparated by the chiral methods listed in Table B when applicable.

TABLE 10 Method for chiral R_(t) min separation/ Example (Table A, m/zESI+ Order of TNF Aryl halide Product # Method) (M + H)⁺ elution/SignIC₅₀ 2-(5-Bromopyrimidin-2- yl)propan-2-ol

10.1 1.95 (a) 452 17/1^(st)/− C 2-(5-Bromopyrimidin-2- yl)propan-2-ol

10.2 1.95 (a) 452 17/2^(nd)/+ B (R)-5-Bromo-2-(2-(methoxymethyl)pyrrolidin- 1-yl)pyrimidine (Preparation #10)

10.3 2.42 (a) 507 18/1^(st)/− B (R)-5-Bromo-2-(2-(methoxymethyl)pyrrolidin- 1-yl)pyrimidine (Preparation #10)

10.4 2.42 (a) 507 18/2^(nd)/+ C

The compounds shown in Table 11 were synthesized in a manner similar toExample #4, Step 1 from(1R,9bR)-8-bromo-1-(2-(difluoromethoxy)phenyl)-2,3-dihydro-1H-pyrrolo[2,1-a]isoindol-5(9bH)-one(Preparation #22) and the corresponding aryl halide.

TABLE 11 R_(t) min Example (Table A, m/z ESI+ TNF Aryl halide Product #Method) (M + H)⁺ IC₅₀ (R)-7-(5-Bromopyrimidin-2-yl)hexahydroimidazo[1,5- a]pyrazin-3(2H)-one (Preparation #9)

11.1 1.81 (a) 533 A (S)-7-(5-Bromopyrimidin-2- yl)hexahydroimidazo[1,5-a]pyrazin-3(2H)-one (Preparation #8)

11.2 1.81 (a) 533 A

The compounds shown in Table 12 were synthesized in a manner similar toExample #4 from6-bromo-1-(1-(2-(difluoromethoxy)phenyl)-3-hydroxypropyl)-5-fluoro-1H-indazol-3(2H)-one(Preparation #24) and the corresponding bromide. Enantiomers wereseparated by the chiral methods listed in Table B when applicable.

TABLE 12 Method for chiral R_(t) min separation/ Example (Table A, m/zESI+ Order of TNF Bromide Product # Method) (M + H)⁺ elution/Sign IC₅₀2-(5-Bromopyrimidin- 2-yl)propan-2-ol

12.1 1.89 (a) 471 19/1^(st)/+ A 2-(5-Bromopyrimidin- 2-yl)propan-2-ol

12.2 1.89 (a) 471 19/2^(nd)/− A

The compounds shown in Table 13 were synthesized in a manner similar toExample #4 from6-bromo-3-(2-(difluoromethoxy)-5-methylphenyl)-7-fluoro-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one(Preparation #29) and the corresponding bromide. Enantiomers wereseparated by the chiral methods listed in Table D when applicable.

TABLE 13 Method for SFC R_(t) min separation/ Example (Table A, m/z ESI+Order of TNF Bromide Product # Method) (M + H)⁺ elution/Sign IC₅₀2-(5-Bromopyrimidin- 2-yl)propan-2-ol

13.1 1.31 (c) 485 1/1^(st)/− A 2-(5-Bromopyrimidin- 2-yl)propan-2-ol

13.2 1.21 (c) 485 1/2^(nd)/+ A

The compounds shown in Table 14 were synthesized in a manner similar toExample #4 from(S)-6-bromo-3-(2-(difluoromethoxy)-5-methylphenyl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one(Preparation #30) and the corresponding bromide.

TABLE 14 R_(t) min Example (Table A, m/z ESI+ Optical TNF BromideProduct # Method) (M + H)⁺ Rotation IC₅₀ (S)-7-(5- Bromopyrimidin-2-yl)hexahydroimidazo [1,5-a]pyrazin-3(2H)- one (Preparation #8)

14.1 1.81 (a) 548 NA A 2-(5-Bromopyrimidin- 2-yl)propan-2-ol

14.2 1.25 (c) 467 NA A

The compounds shown in Table 15 were synthesized in a manner similar toExample #4 from(R)-6-bromo-3-(2-(difluoromethoxy)-5-methylphenyl)-2,3-dihydropyrazolo[1,2-a]indazol-9(1H)-one(Preparation #31) and the corresponding bromide.

TABLE 15 Exam- R_(t) min ple (Table A, m/z ESI+ Optical TNF BromideProduct # Method) (M + H)⁺ Rotation IC₅₀ (S)-7-(5-Bromopyrimidin-2-yl)hexahydroimidazo [1,5-a]pyrazin-3(2H)-one (Preparation #8)

15.1 1.82 (a) 548 NA A 2-(5-Bromopyrimidin-2- yl)propan-2-ol

15.2 1.25 (c) 467 NA A

What is claimed:
 1. A compound of Formula (I),

or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:X, Y and Z are CR⁴; A is —C(R^(z))₂—; E is CH₂ or O and G is CH; or E isCH₂ and G is CH or N; R¹ is optionally substituted aryl or optionallysubstituted heteroaryl; R² is —R^(2a)-R^(2b), wherein: R^(2a) is anoptionally substituted saturated, unsaturated or partially saturatedheterocyclyl, or optionally substituted heteroaryl; and R^(2b) is—N(R^(a))(R^(b)), —O(R^(a)), optionally substituted (C₁-C₅)alkyl,optionally substituted (C₃-C₆)cycloalkyl, —(CH₂)_(p)-optionallysubstituted heteroaryl, or —(CH₂)_(p)-optionally substitutedheterocyclyl; wherein R^(a) and R^(b) are independently selected fromthe group consisting of H, optionally substituted (C₁-C₅)alkyl, and—(CH₂)_(n)-optionally substituted heterocyclyl; each instance of R⁴ isindependently H, halo, CF₃, or (C₁-C₃)alkyl; each instance of R^(z) isindependently H, halo, CF₃, or (C₁-C₃)alkyl; n is 0; and p is 0 or 1;wherein heterocyclyl is: a non-aromatic monocyclic, bicyclic, tricyclic,or spirocyclic ring having 5 to 12 ring atoms which include at least onenitrogran, oxygen, or sulfur ring atom; or an azetidinyl ring.
 2. Thecompound according to claim 1, or a pharmaceutically acceptable salt orstereoisomer thereof, wherein: R^(2b) is —N(R^(a))(R^(b)), —O(R^(a)),optionally substituted (C₁-C₅)alkyl, optionally substituted(C₃-C₆)cycloalkyl, or —(CH₂)_(p)-optionally substituted heterocyclyl;and R^(a) and R^(b) are independently selected from the group consistingof H, optionally substituted (C₁-C₅)alkyl, and —(CH₂)_(n)-optionallysubstituted heterocyclyl.
 3. The compound according to claim 1, or apharmaceutically acceptable salt or streoisomer thereof, wherein E isCH₂, and G is CH or N.
 4. The compound according to claim 1, or apharmaceutically acceptable salt or stereoisomer thereof, wherein X isCH, Y is CH, and Z is CR⁴.
 5. The compound according to claim 4, or apharmaceutically acceptable salt or stereoisomer thereof, wherein R⁴ isF.
 6. The compound according to claim 1, or a pharmaceuticallyacceptable salt or stereoisomer thereof, wherein X is CH, Y is CH, and Zis CH.
 7. The compound according to claim 1, or a pharamaceuticallyacceptable salt or stereoisomer thereof, wherein E is CH₂, and G is N.8. The compound according to claim 1, or a pharmaceutically acceptablesalt or stereoisomer thereof, wherein R¹ is optionally substitutedphenyl, optionally substituted pyrazolyl, optionally substitutedpyridyl, optionally substituted pyrimidinyl, or optionally substitutedthiazolyl.
 9. The compound according to claim 1, or a pharmaceuticallyacceptable salt or stereoisomer thereof, wherein R¹ is optionallysubstituted phenyl.
 10. The compound according to claim 1, or apharmaceutically acceptable salt or stereoisomer thereof, wherein R¹ isoptionally substituted by one or more substituents independentlyselected from the group consisting of —CF₃, —CN, —C(O)NH₂, —OCHF₂,—OCH₃, and (C₁-C₃)alkyl.
 11. The compound according to claim 1, or apharmaceutically acceptable salt or stereoisomer thereof, wherein R¹ isoptionally substituted by one or more substituents independentlyselected from the group consisting of —CH₃ and —OCHF₂.
 12. The compoundaccording to claim 1, or a pharmaceutically acceptable salt orstereoisomer thereof, wherein R^(2a) is optionally substitutedpyrimidinyl or optionally substituted dihydropyranyl.
 13. The compoundaccording to claim 1, or a pharmaceutically acceptable salt orstereoisomer thereof, wherein R^(2a) is 1,2,4-oxadiazolyl, optionallysubstituted pyrazolyl, optionally substituted pyridinyl, optionallysubstituted pyrimidinyl, or optionally substituted 1,2,4-thiadiazolyl.14. The compound according to claim 1, or a pharmaceutically acceptablesalt or stereoisomer thereof, wherein R^(2b) is N(R^(a))(R^(b)),optionally substituted (C₁-C₄)alkyl, optionally substituted morpholinyl,optionally substituted piperazinyl, optionally substituted piperidinyl,1,1-dioxidothiomorpholinyl, optionally substitutedhexahydroimidazo[1,5-a]pyrazin-3(2H)-one, optionally substituted7-azaspiro[3.5]nonane, or optionally substituted pyrrolidinyl.
 15. Thecompound according to claim 1, or a pharmaceutically acceptable salt orstereoisomer thereof, wherein: R^(2b) is —N(R^(a))(R^(b)), optionallysubstituted (C₁-C₃)alkyl, optionally substituted 7-azaspiro[3.5]nonanyl,optionally substituted morpholinyl, 1,1-dioxidothiomorpholinyl,optionally substituted piperazinyl, optionally substituted piperidinyl,optionally substituted hexahydroimidazo[1,5-a]pyrazin-3(2H)-one, oroptionally substituted pyrrolidinyl; R^(a) is H or (C₁-C₃)alkyl, andR^(b) is optionally substituted (C₁-C₃)alkyl, methoxypropyl,-5-oxopyrrolidin-3-ylmethyl, or tetrahydrofuranyl.
 16. The compoundaccording to claim 1, or a pharmaceutically acceptable salt orstereoisomer thereof, wherein R^(2b) is optionally substituted(C₁-C₃)alkyl, —CH₂-pyrazolyl, or —CH₂-triazolyl.
 17. The compoundaccording to claim 1, or a pharmaceutically acceptable salt orstereoisomer thereof, wherein R^(2b) is optionally substituted(C₁-C₃)alkyl, optionally substituted 7-azaspiro[3.5]nonanyl, optionallysubstituted morpholinyl, or hexahydroimidazo[1,5-a]pyrazin-3(2H)-one.18. The compound according to claim 1, or a pharmaceutically acceptablesalt or stereoisomer thereof, wherein R^(2b) is optionally substitutedby —CH₂OH, —C(OH)(CH₃)₂, —C(O)CH₃, —C(O)OH, —OH, or alkoxyalkyl.
 19. Thecompound according to claim 1, or a pharmaceutically acceptable salt orstereoisomer thereof, wherein R^(2b) is optionally substituted by one ormore substituents independently selected from the group consisting ofCH₃, —C(O)CH₂OH, —C(O)CH₃.
 20. The compound according to claim 1 whereinthe compound is selected from the group consisting of:

and pharmaceutically acceptable salts thereof.
 21. A pharmaceuticalcomposition comprising a compound according to claim 1, or apharmaceutically acceptable salt or stereoisomer thereof; and one ormore pharmaceutically acceptable excipients.
 22. The compound accordingto claim 1, wherein the compound is selected from the group consistingof:

and pharmaceutically acceptable salts thereof.
 23. The compoundaccording to claim 1, or a pharmaceutically acceptable salt orstereoisomer thereof, wherein: X is CH; Y is CH; Z is CR⁴, wherein R⁴ isH or F; A is -C(R^(Z))₂- wherein R^(Z) is H; E is CH₂; G is N; R¹ isphenyl optionally substituted by one or more substituents independentlyselected from the group consisting of -CF₃, -CN, -C(O)NH₂, -OCHF₂,-OCH₃, and (C₁-C₃)alkyl; R² is -R^(2a)-R^(2b), wherein R^(2a) ispyrimidinyl, and R^(2b) is selected from the group consisting of:-N(R^(a))(R^(b)) wherein R^(a) is H or (C₁-C₃)alkyl, and R^(b) is(C₁-C₃)alkyl, methoxypropyl, 5-oxopyrrolidin-3-ylmethyl, ortetrahydrofuranyl; (C₁-C₃)alkyl optionally substituted by -CH₂OH,-C(OH)(CH₃)₂, -C(O)CH₃, -C(O)OH, -OH, or alkoxyalkyl;7-azaspiro[3.5]nonanyl optionally substituted -CH₂OH, -C(OH)(CH₃)₂,-C(O)OH, -OH, or alkoxyalkyl; morpholinyl optionally substituted by-CH₂OH, -C(OH)(CH₃)₂, -C(O)OH, -OH, or alkoxyalkyl; piperazinyloptionally substituted by -CH₂OH, -C(OH)(CH₃)₂, -C(O)OH, -OH, oralkoxyalkyl; piperidinyl optionally substituted by -CH₂OH, -C(OH)(CH₃)₂,-C(O)OH, -OH, or alkoxyalkyl; hexahydroimidazo[1,5-a]pyrazin-3(2H)-oneoptionally substituted by -CH₂OH, -C(OH)(CH₃)₂, -C(O)OH, -OH, oralkoxyalkyl; and pyrrolidinyl optionally substituted by -CH₂OH,-C(OH)(CH₃)₂, -C(O)OH, -OH, or alkoxyalkyl.
 24. The compound accordingto claim 1, or a pharmaceutically acceptable salt or stereoisomerthereof, Wherein optionally substituted refers to optional substitutionwith one or more substituents selected from the group consisting of(C₁-C₈)alkyl; (C₂-C₈)alkenyl; (C₂-C₈)alkynyl; (C₃-C₁₀)cycloalkyl; F; Cl;BR; I; halogenated (C₁-C₈)alkyl; -O-(C₁-C₈)alkyl; =O; =CH₂; -OH; -CH₂OH;-CH₂OCH₃; -CH₂NH₂; (C₁-C₄)alkyl-OH; -CH₂CH₂OCH₂CH₃;-S-(C₁-C₈)alkyl; -SH;-NH(C₁-C₈)alkyl; -NH((C₁-C₈)alkyl)₂; -NH₂; -C(O)NH₂;-CH₂NHC(O)(C₁-C₈)alkyl; -CH₂NCH(O)CH₂Cl; -CH₂NHC(O)CH₂CN;-CH₂NHC(O)CH₂CH₂N(CH₃)₂; -CH₂NHC(O)C(=CH₂)CH₃; -CH₂NHC(O)(C₂-C₄)alkynyl;-CH₂NHC(O)CH₂CH₂- piperidinyl; -(C₁-C₄)alkyl-morpholinyl;-CH₂NHC(O)CH₂)-phenyl wherein the phenyl is optionally substituted withhalogen; (C₁-C₄)alkoxy; -C(O)(C₁-C₄)alkyl; -C(O)(C₁-C₄)alkoxy;-C(O)N(CH₃)₂; -N(CH₃)₂; -NHC(O)(C₁-C₄; )alkyl; -NHC(O)(C₂-C₄)alkenyl;-NHC(O)CH₂CN; -S(O)₂(C₁-C₄)alkyl; 4-methylpiperazinecarbonyl;-(C₁-C₄)alkylC(O)NH₂; -C(O)NH(C₁-C₈)alkyl; -C(O)N((C₁-C₈)alkyl)₂;-C(O)N(H)(C₃- C₈)cycloalkyl; -C(O)(C₁-C₄)alkyl -OH;-(C₁-C₄)alkyl(C₁-C₄)alkoxy; -NHC(O)H; -NHC(O)(C₁-C₈)alkyl; -NHC(O)(C₃-C₈)cycloalkyl; -N((C₁-C₈)alkyl)C(O)H;-N((C₁-C₈)alkyl)C(O)(C₁-C₈)alkyl; -NHC(O)NH₂; -NHC(O)NH(C₁-C₈)alkyl;-N((C₁-C₈)alkyl)C(O)NH₂; -NHC(O)N((C₁-C₈)alkyl)₂;-N((C₁-C₈)alkyl)C(O)N((C₁-C₈)alkyl)₂;N((C₁-C₈)alkyl)C(O)NH((C₁-C₈)alkyl; -NCHC₂-heteroaryl; benzyl;-OCH₂-heteroaryl; -C(O)H; -C(O)(C₁-C₈)alkyl; -CN; -NO₂;-S(O)(C₁-C₈)alkyl; S(O)₂(C₁-C₈)alkyl; S(O)₂N((C₁-C₈)alkyl)₂;-S(O)₂NH(C₁-C₈)alkyl; -S(O)₂NH(C₂-C₈)cycloalkyl; -S(O)₂NH₂;-NHS(O)₂(C₁-C₈)alkyl; N((C₁-C₈)alkyl)S(O)₂(C₁-C₈)alkyl;-(C₁-C₈)alkyl-O-(C₁-C₈)alkyl; -O-(C₁-C₈)alkyl-O-(C₁-C₈)alkyl; -C(O)OH;-C(O)O(C₁-C₈)alkyl; NHOH; NHO (C₁-C₈)alkyl; -O-halogenated (C₁-C₈)alkyl;-S(O)₂- halogenated (C₁-C₈)alkyl; -S-halogenated (C₁-C₈)alkyl;-NHC(O)O-(C₁-C₆)alkyl; -N((C₁-C₆)alkyl)C(O)O-(C₁-C₆)alkyl;-C(=NH)-(C₁-C₆)alkyl; -C(=NOH)-(C₁-C₆)alkyl; and-C(=N-O-(C₁-C₆)alkyl)-(C₁-C₆)alkyl.
 25. A pharmaceutical compositioncomprising a compound according to claim 20, or a pharmaceuticallyacceptable salt thereof; and one or more pharmaceutically acceptableexcipients.
 26. A pharmaceutical composition comprising a compoundaccording to claim 22, or a pharmaceutically acceptable salt thereof;and one or more pharmaceutically acceptable excipients.